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Abstract 
The 2-picoline (2-methylpyridine) complex, cis-[PtC12(NH3)(2-pic)] 
(AMD473), is a promising new generation platinum antitumour agent currently in 
clinical trials and highly active against cisplatin resistant cell-lines. The antitumour 
activity of trans platinum complexes has attracted renewed interest since it has been 
shown that some trans compounds, in particular those possessing planar amine 
ligands, are anticancer-active. Therefore, three trans isomers, trans- [PtC12(NH3)(2-
pic)] (1), trans-[PtC12(NH3)(3-pic)] (2) and trans-[PtCl2(NH3)(4-pic)] (3), were 
synthesised and characterised. The crystal structure of I shows steric hindrance 
induced by the 2-methyl group towards an axial approach to Pt, while its 3-pie (2) 
and 4-pie (3) analogues are less sterically hindered. Notable however, is that in the 
solid state complex I is less sterically-hindered than its cis isomer. 15N-Iabelling of 
complexes 1-3 allowed both the hydrolysis rates and pKa values of the complexes to 
be determined using 2D ['H,'3N] NMR spectroscopy. 
Adducts of cis- and trans- [PtCl2(NH 3)(2-pic)] with neutral 9-ethylguanine (9-
EtGH) and anionic (Ni -deprotonated) 9-ethylguanine (9-EtG) were prepared and 
their structures determined by X-ray crystallography. Platinum is coordinated at the 
guanine N7 position with a head-to-tail arrangement of the bases in all cases. Two of 
the complexes exhibited intermolecular triple hydrogen bonding between neutral and 
deprotonated guanine ligands. In addition, adducts of cis- and trans- [PtC12(NH3)(2-
pie)] with guanosine and 2-deoxyguanosine were prepared and characterised in 
solution by NMR spectroscopy and ESI mass spectrometry. The complexes cis-
[Pt(NH3)(2-pic)(Guo)2]2+  , and cis- and trans- [Pt(NH3)(2-pic)(2 -dGuo)2]2+ were 
assigned as head-to-tail conformations, on the basis of their NOE cross-peaks. 
Ii 
The reaction of cis-[Pt('5NH3)(2-pic)(OH2)2]2 and guanosine (Guo) was 
followed by 2D [1 H,15N] NMR spectroscopy and was found to proceed through two 
mono(guanosine) intermediate species to yield the dominant product cis-
[Pt('5NH3)(2-pic)(Guo)2]2 . Initial guanosine substitution trans to 2-picoline was 
faster than substitution cis to 2-picoline due to steric hindrance, but the rates of the 
second guanosine substitution were similar. 
The binding of ' 5N-labelled-1 to a self-complementary DNA duplex, 
d(TATGGTACCATA)2, was investigated using 1D 'H and 2D ['H,'5N] NMR 
spectroscopy. The first aquation step appeared to be the rate-limiting step in the 
formation of the monofunctional adducts. Several DNA products were observed but 
could not be identified unambiguously. 
The rate constants for reactions between '5N-labelled 1 and guanosine 5'-
monophosphate (5'-GMP) were determined via 2D NMR studies, and compared to 
those previously reported for cis-[PtCl2(NH3)(2-pic)]. Complex 1 was very reactive 
towards the thiol glutathione (GSH). Competitive reactions of 1 with GSH and 5'-
GMP showed a clear preference for GSH adduct formation. 
Also, using ['H,15N] 2D NMR spectroscopy together with '5N-labelled 
amines, the reactions of cis- and trans-[PtCl2(NH3)(2-pic)] with L-methionine (L-
MetH) (1:1, 298 K) were investigated. The reactivity of cis-[PtC12(NH3)(2-pic)] with 
L-methionine was greatly reduced compared to cisplatin, with the hydrolysis reaction 
predominating. Trans-[PtC12(NH3)(2-pic)], on the other hand, appeared to react 
without prior aquation and was entirely consumed within 8 h of reaction. 
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Platinum (Pt, atomic number 78, mass number 195.08) is found in Group 10 
of the periodic table. Platinum-containing objects date back as early as 700 BC, 
although Pt was not formally discovered until 1735 by the Spanish astronomer A. de 
Ulloa, in deposits from the Pinto River in Columbia and brought to Europe. A 
systematic study of the chemistry of platinum began soon after its arrival in Europe, 
and by 1830 not only had many of the inorganic compounds been made, but the first 
organometallic derivative K[Pt(C2H4)C]3].H20 had actually been preparedJ'1 The 
chemistry was further developed during the rest of the 9 century and, with 
increasing acceleration in the 20th  century. There were three factors which attracted 
interest to and sustained research on platinum. 
Firstly, in the divalent oxidation state platinum readily forms complexes with 
ligands containing donor atoms from most groups of the periodic table. 
Secondly, there came the recognition of the square-planar geometry of the 2+ 
oxidation state, which opened up the possibility of cis-, trans- isomerisation in such 
complexes. From this followed the discovery of the trans-effect in Pt(II) complexes 
in the 1920s.12' Its elucidation enabled the systematic synthesis of any desired 
platinum(II) complex to be accomplished. These investigations led to the synthesis of 
all three possible geometric isomers of {Pt(pyr)NH3)BrC1]J31  
Thirdly, there followed a tremendous growth in interest in platinum triggered 
off by the burgeoning of its organometallic chemistry. This is a vast subject of great 
intrinsic interest. It has applications in the field of homogenous catalysis in the 
reactions of organic compounds, and also provides a basis for a discussion of the 
mechanisms of organic reactions that are heterogeneously catalysed by the metals 
themselves and by their oxides. 
The abundance of platinum in the earth's crust is approximately 106 % by 
weight. Almost all platinum comes from nickel or copper sulfide ores and must be 
selectively extracted from other Platinum Group metals (ruthenium, rhodium, 
palladium, osmium, and iridium). The world's major deposits are found in South 
Africa, Canada and Russia. 
There are six naturally occurring isotopes of platinum, 190 Pt (0.01 %), "Pt 
(0.78 %), 194Pt (32.9%), 19 Pt (33.8 %), "'Pt (25.3 %), '98Pt (7.21 %), of which '95Pt 
is NMR-active, with a nuclear spin quantum number V2. The principal oxidation 
states of platinum are II and IV, but there is extensive chemistry in the I and III states 
where Pt - Pt bonds are involved, and in the 0 state where PR3, CO, or other it-acid 
ligands are present and metal clusters are also found. The higher states V and Vi 
occur only in a few fluoro compounds. 
1.1.1 Coordination Chemistry of Platinum 
Platinum(II) complexes are d8 and diamagnetic. They are principally square-
planar as the splitting of the d-orbitals in this geometry provides the opportunity to 
place all 8 d-electrons in four lower-energy orbitals leaving the uppermost (dx2 y2) 
orbital empty. As a third row transition metal, the d-orbital splitting is sufficient to 
offset the energy required to pair-up two electrons, leading these complexes to favour 
a square-planar geometry (Figure 1.1). 
Platinum(II) shows soft or class-b characteristics, preferring CN and ligands 
with nitrogen or heavy donor atoms like 1 and it-bonding ligands rather than 0-donor 
or F ligands. Pt" complexes have played an important role in the development of 
3 
various aspects of coordination chemistry, such as geometric isomerism and reaction 
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Figure 1.1 The splitting of d-orbitals in fields of different symmetries, and the 
resulting electronic configurations of the Pt" d8 ion. 
An important phenomenon of reactions of square-planar complexes is the 
trans effect - the effect of the ligand on the rate of substitution of the group trans to 
it. Ligand displacement on Pt 11  occurs almost entirely by an associative pathway, via 
a 5-coordinate intermediate (Figure 1.2). Such substitution reactions follow a two-
term rate law, assuming an excess of solvent, i.e. rate = ki[L3PtYI + k2[L3PtX][Y], 
where k 1 and k2 are first-order and second-order rate constants, respectively. 
Generally, the stereochemistry of the complex is retained but if the intermediate is 
sufficiently long-lived it can undergo pseudorotation leading to the opposite isomer. 
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Figure 1.2 Associative mechanism of ligand substitution in Pt" square-planar 
complexes. 
By comparison with a large number of reactions, it is possible to set up a 
trans-directing series. The ordering of ligands in this series is as follows: [41 
CO, CN, C2H4 > PR3, H> CH3 > C6H5 , NO2 , F, SCN> B(, cr> py, NH3, 0H, H20 
The ligands exerting the strongest trans effect are those for which the bonding to Pt" 
is thought to have the most it-acceptor character. This removes electron density from 
the metal and the reduced density on the opposite side means that nucleophilic attack 
is more likely to take place. The trans effect is a kinetic phenomenon affecting the 
rates of reaction and isomer formation. This series is useful in rationalising known 
synthetic procedures and devising new ones. 
5 
A related property of ligands in square-planar complexes is the trans 
influence. This is a thermodynamic effect of one ligand on the strength of the bond 
trans to it. The ordering of ligands in this series is as follows: [41 
H> PR3 > SCN> F, CH3 , CO, CN> Br> cr> NH3 > 0H 
This effect is greatest for ligands which are strong (Y-donors. 
Platinum(IV) complexes are octahedral and diamagnetic with the low-spin 
t2g configuration. In contrast to Pt11, Pt1V  shows nearly hard or class-a characteristics. 
Pt1'' complexes are thermodynamically stable and kinetically inert. Complexes with 
halide, pseudo-halide and N-donor ligands are especially numerous. K2[PtC16] is the 
most common commercially available form, and it is a useful route into Pt 11 
chemistry, by reduction with sulfur dioxide to K2[PtCI4]J5' 
1.2 Cisplatin 
Although most heavy metals are considered to be very toxic, some may also 
have beneficiary effects in the treatment of diseases. 6' 71  Platinum drugs against 
cancer are one of the most successful applications of metals in medicine. Platinum 
complexes are now among the most widely used drugs for the treatment of cancer 
and one of the world's best selling anticancer drugs is cisplatin, cis-
diamminedichloroplatinum(II), Figure 1.3. 
H3N,, 	CI 
Pt. 
H3 V. 	ci 
Figure 1.3 The anticancer drug cisplatin. 
Cisplatin was chemically described in 1 844 but its anticancer properties went 
unnoticed until the mid-1960s when Dr. Barnett Rosenberg set out to investigate the 
effects of electric fields on the growth of E. coijJ 8' Cell division was found to be 
inhibited in these experiments. Rosenberg and co-workers found that the electric 
field was not responsible for the cell division arrest, but that this could be attributed 
to traces of platinum compounds, and in particular cis-[Pt(NH3)2C14]. Such 
compounds were formed by electrochemical reactions of the platinum electrodes 
used in the experimentJ9' Clinical trials demonstrating the efficacy of cispiatin, cis-
[Pt(NH3)2C12], soon followed. Both cis-diamminedichloroplatinum(ll) and cis-
diamminetetrachloroplatinurn(IV) were shown to have potent antitumour activity 
against sarcoma 180 and leukaemia Li 	tO. II] whereas the trans geometric 
isomers of these compounds were ineffective. [12, 13  After the clear demonstration of 
activity against a broad range of animal tumours, clinical trials were initiated by the 
National Cancer Institute in 1972. These early reports indicated promising anticancer 
activity, particularly against nonseminomatous testicular tumours, but stressed the 
limitations imposed by severe toxicity to the kidneys and bone marrow. t141  Nausea 
and vomiting and sometimes audiotoxicity were also severe. However, subsequent 
studies showed that high doses could be tolerated by means of forced diuresis. [15] 
The development of cisplatin marked a watershed in the treatment of cancer. 
The three major classes of anticancer drugs then available - antimetabolites, 
alkylating agents, and anthracyclines - shared a common origin in the treatment of 
leukaemias. The exception, 5-fluorouracil, was developed as a thymidine analogue, 
but surprisingly was relatively inactive in the more rapidly replicating acute 
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investigation was targeted to solid tumours. Now, almost 40 years after the 
description of its anticancer activity, the continuing central role of cisplatin in the 
management of several major solid tumours attests to its therapeutic importance. 
Despite the successful therapeutic use of cisplatin, there are still serious 
drawbacks associated with this drug including severe toxicity (e.g. nausea, ear 
damage, vomiting, diarrhoea, loss of sensation in hands and kidney toxicity), poor 
solubility in saline and resistance to the drug, either intrinsic or acquired. Also, 
cisplatin is only effective in a relatively narrow range of tumour types. These 
drawbacks have provided the impetus for the development of new generations of 
platinum drugs which can overcome these limitations. 
1.2.1 Mechanism of Action 
It is widely accepted that the cytotoxic effects of cisplatin are due to the 
formation of a variety of stable adducts on DNA which then block replication or 
inhibit transcription. Some of the important events relating to the mechanism of 
action of cisplatin and cellular resistance are summarised in Figure 1.4. 
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Figure 1.4 Schematic representation of reactions of cisplatin in the cell) '61  
After administration, either by injection or infusion, cisplatin is transported 
through the body. Due to the relatively high chloride ion concentration in blood 
(lOO mM), the hydrolysis of cisplatin is inhibited and the complex remains almost 
unchanged before entering both normal and tumour cells. The precise mechanism of 
cellular uptake of cisplatin still remains unclear. There are some data to suggest that 
cisplatin enters the cell via passive diffusion, [17]  although there is also evidence for 
an additional pathway involving active transport, and an altered expression of some 
membrane proteins is reported for cisplatin-resistant cells)18' 19] 
Once inside the cell, cisplatin hydrolyses to give active forms such as cis-
{PtCl(NH3)2(H20)f and cis-[Pt(NH3)2(H2O)2]2 because of the much lower chloride 
ion concentration (4-25 mM))201 Hydrolysis is known to be the rate-limiting step in 
the binding of cisplatin to DNA. 211 A summary of the hydrolysis reactions, including 
half lives of aquation1221 and pKa values, 
[231  is given in Figure 1.5. 
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Figure 1.5 Hydrolysis scheme of cisplatin in aqueous solution with half-lives for 
hydrolysis (3 10 K) 22' and pKa values (300 K) of its aqua adducts. 231 
In theory, a large variety of biological molecules could be potential targets for 
platinum compounds, including DNA, RNA and proteins. From the Hard-Soft Acid-
Base theory, sulfur-donor ligands in proteins would bind strongly and generate the 
most stable bonds. Binding to lone pairs of nitrogen atoms can also be very strong. 
These types of binding would involve amino acid side chains of proteins from 
cysteine, methionine, histidine and the solvent-exposed N7 atoms of adenine and 
guanine in the major groove of double-stranded DNA. Usually, interactions of 
platinum antitumour complexes with S-containing biomolecules are thought to have 
an overall negative effect on antitumour activity. Such interactions can be 
responsible for the inactivation of Pt" species, development of resistance and toxic 
side effects such as nephrotoxicity. Nevertheless, studies have shown that sulfur 
ligands, especially the thioether of methionine and perhaps thiol of glutathione, could 
also play a key role in the transfer of platinum to the nucleic acids. 124, 
1.2.1.1 DNA Platination 
The antitumour activity of cisplatin depends on its ability to modify the 
structure of the DNA of cancer cells. Approximately 1% of the intracellular cisplatin 
reacts with genomic DNA and yields a variety of mono-adducts and intra- and inter-
strand cross-links. The most nucleophilic sites in duplex DNA are known to be 
guanine residues located adjacent to a second guanine residueJ261 For platinum 
coordination, the guanine-N7 position appears to be the preferred binding site. 
Therefore, it is not surprising that the major DNA lesions both in vitro and in vivo are 
intrastrand d(GpG) cross-links. Besides GG intrastrand cross-links (-65%), the other 
major DNA adducts of cisplatin are intrastrand AG (but not GA) cross-links (-25%) 
with the remainder being minor 1,3-intrastrand cross-links, interstrand cross-links 
IDJ 
and monofunctional adducts, [271  Figure 1.6. DNA-protein cross-links have also been 
reported. 28' 291  Platination of DNA by transpiatin was found to give the following 
adducts after digestion: dG-Pt-dC (50%), dG-Pt-dG (40%), dG-Pt-dA (10%)J3°1  As 
expected, transpiatin does not form intrastrand chelates between adjacent 
nucleotides. 
Pt 
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Figure 1.6 Cisplatin-DNA binding modes. 
Since the most prevalent adduct formed on treatment of DNA with cisplatin 
is the I ,2-intrastrand cross-link, it was suggested that these may be important for 
anticancer activity. The assumption is supported by the finding that nucleotide 
excision repair (NER), an important DNA-repair system, repairs 1,3-intrastrand 
adducts more efficiently than 1,2-adducts, while the 1 ,2-d(GpG) adducts are repaired 
the least effectivelyJ311  However, the possible importance of other adducts should not 
be neglected. Many structural studies have been carried out to determine the nature 
of this 1 ,2-intrastrand cisplatin adduct on double and single-stranded DNA 
fragments. [32] 
The first X-ray crystal structures determined of cis-GG cross-links were for 
the dinucleotide d(pGpG) 331  and the trinucleotide d(CpGpG). 341  These structures are 
shown in Figure 1.7. The dinucleotide structure has the guanine bases in a head-to- 
head configuration, with the two 06 atoms on the same side of the coordination 
plane. The bases are forced to destack with an average dihedral angle of 81.2°. There 
is intramolecular hydrogen bonding between the coordinated ammine and the oxygen 
atom of the 5'-phosphate group. Similarly, the trinucleotide structure has a head-to-
head orientation of the guanine bases, with an average dihedral angle of 82°. Also, 
there is a weak intramolecular hydrogen bond between the NH3 ligand and 06 of the 
central guanine. 
Figure 1.7 X-ray crystal structures of A) d(pGpG) containing a cis-GG Pt adduct [331 
and B) d(CpGpG) containing a cis-GG Pt adduct. 34 
More recently, several structures of 1 ,2-dGG adducts have been determined 
in longer oligonucleotides (8-12 base pairs) by X-ray crystallography [35, 361 and NMR 
spectroscopy. [17-391  These indicated a bending and unwinding of the DNA duplex 
structure. Takahara et al.135' 361  determined an important X-ray structure of a DNA 
dodecamer duplex containing a 1 ,2-intrastrand cross-link, Figure 1.8. The structure 
contained two molecules in the asymmetric unit with very similar structures. The two 
12 
Figure 1.8 X-ray crystal structure of d(CCTCTG*G*TCTCC).d(GGAGACCAGAGG), 
where G*G*  represents the platination site of cis-{Pt(NH3)2}2t 35' 361  
Figure 1.9 NMR solution structure of d(CCTCTG*G*TCTCC).d(GGAGACCAGAGG), 
where G*G*  represents the platination site of cis-{Pt(NH3)2}239  
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duplexes show a significant bend towards the major groove (39° and 550).  The 
dihedral angle between the guanine bases is 300,  considerably less than that of the 
d(pGpG) and d(CpGpG) structures. A consequence of the platinum binding is a 
widened shallow minor groove, a feature that may be important for protein 
recognition and anticancer activity. 
An NMR structure of the same platinated dodecamer duplex has been 
determined, t391  allowing comparison of solid and solution phase structures. This 
structure (Figure 1.9) shows an overall helix bend of 78° and a dihedral angle 
between adjacent guanines of 47°. These values are larger than those observed for 
the crystal structure reflecting the influence of crystal packing. The base pairing is 
also more distorted in the solution structure but overall, the helix structure is similar 
with a wide flat minor groove. 
1.2.1.2 Protein Recognition of Cisplatin-DNA Adducts 
Since the discovery of a protein that preferentially binds to cisplatin-damaged 
DNA,t401 the HMG protein, many such proteins have been identified with similar 
binding affinities toward cisplatin-modified DNA. These proteins may participate in 
the DNA-repair process, but their in vivo function is largely unknown. Damage 
recognition proteins reported to bind to the kink in DNA induced by cisplatin adducts 
have been reviewed, t281  and include the XPA-RPA complex, the TATA-box binding 
protein TBP, hMSH2, and nonhistone HMG1 and HMG2.t28 29, 41-431 Although it is 
evident that multiple factors are involved, the recognition of adducts by these 
proteins may be the first step towards the triggering of apoptosis. 
The HMG (high mobility group) proteins have been studied the most 
extensively. [21, 	HMG domains are DNA-binding motifs of approximately 80 
14 
amino acids that bind specifically to kinks in DNA. The crystal structure of a 
cisplatin-1,2 GpG adduct in an oligonucleotide complexed with a HMG protein has 
been reported 1291  (Figure 1.10). The HMG domain specifically recognises the kinks 
formed by 1,2 adducts of cisplatin with GpG and ApG, but not the less kinked 1,3-
d(G-X-G) adducts. t43' 451  
Figure 1.10 X-ray crystal structure of a UMG1 protein bound to a cisplatin I ,2-GG 
intrastrand adduct. [291 
1.2.1.3 Pt - Sulfur Interactions 
Although the major target for cisplatin in cells appears to be DNA, many 
other molecules can react with the platinum compound. Pt(II) being a 'soft' metal ion 
is known to have a very high affinity for 'soft' ligand atoms such as sulfur. Sulfur-
containing ligands, e.g. glutathione, N-acetyl-L-cysteine, have been investigated as 
15 
rescue agents for the removal of platinum from the body. The amino acid and 
thioether L-methionine (L-HMet) is thought to play an important role in the 
metabolism of cisplatin. One of the few characterised metabolites of cisplatin is Pt(L-
Met)7 which has been isolated from urinej461 [Pt(L-Met)2] exists as a mixture of cis 
and trans isomers in aqueous solution,F47 48] Figure 1 .I1. At neutral pH the isomers 
interconvert extremely slowly (half-lives of 22.4 h and 3.2 h for the cis and trans 
isomers respectively, at 310K) with the cis isomer predominating at equilibrium 
(10:1, K = 7.0). [41] 
ooc 	 coo ooc 	CH3 
tH2  H2 / 	 \ H2 	I 
ii 
CH3 CH3 	 CH3 2 
Figure 1.11 Cis and trans isomers of[Pt(L-Met)2] in aqueous solution. 
The sulfur-containing tripeptide glutathione (y-Glu-Cys-Gly)(Figure 1.12) is 
present in cells at millimolar concentrations. The formation of Pt:GSH complexes 
may play an important role in the biological activity of platinum complexes. GS-Pt 
complexes can be pumped out of cells through an ATP-dependent process. 49' 50' 
0 	 0 	 0 




Figure 1.12 The sulfur-containing tripeptide glutathione (GSH). 
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During the reaction of cis-[PtC12(15NH3)2] with GSH, the monosubstituted complex 
cis-[PtCI(SG)('5NH3)2] is formed first, but several other species containing a 
Pt-S linkage are present within a few minutes. [5  Release of "_NH3  ligands has been 
observed and no coordinated 15  NH3  is contained in the final product, which is 
consistent with a high molecular mass polymer with a 1:2 Pt:GSH stoichiometry. A 
product containing a dinuclear Pt2S2 four-membered ring has been observed from 
reactions of cis-[Pt(NH3)2(H2O)2]2 with GSH . 52 ' Glutathione can also affect the 
macrochelate ring closure of cis- and trans-platin monofunctional adducts on 
DNA. 53' Compared with cisplatin, the reaction between GSH and transplatin 
monofunctional adduct more rapidly leads to the formation of sulfur-bound, 
glutathione-trapped monofunctional adducts. GSH does not appear to react with cis-
or trans-platin bifunctional adducts. These results are consistent with proposals that 
the biological inactivity of transpiatin may arise from selective trapping of 
monofunctional adducts before they ring-close to form bifunctional lesions. 
Metallothionein (MT) is a low-molecular-weight protein rich in cysteine 
(30%) and thought to be responsible for cisplatin detoxification. The tetrapeptide 
Boc-Cys(SMe)-Ser-Ala-Cys(SMe)-CONH2(CSAC) has been used as a model for MT 
for reactions of cis- and trans-platinJ 41 The reaction with cisplatin forms a mixture 
of different stereoisomers and polymeric species, with NH3 liberation due to the 
strong trans-effect of sulfur. Transplatin, on the other hand, forms a 2:1 complex 
coordinated to the —S-CH3 groups and no amine release is observed. 
Therapeutic nucleophilic agents for cisplatin, such as Na(ddtc) (sodium 
diethyldithiocarbamate) and thiourea, can help to remove platinum from certain 
proteins so as to relieve toxicity. 1 The mechanism may be based on the relatively 
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easy reversal of platinum binding to methionine side chains. In contrast, 
nephrotoxicity, thought to be caused by formation of Pt-cysteine adducts (Pt(II) 
thiolate bonds), cannot be reversed by Na(ddtc) and thiourea. 
Although the kinetic reactivity of sulfur is high, the Pt-thioether bond is labile 
in the presence of other nucleophiles)251 This could provide a novel pathway for 
DNA platination. The competitive binding of Met, His, 5'-GMP, 5'-AMP, 5'-TMP 
and 5'-CMP to {Pt(dien)Cl} in aqueous solution shows that 5'-GMP selectively 
displaces S-bound Met. Initially only L-Met coordinates to platinum with little GMP 
coordination, but in the later stages of the reaction coordinated L-Met is displaced by 
N7 of GM p.511It  is notable that thioethers such as L-Met react with Pt(II) amines 
faster than thiols such as GSH, and reactions of thiols tend to be irreversible. 571  
1.2.1.4 Resistance Mechanisms 
The occurrence of resistance in cancer chemotherapy is a common problem, 
and cisplatin is no exception. Some types of cancer are intrinsically insensitive to 
cisplatin treatment, whereas other cancers develop resistance during the 
chemotherapy. The mechanisms of resistance against cisplatin can be divided into 
two groups: I) mechanisms that prevent cisplatin reaching its therapeutic target, 
DNA, and 2) mechanisms that block the induction of apoptosis after the formation of 
the cisPt-DNA adduct. In resistant cancer cells, several resistance mechanisms often 
act simultaneously. 
Decreased uptake/increased efflux leads to lower intracellular drug 
concentrations. 581 As a result, higher drug doses are needed to induce the same 
amount of cell damage. A more established mechanism of resistance is the 
scavenging of platinum drugs by intracellular thiol-containing molecules, especially 
EI 
glutathione (GSH) which is available in cells at high concentrations (0.5-10 mM). 591  
Glutathione reacts with platinum drugs to form deactivated conjugates that are 
readily excreted by a glutathione S-conjugate export pump. 49' Raised intracellular 
concentrations of GSH often correlate with cisplatin resistance, but other platinum 
complexes may be less sensitive towards GSH deactivation. 601  
An important resistance mechanism that occurs after platinum binding is the 
repair of DNA damage. For I ,2-intrastrand adducts of cisplatin, the nucleotide 
excision repair (NER) system is of particular importance. ôH  The mechanism 
recognises the kink induced by cisplatin, and subsequently excises the part of the 
DNA strand that includes the kink. The gap that remains is then filled again by DNA 
polymerase. 
The post-binding mechanism described as 'increased tolerance' is probably 
one of the most general resistance mechanisms encountered in cancer 
chemotherapy)62' 631  In this case, the cellular damage inflicted by the drug fails to kill 
the cancer cell. This phenomenon is generally associated with the failure of apoptotic 
pathways. In order to trigger apoptosis, it is believed the cellular damage has to pass 
a certain threshold level. However, damaged genes are common in cancer cells, and 
proteins involved in the apoptotic pathways often malfunction, thus making certain 
cancer types rather insensitive to damage. In particular cancer apoptosis is very hard 
to trigger, although all cells may eventually be killed when cellular damage rises to 
levels where essential processes are simply not functioning anymore. '63' 
19 
1.3 Development of New Platinum Anticancer Drugs 
Although cisplatin is currently one of the best-selling anticancer drugs in the 
world there are still many drawbacks associated with it. Patients treated with the drug 
experience many toxic side effects including nausea, vomiting, loss of high 
frequency hearing and kidney toxicity. Drug resistance is also a problem as some cell 
lines are not affected by the drug. So far, cisplatin is used only against testicular and 
ovarian cancers and increasingly against cervical, bladder and head/neck tumours. 
More recently trials have shown acquired drug resistance developing in certain 
tumours after repeated treatment with the drug. In an attempt to overcome these 
problems over 3000 platinum compounds have been synthesised and tested for 
antitumour activity. 1281  In order to design new drugs in a logical manner, a set of 
structure-activity relationships (SARs) was established for platinum compounds with 
the general formula cis-[PtX2(Am)2] (in which X is an anionic leaving group and Am 
is ammonia, primary or secondary amine), and include the following: [64]  
the complexes exchange only some of their ligands quickly in reactions with 
biomolecules, 
the complexes should be neutral, although the active form may be charged 
after undergoing ligand exchanges, 
the leaving groups (e.g. Cl in cisplatin) should be in the cis configuration and 
their lability should be neither too high nor too low, 
relatively inert amine type systems are required and there must be at least one 
N-H group on the amine. 
These restrictions led to a second generation of platinum drugs, all of which were 
analogues of cisplatin containing two cis primary or secondary amine groups and two 
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anionic leaving groups. 
1.3.1 Cisplatin Derivatives 
The structures of some interesting new platinum compounds are shown in Figure 
1.13. The most successful of these second generation platinum compounds is 
carboplatin (1). Since its introduction in 1986 it has largely replaced cisplatin in the 
treatment of many platinum-sensitive malignancies. Carboplatin has less severe side 
effects and nephrotoxicity and vomiting are reduced but it is cross-resistant with 
cisplatin. Its activity is equivalent to cisplatin in the treatment of ovarian cancers, but 




















Figure 1.13 Second generation Pt anticancer agents, clinically approved or in human 
trials. 
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Two other second generation compounds have been approved for clinical use. 
Nedaplatin (2) has been approved for use in Japan, [66]  and oxaliplatin (3) has been 
approved in France, Asia and Latin America. 166' 671  Both are effective in the treatment 
of lung, colorectal and ovarian cancers. However, like carboplatin, nedaplatin is 
cross-resistant with cisplatin, meaning that these drugs are affected by the same 
resistance mechanisms. 1681 This may be related to the fact that the drugs form the 
same type of DNA damage. Thus, although useful for patients suffering from toxic 
side effects, these cisplatin derivatives are not expected to circumvent the resistance 
problem. 
On the other hand, oxaliplatin can circumvent cisplatin resistance and is 
being increasingly used in chemotherapyJ671 Oxaliplatin features a dicarboxylate 
leaving group and a chelating 1 ,2-diaminocyclohexane carrier ligand which increases 
the lipophilicity, which helps the drug to permeate cell membranes. The DNA 
adducts of oxaliplatin are more effective than those of cisplatin in inhibiting DNA 
chain elongationJ691 Better cellular uptake and different DNA adducts are believed to 
help oxaliplatin in circumventing cisplatin resistance mechanisms. In clinical trials, 
oxaliplatin displayed activity against a wide range of tumours, but neurotoxicity is a 
dose-limiting factor in its clinical useJ66' Most recently, oxaliplatin has been 
approved in the USA for the treatment of colorectal cancer. [70] 
The complex JM216 (4), also known as satraplatin, was shown to have 
superior activity against cervical, small cell lung, and ovarian cancer cell lines. [711 
This Pt(IV) complex has a big advantage over most Pt(II) drugs as it can be 
administered orally. This is much more convenient for patients and also reduces costs 
of therapy. Moreover, JM2 16 circumvents cisplatinlcarboplatin resistance and 
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showed low nephrotoxicity and neurotoxicity in phase I clinical trials. 721 Phase II 
trials are ongoing and some results have been reported. 171  The decreased toxicity is 
thought to be due to the fact that Pt(IV) complexes are kinetically more inert than 
Pt(II) complexes. It is known that the Pt(IV) complex undergoes a biotransformation 
into its Pt(II) analogue in patients, and thus acts as a prodrug.1731 
Another promising complex currently in clinical trials is cis-[PtCl2(NH3)(2-
picoline)1 (AMD473) (5)1741  which will be further discussed in Section 1.4. The steric 
hindrance exerted by the methyl group of the 2-picoline ligand makes this compound 
less reactive, especially with respect to deactivating scavengers such as 
glutathioneJ75' 761  AMD473 was found to be active against cisplatin-resistant 
tumours, and has been shown to be orally active in preclinical tumour models. 711 It 
has the added advantage that it lacks nephrotoxicity. Also, this complex appears to 
form a highly stereoselective G*G*  adduct with duplex DNA which may be 
recognised differently to that of cisplatin by the excision repair system. [771 
1.3.2 New Concepts in Platinum Anticancer Chemistry 
Although the second generation of platinum drugs is less toxic than cisplatin, 
many appear to be cross-resistant with cisplatin. In the last decade, nearly all the 
previously accepted structure activity relationships (SARs) have been disproved and 
now new generations of drugs are being designed with much more widely ranging 
structures. Requirements which are influencing the search for new generations of 
active complexes include (1) lower toxicity to normal cells than cisplatin, (2) activity 
against tumours with acquired cisplatin resistance, (3) activity against a wider 
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Figure 1.14 Lobaplatin (6) and cis-bis(neodecanoato)(trans-R,R-1 ,2 diaminocyclo-
hexane)Pt" (7). 
There are currently various platinum complexes at different stages of clinical 
trials. Laboplatin, 6, (Figure 1.14) which has a cyclobutane-derived carrier group, 
and lactate as a leaving group, was introduced into clinical trials in 1992. Lobaplatin 
has been approved in China for the treatment of chronic myelogenous leukaemia 
(CML) and inoperable, metastatic breast and small cell lung cancer. 781 It has also 
completed phase II trials in the US, Australia, Europe, Brazil and South Africa for 
the treatment of several cancers including oesophageal, lung and ovarian cancers as 
well as CML.1781 Complex 7 (Figure 1.14), cis-bi s(neodecanoato) (trans- R, R-1,2 
diaminocyclohexane) platinum(lI), is a liposome-incorporated lipophilic cisplatin 
analogue with in vivo activity against liver metastases and tumours resistant to 
cisplatin 791 and is currently under clinical evaluation. This drug may be activated by 
forming intermediates in lipid bilayers, and the activity is highly dependent on the 
presence of liposomes.1801 The only active intermediate identified so far is cis-
dichloro-trans-R, R- 1 ,2-diaminocyclohexane platinum(II) ["I  
1.3.2.1 Multinuclear Platinum Complexes 
Dinuclear and trinuclear compounds present a new class of platinum 
anticancer complexes (Figure 1.15). BBR3005 (8) is a dinuclear complex that 
exhibits antitumour activity especially in cisplatin-resistant cell lines. Binding studies 
24 
showed that DNA binding for this compound is different to that of cisplatin, as 
illustrated by the increased interstrand cross- linking.182' 83]  In June 1998 the trinuclear 
complex BBR3464 (9) entered phase I clinical trials and is currently in phase II 
clinical trials in the UK. 
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Figure 1.15 Multinuclear Pt complexes BBR3005 (8) and BBR3464 (9). 
The central platinum unit is capable only of H-bonding interactions with 
DNA. 84' The overall charge (+4) greatly enhances DNA affinity, which is 
characterised by long-range inter- and intra-strand cross-linking and irreversible 
conversion of B- to Z- DNA. [14, 851 In contrast to cisplatin, DNA intrastrand adducts 
induced by BBR3464 do not lead to DNA bending and are not recognised by high 
mobility group (HMG) proteins, which recognise cisplatin-damaged DNA. These 
features could be a critical reason for the ability of BBR3464 to overcome cisplatin 
resistance. BBR3464 is approximately 40-fold more potent than cisplatin on a molar 
basis and is active in both cisplatin-sensitive and cisplatin-resistant tumour 
models. [85] 
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1.3.2.2 Trans Platinum Complexes 
Trans platinum complexes are another class of compounds where reduction 
of activity has lead to improved anticancer drugs. The trans isomer of cisplatin, 
trans-[PtCl2(NH3)2] (10) is clinically inactive. [861  Reasons that have been invoked to 
explain the lack of antitumour activity of transpiatin include its inability to form the 
I ,2-intrastrand cross-link and structural differences between interstrand cross- 
links. 861  
H3N/CI 	 Pt 
C1'0 	NH3 	Cl'0 
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Figure 1.16 Trans Pt complexes. 
Whereas cisplatin forms a 1 ,2-intrastrand cross-link between guanines of adjacent 
base pairs, definitive evidence shows that monofunctional adducts of transplatin 
slowly transform into interstrand adducts involving guanine-N7 and complementary 
cytosine-N3 of the same base pair. 87' 881 However, substitution of the ammonia 
ligands has lead to an increasing number of antitumour-active trans complexes. [86] 
Apart from the fact that trans complexes form DNA adducts different from cisplatin, 
there are also indications that preliminary deactivation by binding to proteins and 
other non-DNA components is an explanation for the lack of anticancer activity of 
transplatinJ89' 90]  Sterically more demanding ligands, as in cis-[PtC12(NH3)(2-pic)], 
may reduce the detoxification reactions, thus evading preliminary detoxification 
before binding to DNA. 
The four known types of antitumour active mononuclear trans compounds 
are:1901 1) trans-Pt(II)C12 complexes with planar aromatic ligands (11, 12), 2) trans-
iminoether compounds (13), 3) trans-Pt(I1)C12 compounds with asymmetric aliphatic 
amines (14), and 4) trans-Pt(IV) mixed amine complexes(15), Figure 1.16. 
For the first class, trans-Pt(1I)C12 complexes with planar aromatic ligands, 
three distinct series of trans- [PtCl2(L)(L!)][9H  complexes were examined: a) L = L' 
pyridine, N-methylimidizole, or thiazole b) L = quinoline and U = RR'SO (R = Me, 
= Me, Bz or Ph) and c) L = quinoline or thiazole and L' = NH3. In general, the 
cytotoxicity of all trans complexes examined was approximately one order of 
magnitude greater than that of transplatin and furthermore, the trans complexes were 
at least as cytotoxic as their direct cis-analogues. 921 As a general feature, trans 
complexes with bulky planar ligands were not cross-resistant to cisplatin (the 
resistance factor defined as IC50 (acquired resistance cells)/IC50 (sensitive cells), was 
< 1) in both murine L1210 leukaemia and human ovarian tumour cells resistant to 
cisplatin. 921 Importantly, the thiazole complex, trans- [PtCl2(NH3)(tz)], also shows in 
vivo antileukaemic activity, thus overcoming the main caveat of trans bispyridine 
complexes, i.e. the lack of in vivo efficacy. [90] 
The enhanced cytotoxic potency of trans-platinum complexes with pyridine-
like ligands along with their ability to overcome cisplatin resistance disclosed novel 
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mechanistic implications, suggesting that complexes structurally different from 
cisplatin may be characterised by distinct cellular pharmacological properties. 
Coluccia and Natile 931 have reported another class of active trans-platinum 
complexes having the general formula trans-[PtC12(iminoether)2] or trans-
[PtC12(NH3)(iminoether)J, where iminoether = HN=C(OR)R'. Iminoether ligands are 
unsymmetrical with the possibility of isomerism within the ligand moiety. The in 
vitro cell growth inhibitory activity was evaluated in comparison to those of cisplatin 
in a panel of human tumour cell lines containing examples of ovarian, colon, lung 
and breast cancers, as well as a subline of ovarian cancer cells with acquired 
resistance to cisplatin (A2780/cp8))941 The trans- im i noether compounds showed a 
growth inhibitory potency similar to that of cisplatin (mean IC50 = 8 jiM). Moreover, 
trans- i mi noether compounds were able to circumvent the cisplatin resistance of 
A2780/cp8 cells which are characterised by having a reduced cisplatin accumulation 
and greater intracellular glutathione content with respect to the parental cell line. The 
trans- {PtC12(NH3)(iminoether)] compounds also showed cytotoxic potency higher 
than that of transplatin in a panel of human tumour cell lines. 
Compounds with asymmetric aliphatic amines, such as the trans-
[PtC12(amine)(isopropylamine)] complexes, exhibit activity comparable to that of 
cisplatin. 95' 961 These compounds have IC50 values lower than that of cisplatin in HL-
60 leukaemic cells (tumour cells overexpressing c-myc and N-ras oncogenes).1951 The 
same complexes exhibit IC50 values significantly lower than those of cisplatin against 
cisplatin resistant murine keratinocytes transformed by H-ras oncogene (Pam 21 2-ras 
cells). Contrary to cisplatin, these complexes display a much lower cytotoxicity in 
normal Pam 212 murine keratinocytes than in Pam 212-ras transformed murine 
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keratinocytes. [96]  Trans- [PtCl2(dimethylamine)(isopropylamine)] is also able to 
circumvent resistance to cisplatin in A2780 cells. [971 
The fourth class of active trans-platinum compounds are the trans-
[Pt"C12X2(L)(L')] complexes where X = hydroxide, carbamate or carboxylate, L = 
amine and U = ammine. Many of these trans complexes studied in vitro against a 
panel of human cell lines exhibited comparable potency to cisplatin and also 
overcame acquired cisplatin resistance (mainly due to either reduced uptake or 
enhanced platinum-DNA removal)J981  Fourteen of these trans complexes showed 
significant in vivo antitumour activity against the subcutaneous murine ADJ/PC6 
plasmacytoma model. All were Pt IV  complexes possessing axial hydroxide ligands, 
except one which had axial ethylcarbamate ligands. When tested, all of their 
dichloroplatinum(I I) or tetrachloroplatinurn(IV) counterparts were inactive. 
1.4 AMD473 
Cis- [PtCl2(NH3)(2-picoline)] (AMD473), is a recently reported anticancer 
complex for which phase I and phase II clinical trials are currently underway in a 
range of tumour types, including lung, colorectal and small cell lung cancers. 99' 
AMD473 has demonstrated promising activity against several tumours including 
ovarian, lung and breast. It was developed at the Institute of Cancer Research, in 
collaboration with Johnson Matthey Technology Centre/AnorMED, and has recently 
been licensed to NeoRx Corporation, Seattle. AMD473 is reported to possess activity 
against cisplatin-resistant cell lines, and against an acquired cisplatin-resistant 
subline of a human ovarian carcinoma xenograph, by injection and oral 
administrationJ'°°1 It showed significantly reduced cross-resistance to cisplatin in a 
panel of three cell lines with known acquired platinum drug resistance mechanisms: 
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reduced accumulation, increased cytoplasmic detoxification by cellular thiols and 
increased DNA repair/tolerance of Pt-DNA adducts. °'1 The toxicity of AMD473 is 
also greatly reduced, with no renal toxicity observedj1001 
AMD473 was designed specifically to circumvent thiol mediated drug 
resistance by sterically hindering its reaction with glutathione (GSH), but still having 
the ability to form cytotoxic lesions with DNA. Interestingly, AMD473 also 
circumvents cisplatin resistance in tumour cell lines where cisplatin resistance is 
known to include some non-glutathione based mechanisms. '°21  
The crystal structure of AMD4731751 showed that the complex has a typical 
square-planar configuration. The most notable feature is the orientation of the 
picoline ring which is almost perpendicular (103°) to the platinum square-plane, so 
that the 2-methyl group lies directly over the Pt centre. This introduces steric 
hindrance to an axial approach to platinum from above, leading to a destabilisation of 
the expected bipyramidal transition state. 
Hydrolysis may be an important step in the intracellular activation and 
interaction with DNA. Hydrolysis rates and pKa values of AMD473 have been 
determined using ['H, t5N] NMR spectroscopy. [751  The Cl- ligand cis to 2-picoline 
(trans to NH3) hydrolyses about 4 times more slowly than that in cispIatin 22 4112 = 
8.7 h at 310 K, compared with 1.9 h for cisplatin), whilst the Cl- ligand trans to 2-
picoline (cis to NH3) hydrolyses about three times more slowly than that in cisplatin 
(t172 = 6.0 h at 310 K). The PKa values for the monoaqua adduct are 6.13 and 6.49, 
and values of 5.22 and 7.16 are reported for the diaqua adduct, all of which are> 0.3 
units lower than for cisplatinJ231 The slowness of the hydrolysis, combined with the 
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dominance of (inert) hydroxo species, is expected to contribute to a greatly reduced 
reactivity of AMD473 under intracellular conditions. 
1.5 Aims of this Thesis 
The overall aim of this thesis is to generate a greater understanding of the 
chemical and biochemical properties of sterically hindered Pt" compounds, including 
the anticancer drug AMD473, to aid the development of more novel platinum 
chemotherapeutic agents, capable of further improving antitumour activity in 
resistant tumours. 
In order to investigate the influence of steric hindrance on trans Pt" 
complexes, the initial challenge is to synthesise and perform a full structural 
characterisation of a series of trans picoline complexes. As hydrolysis may be an 
important step in the mechanism of action of such compounds with DNA, the 
determination of hydrolysis rates and pKa values will be investigated also. 
To gain further insight into stereochemical effects on the structure and 
dynamics of nucleobase adducts in solution and in the solid state, a study will be 
undertaken of AMD473 and its trans isomer, trans- [PtC12(NH3)(2-pic)](AMD443), 
with the mode! nucleobase 9-ethylguanine (9-EtGH). This work will also be 
extended to include the investigation of nucleosides. The kinetics of the reaction of 
aquated AMD473 with guanosine will be studied and nucleoside adducts of both 
AMD473 and AMD443 will be characterised. 
Since DNA is the major target for Pt" drugs in the body, it is of much interest 
to study the interaction of trans- [PtC12(NH3)(2-pic)] with duplex DNA, which is 
likely to form distinct adducts with both its cis isomer and cisplatin. 
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Finally, the nature of interactions with small sulphur-containing biomolecules 
is of particular significance for such sterically hindered Pt complexes, as a reduced 
susceptibility to deactivating molecules such as glutathione could lead to enhanced 
anticancer activity. Studies will be performed using the dominant intracellular thiol, 
glutathione, and the thioether methionine. 
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2.1 NMR Spectroscopy 
NMR signals were first recorded in 1946 and can now routinely be detected 
for almost any magnetic nucleus. Many textbooks have been published describing 
the theory and applications of NMR.H81 
Nuclear magnetic moments are exquisitely sensitive to their surroundings and 
yet interact very weakly with them. When a magnetic nucleus is placed in a magnetic 
field, it adopts one of a number of allowed orientations of different energy. For 
example, the nucleus of the hydrogen atom (a proton) has just two permitted 
orientations. The magnetic moment can point in the same direction as the field or in 
the opposite direction. These two states are separated by an energy AE, which 
depends on the strength of interaction between the nucleus and the field, i.e. on the 
size of the nuclear magnetic moment and the strength of the magnetic field. AE may 
be measured by applying electromagnetic radiation of frequency v, which causes 
nuclei to flip from the lower energy level to the upper one, provided the resonance 
condition AE = hv (h is Planck's constant) is satisfied. This is nuclear magnetic 
resonance spectroscopy. 
The magnetic properties of some useful nuclei are listed in Table 2.1 •18, 91 The 
most important aspects of '5N and 195  Pt NMR spectroscopy are reviewed here. A 
selection of 2D correlation NMR techniques, relevant to this thesis, will also be 
mentioned. 
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Table 2.1 NMR properties of common nuclei (in an 11.74 T magnetic field).18' 91  
Nucleus % Natural Spin Gyromagnetic Resonant Relative 
Abundance Quantum Ratio Frequency Sensitivity 
Number (1) (107  rad T' s1) (MHz) 
99.98 V2 26.75 500.00 1.00 
2H 0.02 1 4.11 76.75 1.5 x 106 
1.11 V2 6.73 125.72 1.8x 10 
14 N 99.63 1 1.93 36.12 1.0 x 10 
0.37 -2.71 50.66 3.9 x 106 
195 Pt 33.8 '/2 5.77 107.50 3.4 X 10 
2.1.1 195Pt NMR Spectroscopy 9' 
195 pt is a reasonably sensitive nucleus for NMR detection, with natural 
abundance of 33.8%, nuclear spin quantum number I = V2, and a receptivity relative 
to 'H of 3.4x 10. 
The 19 Pt chemical shift range is very large, about 15000 ppm (usually in the 
range from -6000 to 9000 ppm relative to [PtCI6]2 ), and often allows easy 
differentiation between Pt"  and PtW,  which tend to have chemical shifts at the high-
field and low-fields ends of the range, respectively. The 19 Pt chemical shift in 
monomeric complexes is sensitive primarily to the set of bound donor atoms. Some 
caution is required in searching for peaks, because the shifts of PtR'  halides alone 
span 12000 ppm. Also, usually there are 1 95p chemical shift differences between 
geometrical isomers and between diastereomers (chiral ligands). For 15N-enriched 
ligands, the splitting pattern in the 195Pt spectrum indicates the number of non-
equivalent 15N atoms coordinated. These characteristics of the 195Pt chemical shift 
can be utilised in the detection of different intermediates formed during the reactions 
of Pt complexes with biomolecules. Sometimes even isotopomers are 
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distinguishable: the 195  Pt isotope shift difference for 195Pt-35137C1 is 0.17 ppm and for 
195Pt-79181 Br is 0.03 ppmJ10' It is therefore in principle possible to count the number 
of Cl and Br ligands bonded to Pt via the isotope splitting pattern. In practice it is 
difficult to resolve because of line broadening, which is usually due to either 
relaxation mechanisms or poor temperature control of the sample. The latter is a 
problem because of the strong temperature dependence of 195  Pt NMR resonances (0.5 
to 1.1 ppm/ K). The spin-lattice relaxation time (T1 ) for 195Pt is usually in the range 
of 0.3 to 1.3s. 
The quadrupolar effects of natural abundance '4N (i.e. 99.6% '4N, I = I) from 
am(m)ines which coordinate to Pt can broaden the 195  Pt resonances. Such 
quadrupolar effects of '4N have the beneficial effects of shortening the 
195  Pt 
relaxation times and allowing rapid pulsing without saturation effects. '9  Pt- '4N 
couplings in 195Pt NMR spectra are usually better resolved at higher temperature, 
because of the decreased quadrupolar relaxation rate of '4N due to the decrease in 
correlation time. Even in the absence of ' 4N ligands, 195  Pt resonances can still be 
very broad owing to chemical shift anisotropy (CSA) relaxation, which can be the 
dominant relaxation mechanism for Pt complexes at high magnetic field stength. The 
limit of detection (ca. 10 mM) precludes detection of natural abundance 195Pt signals 
at physiologically relevant concentrations and has therefore not been used in this 
thesis. The receptivity can be improved by a factor of three by isotopic enrichment of 
'95 t (> 95%). 
195Pt satellites in '5N and 'H spectra of Pt" complexes are often broadened 
beyond detection owing to CSA relaxation of Pt.['H  The linewidths of 195Pt 
satellites of 'H NMR resonances are dependent on the spin-lattice relaxation time of 
195 Pt: 
Av 2(H) = [7tT2*(H)T I + [27rTi (Pt)]- ' 
where [ltT2*(H)]-'  is the natural linewidth plus the contribution from magnetic 
inhomogenity broadening (measurable from the linewidth of the centre peak). The 
contribution to 195  Pt T, relaxation from CSA is given by: 
[icT,(Pt)]' (CSA) = (6/7)X[itT2(Pt)f' (CSA) = (2/15) X ypt2 X B02 X A 2 X Tc 
In general, 195Pt satellites (and 195  Pt resonances) are sharper in PtW complexes 
which are six coordinate and hence more symmetrical (smaller anisotropy A) and 
are broader at higher fields of measurement (Bo) and in larger molecules (longer 
correlation time 'ta). 
2.1.2 '5N NMR Spectroscopy 
'4N NMR spectroscopy can be useful for am(m)ine complexes, but '4N is a 
quadrupolar nucleus, and quadrupolar relaxation is dominant when the environment 
of '4N has a low symmetry. This can lead to very broad lines and a consequent 
reduction in sensitivity. On the other hand, short relaxation times also have the 
advantage of allowing rapid pulsing so that a large number of transients can be 
acquired. Thus, it is possible to follow reactions of cisplatin in blood plasma and cell 
culture media at millimolar drug concentrations and to detect ammine release. [12] 
By using '5N enriched am(m)ine complexes, the broadening of '9 Pt signals 
caused by the quadrupolar effects of '4N can be avoided. Both '5N NMR chemical 
shifts and 'J('95Pt-' 5N) coupling constants are sensitive to the nature of the trans 
ligand in Pt am(m)ine complexes, which can provide useful information for 
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identifying the ligands in the coordination spheres of both Pt(II) and Pt(IV) 
complexes. Typical '5N and 'H shift ranges for Pt(II) are shown in Figure 2.1. 
I 	H3N-Pt-0 	I 
15N 
7 	 6 	 5 	 4 	 3 
6 1 H 
Figure 2.1 Variation of 'H and ' 5N NMR chemical shifts with the trans ligand in 
Pt(II)-NH, Pt(lI)-NH2 and Pt(II)-NH3 complexes. 
In general, ligands (X) with high trans influences give rise to smaller X-195Pt-
15N coupling constants (X = S<I<Br<C1<H20) and cause a low-field shift of the ' 5N 
resonance. The dominant contribution to one-bond coupling constants between 195Pt 
and '5N is usually interpreted in terms of the Fermi contact interaction involving Pt 
6s and N 2s orbitals. '31 The usefulness of 'J(195Pt-15N) values is limited by the 
difficulty in determining them for larger molecules especially at high observation 
frequencies on account of the dominance of relaxation via chemical shift anisotropy 
(CSA). The 'J(195Pt-15N) values for Pt(IV) are smaller by a factor of about 1.5 to 1.2 
and are 1.4 times larger than 'J(195 Pt-14N) values. 
in 
The low receptivity of ' 5N (3.9 x 106  relative to 'H) limits to some extent its 
usefulness for directly-detected '5N NMR studies of Pt ammine and amine 
complexes. However, the sensitivity of detection can be improved by '5N isotopic 
enrichment combined with enhancement by polarization transfer from 'H (e.g. '5N-
{'H} DEPT and INEPT pulse sequences). The maximum enhancement in 15N signal 
intensity achievable via polarization transfer is only 9.8 (yH/yN), which means that 
inverse ('H-detected) ' 5N methods are usually preferred due to the superior 
enhancement for 1 5N-detection (vide infra). The repetition time of the pulse sequence 
is governed by the 'H rather than the longer '5N spin-lattice relaxation time (T,), 
which is an additional advantage because it allows more rapid pulsing. For example, 
' 5N-{'H} DEPT sequences enable detection of rapidly-changing intermediates in the 
reaction of 15N-cisplatin with glutathione, and also ammine release following the 
reaction of 15N-cisplatin with intracellular components in intact red blood cells at 
concentrations as low as I mM)141 
2.1.3 Water Suppression 
NMR spectra for biomolecules are normally obtained from aqueous media, 
such as D20 (99.9%) or H20/D20 (90%:10%, v/v). However, for metal anticancer 
complexes, such as Pt am(m)ine complexes, the Pt - NH 'H NMR resonances cannot 
be readily detected in D20 solutions because the half-life for H-D exchange is only a 
few minutes at ambient temperaturesJ15' 16]  In H20 solutions, the intense H20 peak 
causes severe dynamic range problems. Therefore, most studies in aqueous media are 
carried out in H20/D20 (90%:10%, v/v), the D20 being added to provide a field 
locking signal. Special techniques are needed to suppress the large HOD (or H20) 
signal. Presaturation and WATERGATE (WATER suppression by GrAdient 
FIE 
Tailored Excitation) were used in this study. 1171 The former method is applied by 
irradiation at the frequency of the HOD (H20) resonance during the relaxation delay 
between pulses, before the observe pulse in an experiment. The disadvantage is that 
exchangeable NH protons can also be saturated resulting in loss of intensity. The 
WATERGATE method uses selective 1800  pulse field gradients to select different 
coherence pathways, and yields superior water suppression. 
2.1.4 2D Spectra 
H SQC (heteronuclear single-quantum correlation) experiments allow 
identification of the chemical shifts of protons and X-nuclei that are directly coupled. 
One use of such correlations is to allow assignments already made for one nuclear 
species to be transferred to the other. A more important use is in overcoming 
problems caused by overlap in the proton spectrum: in the heteronuclear 2D 
spectrum the proton resonances are spread out according to the shifts of the 
heteronuclei to which they are coupled. 
The HSQC technique belongs to the family of indirect (or inverse) detection 
techniques. An important feature of the experiment is that the proton magnetisation 
which is detected during t2 originated as proton magnetisation at the start of the 
sequence. The major advantage of this technique is the sensitivity of detection, which 
is enhanced by a theoretical maximum of 306 {(IyH4yNI)512} with respect to directly 
detected '5N, such that signals can be detected from platinum am(m)ine complexes in 
aqueous solution at concentrations of physiological relevance.191 These methods are 
widely applicable to any complex which has a '5N atom with a measurable spin-spin 
coupling to 'H (i.e. ammine, primary and secondary amines, but not tertiary amines). 
IN 
In practice the best results are obtained with large one-bond couplings (about 73 Hz 
for 15 NH3). The basic HSQC pulse sequence is shown in Figure 2.2. 
90° 	1800 	900 	1800 	900 	1800 
	
IHW Lii JA  
1800 	900 	 90° 	1800 
xF1H fl_F flGARP dec.) 
Figure 2.2 Basic HSQC pulse sequence. The delays A = V2  J(X,l-I), where J is the 
one-bond HX coupling constant, and one-dimensional ' 5N-edited spectra are 
obtained by setting the evolution period t1 to zero. Spectra may be recorded with or 
without decoupling of '5N spins (GARP) during the acquisition period. 
The Pt - 15 NH protons can be detected selectively by the use of ['H,' 5N] 
single quantum coherence (HSQC) pulse sequences. A ID 'H spectrum containing 
only resonances from Pt - 15 NH species is obtained by acquiring only the first 
increment in a 2D experiment; resonances for CH and OH (including water) are 
eliminated. This is particularly useful in studies of body fluids or cell culture media, 
where only the signals from the platinum complexes are detected and thousands of 
other overlapping 'H resonances are filtered out. If '5N decoupling is employed 
during acquisition (e.g. the GARP method), then each type of Pt - NH resonance 
appears as a singlet. In practice, the water resonance is so intense that it is usually 
necessary to use additional solvent suppression techniques such as presaturation. The 
addition of an H20 T2 relaxation agent (e.g. 0.5 M (NH4)2SO4) can also be helpful to 
detect NH peaks very close to the H20 peak. A large improvement in water 
I 
suppression is achieved by the use of pulsed field gradients for coherence selection, 
for example, by use of the HSQC sequences of Stonehouse etal.1181 
(15N) 
Figure 2.3 General appearance of a 2D ['H,'5N] HSQC spectrum. The 
195  Pt satellites 
are usually more intense for symmetrical Pt species (Pt"' rather than Pt"). 
The combined detection of 'H and ' 5N in a 2D inverse NMR experiment is 
especially powerful, since both the '5N NMR chemical shift and the one-bond 
coupling constant 'J('H-'5N) are diagnostic of the trans ligand. As shown in Figure 
2.3, the '9'Pt satellites (when not broadened beyond detection by the effects of CSA 
relaxation) in a 2D ['H, '5N] spectrum appear as diagonal peaks which correspond to 
the 2J(19 Pt-1 H) coupling constant in the F-,(' H) dimension and to the 'J(195 Pt-15N) 
coupling in the F,('5N) dimension. Pt" and pt" am(m)ine complexes can be 
distinguished by the combination of 'H and 'N chemical shifts. 
COSY (correlated spectroscopy) is a two-dimensional homonuclear (H, H)-
correlated NMR experiment which yields NMR spectra in which 'H chemical shifts 
along both frequency axes are correlated with each other. '9' 201  It is the standard 2D 
experiment that can be used to identify pairs of protons that have scalar spin-spin 
1i] 
coupling connectivities. There are two inherent drawbacks that limit its usefulness 
with macromolecules: one is that the fine-structure components that make up each 
cross-peak appear in anti-phase; the other is that the diagonal peaks and the cross-
peaks are 900  out of phase in both dimensions. These give rise to poor sensitivity and 
extremely harsh weighting functions must be used to give spectra with usable line 
shapes which in turn gives a further reduction in sensitivity. 
TOCSY provides a different mechanism of coherence transfer than COSY 
for 2D correlation spectroscopy. 6' 211  In TOCSY, cross-peaks are generated between 
all members of a coupled spin network. An advantage is that the "net" coherence 
transfer produced can be arranged to create pure absorption mode spectra with 
positive intensity peaks (rather than "differential" coherence transfer which causes 
spectra with equal positive and negative intensities). In traditional COSY, cross-
peaks have zero integrated intensity and coherence transfer is restricted to directly 
spin-coupled nuclei. In TOCSY, oscillatory exchange is established which proceeds 
through the entire coupling network so that there can be net magnetisation transfer 
from one spin to another even without direct coupling. The isotropic mixing which 
occurs during the spin-lock period of the TOCSY sequence exchanges all in-phase as 
well as anti-phase coherences. 
The NOESY experiment 122, 231 is often used to identify pairs of protons that 
are undergoing cross-relaxation, i.e. protons that would show an NOE in 1D 
experiments. The characteristic feature of the NOESY pulse sequence is the mixing 
time t. The cross-peaks are generated by magnetisation transfer that takes place 
during the mixing time so the length of this delay must be chosen according to the 
rate of the transfer process. In contrast to the COSY experiment, both cross-peaks 
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and diagonal peaks in NOESY spectra can be obtained with absorption-mode 
lineshapes. The experiments are therefore very suitable for studying macromolecules. 
If presaturation is used in a NOESY experiment it is usually also necessary to 
irradiate the solvent during the mixing time. A complicated factor is that the NOESY 
pulse sequence cannot distinguish between magnetisation transfer caused by cross-
relaxation and magnetisation transfer by chemical exchange. In macromolecules, 
both give cross-peaks of the same sign as the diagonal. 
The ROESY experiment 15, 61 is a rotating frame NOESY that provides some 
advantages for small and medium-sized, as well as large molecules. Whereas the 
NOE decreases to zero and becomes negative as the mean correlation time, 're, for 
molecular rotation increases (larger molecules move more slowly), in the rotating 
frame the maximum NOE remains positive and even increases from 50 % to 67.5 %. 
The pulse sequence for ROESY is similar to TOCSY although the period of spin 
locking is chosen to optimise magnetisation transfer through the NOE (dipolar 
interactions) rather than through scalar couplings. In addition to greater signal 
enhancement, the ROESY experiment also decreases the effects of spin diffusion, so 
that it offers advantages for larger molecules. 
2.2 High Performance Liquid Chromatography (HPLC) 24' 
HPLC is one of the fastest developing analytical techniques. It has arisen 
from the theories of liquid chromatography (LC) and instrumentation that were 
originally developed for gas chromatography (GC). The mixture to be analysed is 
dissolved in a suitable solvent, injected at one end of the column, and carried through 
the column by a continuous flow of the same solvent (mobile phase). The separation 
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takes place in the column, which contains 'sorptive' particles of large surface area. 
These particles are referred to as the 'stationary phase'. Injected sample components 
interact reversibly with the stationary phase in a continuous manner. If a component 
mixture (a solute) is absorbed weakly onto the surface of the solid stationary phase it 
will travel down the column faster than another solute that is more strongly absorbed. 
The mobile phase is pumped through the column bed of tightly packed 
chromatographic particles using a solvent delivery system (pump). With the selection 
of proper mobile phase and column packing material, a separation of different 
components can be achieved. As the sample components emerge from the column, a 
suitable detector is used to monitor and transmit a signal to a recording device. The 
chromatogram is a record of the detector response as a function of time and indicates 
the presence of the components as peaks. 
Reverse phase (RP) chromatography is so named because it behaves in the 
opposite way to normal phase (NP) chromatography. The stationary phase is silica 
chemically bonded with an alkylsilyl compound to give a non-polar, hydrophobic 
surface. Solute retention is mainly due to hydrophobic interactions between the 
solutes and the hydrocarbonaceous stationary phase surface. Polar mobile phases, 
usually water mixed with methanol, acetonitrile and/or other water-miscible organic 
solvents, are used for elution. Solutes are eluted in order of decreasing polarity 
(increasing hydrophobicity), and increasing the polar (aqueous) component of the 
mobile phase increases the retention of the solutes. 
In analytical HPLC, the mobile phase is normally pumped through the 
column at a flow rate of 1-5 ml/min. If the composition of the mobile phase is 
constant, the method is called 'isocratic elution'. The composition of the mobile 
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phase can be a binary, ternary, or quaternary solvent mixture. Alternatively, the 
composition of the mobile phase can be made to change in a predetermined way 
during the separation, a technique called 'gradient elution'. Modern solvent delivery 
systems allow the selection of a wide range of gradient profiles and variation of the 
time over which the gradient is delivered. Besides the shape of the gradient, other 
factors including compatibility of the two solvents with the detector, and miscibility 
with the sample solution, have to be considered. 
Some of the important concepts defining the quality of a chromatographic 
separation are listed below. 
Capacity ratio or capacity factor, k' 
k1 '= 
t i  - to 	 t2 -to 
to to 
- where to is the retention time of an unretained compound, usually a solvent used to 
dissolve the solutes. It represents the column void volume and the peak is often 
referred to as the 'solvent front'; t1 and t2 are the retention times of compounds I and 
2 respectively. k!  is a measure of solute retention. 
Selectivity, a 
ki a = 
- a measures the ability of a column to separate components 1 and 2 due to different 
affinity and therefore retention. 
Efficiency of the column, which can be measured using quantities of plate number 
(N) and plate height (H). 
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N=l6I'--) 	 H= 
W1 ) N 
- ti is the retention time of the component, w1 is the peak width of solute 1, L and N 
are the length and plate number of the column, respectively, and H is the height. 
Resolution factor, R 
R = 	
t2 -tt 
0.5(w2 —w1 ) 
- R measures the resolution between two components and is dependent on k', a and 
N 
2.3 Mass Spectrometry 
Mass spectrometry is a versatile technique that can provide information on 
the elemental composition of samples of matter and the structures of inorganic, 
organic or biological molecules. The general principle of mass spectrometry is the 
conversion of an analyte sample into gaseous ions which are attracted through the 
slit of the mass spectrometer and separated according to their mass-to-charge 
ratios. A spectrum is provided which is like a bar chart depicting the relative 
intensity of mass peaks according to this ratio. The components of a mass 
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Figure 2.4 Components of a mass spectrometer. 
Electrospray lonisation 
Electrospray ionisation (ES 1)[11-281  is a desorption ion source where a sample 
in solution is converted directly into gaseous ions. It is a soft ion source in that it 
does not impart enough energy to the analyte molecules to fragment ions during 
analysis. 
An electrospray is produced by applying a strong electric field, under 
atmospheric pressure, to a liquid passing through a capillary tube with a weak flux 
(normally 1-10 p1/mm). The electric field is obtained by applying a potential 
difference of 3-6 kV between this capillary and the counter electrode, separated by 
0.3-2 cm. This field induces a charge accumulation at the liquid surface located at the 
end of the capillary, which will break to form highly charged droplets. Driven by the 
electric field, the droplets migrate towards the inlet end of the glass capillary at the 
end wall of the chamber. A drying gas at 320 to 350 K, encourages evaporation of 
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solvent from each droplet, decreasing its diameter. Consequently, the charge density 
at its surface increases until the Rayleigh limit is reached at which point the Coulomb 
repulsion becomes of the same order as the surface tension. The resulting instability 
tears the droplet apart, producing charged daughter droplets that also evaporate. This 
sequence of events repeats until the radius of curvature of the daughter droplet 
becomes small enough that the field due to the surface charge density is strong 
enough to desorb ions from the droplet into the ambient gas. 
The ESI mass spectra normally correspond to a statistical distribution of 
consecutive peaks characteristic of multiply charged molecular ions obtained through 
protonation (M + zH)', while avoiding the contributions from dissociations or from 
fragmentations. ES! can also be used in the case of molecules without any ionizable 
site through the formation of sodium, potassium, ammonium or other adducts. 
Obtaining multiply charged ions is advantageous as it improves the 
sensitivity and it allows the analysis of high molecular weight molecules using 
analysers with a weak nominal mass limit. 
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Chapter 3 
Hydrolysis of Cis and Trans Picoline 
Pt" Diamine Anticancer Compounds 
3.1 Abstract 
Cis-[PtC12(NH3)(2-picoline)] (AMD473) is currently on clinical trials as an 
anticancer drug. The trans isomer, AMD443 (1), is also cytotoxic in a variety of 
cancer cell lines. The X-ray crystal structure of the trans isomer (1) shows that the 
pyridine ring is tilted by 69° with respect to the platinum square-plane in contrast to 
the cis isomer in which it is almost perpendicular (103°). In the 3-picoline (2) and 4-
picoline (3) trans isomers, the ring is tilted by 58°/60° (2 molecules per unit cell) and 
by 56°, respectively. Hydrolysis may be an important step in the intracellular 
activation and anticancer mechanism of action of these complexes. The first 
hydrolysis step is relatively fast even at 277 K, with rate constants (determined by 
'H,'5N NMR) of k1 = 2.6 x 10 s_ I , 12.7 x 10 s 1 and 5.2 x 
10-5s1  (I = 0.1 M) for 
formation of the monoaqua complexes of 1, 2 and 3, respectively. Although the 
hydrolysis of 3 is slower than 2, it is hydrolysed to a greater extent. No formation of 
the diaqua complex was observed for any of the three complexes at 277 K, and it 
accounts for <3 % of the platinum species at 310 K. In general the extent of 
hydrolysis of the trans complexes is much less than for their cis analogues. The pKa 
values for the monoaqua adducts of 1, 2 and 3 were determined to be 5.55, 5.35 and 
5.39, respectively, suggesting that they would exist largely as the monohydroxo 
complex at physiological pH. The pKa values for the diaqua adducts were determined 
to be 4.03 and 7.01 for 1, 3.97 and 6.78 for 2, and 3.94 and 6.88 for 3, the first pKa 
being> 1 unit lower than for related cis complexes. 
rel 
3.2 Introduction 
Cisplatin is now a widely-used clinical drug for the treatment of various 
neoplastic diseases, including testicular and ovarian cancers, while its congener 
transplatin is therapeutically inactive)'I This observation, which is considered a 
paradigm for the Structure-Activity Relationships (SARs) of platinum-based 
antitumour compounds, has dominated development in this field for more than two 
decades. The SARs have aided the design of new drugs and guided attempts to 
overcome some of the drawbacks associated with cisplatin, such as nausea, 
neurotoxicity, nephrotoxicity and ototoxicity, as well as drug resistance. These SARs 
led to a second generation of platinum drugs, all of which are analogues of cisplatin 
containing two cis primary or secondary amine groups and two anionic leaving 
groups. The most successful of these is carboplatin, which has less severe side-
effects than cisplatinJ2' 3]  However, many of the second-generation platinum drugs 
appear to be cross-resistant with cisplatin. [4] 
Much recent research work has been aimed at the discovery of platinum 
complexes which are not cross-resistant with cisplatin, have fewer toxic side-effects, 
are active against a broader range of types of cancer, and can be administered orally. 
In 1989, two exceptions to the classic SAR were reported showing that the overall 
charge on the complex and the cis orientation of the N-bound ligands are not a 
prerequisite for antitumour activity of Pt" complexes. Hollis et al. 51 reported that 
positively-charged triaminemonochloroplatinum(II) complexes of the general 
formula [Pt(NH3)2(Am)Cl] (where Am = planar heterocyclic amine) possess 
antitumour activity. These complexes were neither neutral nor did they possess two 
cis weakly bound leaving groups. Subsequently, Farrell et al J61 reported that trans 
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platinum complexes with planar amine ligands have antitumour activity superior to 
transpiatin, especially in cisplatin-resistant cell lines. These were the first examples 
of platinum-based anticancer agents that defy the classic SARs. 
The presence of planar ligands in trans-[PtC12(L)2] (L = pyridine, thiazole) 
and 	trans- {PtCl2(NH3)(L)] (L = quinoline) complexes greatly enhances the 
cytotoxicity of such species, with respect to their corresponding cis isomers and also 
to transplatin.171 The cytotoxicity is further marked by high activity towards both 
sensitive and cisplatin-resistant murine leukaemia (L1210) cells (Table 3.1)J7' 81 
Thus, the activity is an order of magnitude greater than transpiatin. DNA interstrand 
cross-linking is enhanced relative to transplatin and conformational changes such as 
unwinding are accentuated in the presence of the planar ligand. The sequence 
specificity is also altered, with the trans complexes exhibiting a higher affinity for 
alternating purine-pyrimidine (GC) runsj91  
Table 3.1 Cytotoxicity of Pt" complexes in L1210 and cisplatin-resistant (L12I0R) 
leukaemia cells. 7' 8]  






cis-[PtC12(py)2] 4.4 3.3 
trans-[PtCl2(py)2] 1.2 1.1 
cis-[PtC12(tz)21 2.8 7.3 
trans-[PtCl2(tz)7] 1.6 7.4 
cis-[PtC12(NH3)(quin)] 0.5 2.8 
trans- [PtCl2(NH3)(quin)] 0.5 1.4 
cis-{PtC12(NH3)(tz)] 3.2 3.1 
trans-[PtC12(NH3)(tz)J 4.2 15.0 
cis-[PtCl2(NH3)2] 0.3 9.2 
trans-[PtC12(NH3)2] 15.7 22.0 
py = pyridine, tz = thiazole, quin = quinoline 
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Unfortunately, high antitumour activity of such trans complexes has not yet 
been obtained in vivo. Nevertheless, the observations on the enhanced cytotoxicity 
are important mechanistically, because they demonstrate that there is no restriction, 
per Se, to development of active antitumour trans platinum complexes. The 
mechanistic importance of these findings is also emphasised by the fact that the vast 
majority of studies examining the differences between cis- and trans-platin have 
been carried out in tissue culture or in cell-free systems. Factors such as water 
solubility and pharmacokineti c considerations (e.g. partition coefficient, drug 
metabolism and tissue distribution) may all contribute to in vivo deactivation of 
cytotoxic agents. 
Two major chemical differences between NH3 and a planar amine are 
evident: steric hindrance by the appropriately positioned H atoms of the ring system 
reduces chemical reactivity, and surface and stacking interactions become more 
pronounced over the H-bonding associated with the NH3 groups. These structural 
features suggest simple chemical solutions to the design of sequence-specific agents 
as well as using steric effects to prevent metabolic deactivation. 
An understanding of the aqueous chemistry of diamine Pt 11  complexes is 
crucial for establishing their mechanism of action. Once dissolved in water, the labile 
chloride ions of cisplatin are slowly replaced by water molecules in a stepwise 
manner: first forming monoaqua species, then further hydrolysis to form diaqua 
speciesJ'°' The relative amounts of all these hydrolysis species vary as a function of 
pH and chloride concentration. Hydrolysis is likely to be more extensive inside the 
cells where the CY concentration is much lower (4-23 mM) than outside cells (100 
mM).t 111 Hydrolysis is the rate-limiting step in the reaction of cisplatin with DNA. 
Since water is a far better leaving group than chloride and hydroxide, [121  it is 
important to determine the pKa values of the aqua adducts. 
Although both the kinetics and thermodynamics of hydrolysis reactions of 
cisplatin and related cis-Pt' amine complexes are well understood, surprisingly little 
is known about analogous reactions of trans complexes. For transplatin the first 
aquation step is rapid, whereas the second aquation step is very slowJ'3' This is due 
to the stabilising effect of the entering trans oxygen ligand. Moreover, it has been 
postulated that since transplatin is more reactive than the cis isomer, undesired side 
reactions occurring on its way to the pharmacological target are likely to contribute, 
at least in part, to the lack of anticancer activity. Sterically-demanding ligands, like 
iminoethers in trans- [PtCl2 { (E)-HN=C(OMe)Me } 2] (trans-EE) and substituted 
pyridine ligands in cis-[PtC12(NH3)(2-pic)], could in principle reduce the axial 
accessibility of the platinum centre and slow the hydrolysis reaction and the 
subsequent substitution of the aqua ligand by biologically relevant substrates. '41  
In this work, three trans isomers of cis-[PtC12(NH3)(2-pic)] (2-pic = 2-
methylpyridine), AMD473, a recently reported anticancer complex currently in phase 
II clinical trials, have been studied. AMD473 is active against cisplatin-resistant cell 
lines, and against an acquired cisplatin-resistant subline of a human ovarian 
carcinoma xenograph, by injection and oral administrationJ'5' 16]  It has shown 
significantly reduced cross-resistance to cisplatin in a panel of three cell lines with 
known acquired platinum drug resistance mechanisms: reduced accumulation, 
increased cytoplasmic detoxification by cellular thiols or increased DNA 
repair/tolerance of platinum-DNA adductsJ15' 16]  The toxicity of AMD473 is also 
greatly reduced, with no renal toxicity observed. The trans isomers [PtC12(NH3)(2- 
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Pic)] (1), [PtC12(NH3)(3-pic)] (2) and [PtC12(NH3)(4-pic)] (3) have been labelled with 
' 5N, and 2D ['H,'5N] HSQC spectroscopy used to compare their hydrolysis 
behaviour, and to determine the pKa values for the mono- and di-aqua complexes. 
The data reveal notable differences between the chemistry of these trans complexes 
(1 —3) and that of cis-[PtC12(NH3)(2-pic)] and cisplatin. 
3.3 Experimental 
Materials: 2-, 3- and 4-Picoline and '5NH4C1 (>98 % '5N) were purchased from 
Aldrich, and 15NH40H (>98 % '5N) from Isotec. Cis-[PtC12(NH3)2] and cis-
[PtCl2('5NH3)2] were prepared according to a reported procedureJ' 71 Complexes 2 
and 3 were prepared by a general procedure described in the literature for natural 
abundance, mixed-ligand arnmine/amine Pt" complexes. [18] 
Preparation of trans-IPtCL2(NH3)(2-pic)I (AMD443) (I): cis-[PtCl2(2-pic)2] (0.392 
g, 0.866 mmol), prepared by literature rnethods)'9 was dissolved in deionised water 
(7 mL), heated at reflux and then NH40H (2.77 mL, 2.5 M) was added to give a 
yellow suspension which was heated at reflux and stirred overnight. This produced a 
clear solution which was filtered and then rotary evaporated. The cis-[Pt(NH3)2(2-
pic)2]Cl2 intermediate was dissolved in water (2 mL) and heated and stirred under 
reflux. HC1 (289 jiL, 11.98 M) was added to the solution and the mixture allowed to 
stir under reflux for 5 days under nitrogen, during which time it was necessary to add 
additional aliquots of water. The mixture was then placed on an ice bath to induce 
precipitation. The yellow product was then filtered off, washed with ice-cold water, 
and dried in vacuo overnight. The product was recrystallised from 0.1 M HC1, giving 
small yellow crystals. Yield: 258.5 mg, 79%. Anal. Calcd for C6H,0C12N2Pt: C, 
19.16%; H, 2.68%; N, 7.45%. Found: C, 18.87%; H, 2.54%; N, 7.11%. 'H NMR (d6- 
acetone): 8 = 8.81 (d, J = 5.7 Hz, 1H, H-6), 7.78 (t, 1H, H-4), 7.43 (d, J = 7.9 Hz, IH, 
H-3), 7.27 (t, 1H, H-5), 3.69 (broad, NH3), 3.14 (s, 3H, CH3). m/z 399.3 
corresponding to [PtCl2(NH3)(2-pic)]Na. Trans-[PtC]2(15NH3)(2-pic)] ('5N-1) was 
prepared by the same method using 15NH40H. 
Preparation of trans- IPtC12(NH3)(3-pic)] (2): Cisplatin (0.233 g, 0.775 mmol) was 
suspended in 23 mL water, which had been bubbled with argon, and 2 mol equiv 3-
picoline (151 tL, 1.55 mmol) were added. The mixture was stirred at 363 K for 3 h, 
allowed to cool to room temperature, filtered to remove any traces of precipitate, and 
then conc. HC1 (1.6 mL) was added to the clear solution. The acidic mixture was 
refluxed under nitrogen overnight. The resulting solution was bright yellow and was 
placed in ice for several hours to induce precipitation. The yellow precipitate was 
filtered off, washed with ice-cold water, followed by diethyl ether, and dried in 
vacuo overnight. Yield: 188.3 mg, 64.6%. Anal. Calcd for C6H10C12N2Pt: C, 19.16%; 
H, 2.68%; N, 7.45%. Found: C, 19.30%; H, 2.63%; N, 7.39%. 1 H NMR (d6-acetone): 
= 8.66 (s, 1H, H-2), 8.64 (d, J = 5.49 Hz, IH, H-6), 7.78 (d, J = 7.68 Hz, 1H, H-4), 
7.32 (t, 1H, H-5), 3.73 (broad, NH3), 2.37 (s, 3H, CH3). mlz = 399.0 corresponding to 
[PtCl2(NH3)(3-pic)]Nat Trans-[PtC12( 15 NH3)(3-pic)] ('5N-2) was prepared by the 
same method using 'N-cisplatin as the starting material. 
Preparation of trans- IPtC12(NH3)(4-pic)] (3): Cisplatin (0.188 g, 0.627 mmol) was 
suspended in 19 mL water, which had been bubbled with argon, and 2 mol equiv 4-
picoline (122 pL, 1.25 mmol) were added. The mixture was stirred at 363 K for 3 h, 
allowed to cool to room temperature, filtered to remove any traces of precipitate, and 
then conc. HC1 (1.6 mL) was added to the clear solution. The acidic mixture was 
refluxed under nitrogen for 6 h. The resulting solution was bright yellow and was 
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Figure 3.1 1 H NMR spectra of A) complex 1, B) complex 2 and C) complex 3. 
placed in ice for several hours to induce precipitation. The yellow precipitate was 
filtered off, washed with ice-cold water, followed by diethyl ether, and dried in 
vacuo overnight. Yield: 80.0 mg, 33.9%. Anal. Calcd for C6H,0C12N2Pt: C, 19.16%; 
H, 2.68%; N, 7.45%. Found: C, 19.35%; H, 2.66%; N, 8.42%. 'H NMR (d6-acetone): 
= 8.66 (d, J = 6.3 Hz, 2H, H-2), 7.26 (d, J = 5.65 Hz, 2H, H-3), 3.70 (broad, NH3), 
2.41 (s, 3H, CH3). m/z = 399.1 corresponding to {PtC12(NH3)(4-pic)]Nat Trans-
{PtC12(15NH3)(4-pic)] ('5N-3) was prepared by the same method using 15N-cisplatin 
as the starting material. 
X-ray Crystallography: Diffraction data were collected with Mo-Ka radiation on a 
Bruker Smart Apex CCD diffractometer equipped with an Oxford Cryosystems low-
temperature device operating at 150 K. Data were corrected for absorption using the 
SADABS 1211  procedure. The structure of 1 was solved by Dr. Simon Parsons using 
direct methods (SHELXS), 21' while those of 2 and 3 were solved using Patterson 
methods (DIRDIF1221 and SHELXS, respectively). The structures were refined 
against F2 using all data (SHELXL). 231 All non-H atoms were modelled with 
anisotropic displacement parameters, and H-atoms were placed in calculated 
positions. CH3 and NH3 groups were treated according to the Sheldrick rotating rigid 
group modelJ23  
Crystal data for 1: The sample was a pale-yellow needle of dimensions 1.00 x 0.14 x 
0.14 nun 3; the crystals tended to split into smaller needles when cut. Orthorhombic, 
space group Pccn, a = 10.5710(12), b = 22.826(3), c = 7.9743(9) A, V= 1924.1(7) 
A3, Z = 8, Dcaic = 2.597 Mg m 3. The final conventional R-factor [RI, based on IFI 
and 2018 data with F> 4G(F)] was 0.0431, and wR2 (based on F and all 2374 
Me 
unique data to e ax = 28.7°) was 0.0921. The final AF synthesis extremes were + 
2.32 and -1.82 eA 3. 
Crystal data for 2: The sample was a yellow block of dimensions 0.70 x 0.25 x 0.25 
mm3. Monoclinic, space group P21 /c, a = 8.5867(2), b = 22.8583(3), c = 9.85 14(3) 
A, V= 1930.00(13) A3, Z = 8 (there are two molecules in the asymmetric unit), Dca i c 
2.589 Mg m 3. The final conventional RI-factor (based on 4034 data) was 0.0386, 
and wR2 (based on 4576 unique data to Om = 28.6°) was 0.0865. The final AF 
synthesis extremes were + 2.31 and -2.22 e 3. 
Crystal data for 3: The sample was a pale-yellow needle of dimensions 1.06 x 0.08 x 
0.04 mm3. Orthorhombic, space group Pccn, a = 11.5185(4), b = 22.3413(7), c 
7.6232(3) A, V = 1961.74(12) A3, Z = 8, Dcaic = 2.547 Mg m 3. The final 
conventional Ri-factor (based on 2193 data) was 0.0307, and wR2 (based on 2828 
unique data to Omax = 30.5°) was 0.0668. The final AF synthesis extremes were +1.70 
and -0.81 eA 3. 
NMR Spectroscopy: NMR spectra were recorded at 298 K, unless otherwise stated, 
on Bruker DMX500 ('H 500.13 MHz) or Bruker AVA600 ('H 599.81 MHz) 
spectrometers using 5 mm NMR tubes. 1 H NMR chemical shifts were referenced to 
TSP via dioxane (8 3.75) and '5N chemical shifts to I M 15NH4C1 in 1.5 M HC1 
(external). Water suppression was achieved by presaturation. Spectra were processed 
using XW[NNMR (Version 3.5, Bruker UK Ltd). 
Sample Preparation: NMR samples for hydrolysis reactions were prepared by 
dissolving the platinum complex in an aliquot of DMF, followed by dilution with 
H20/D20 to the required concentration. For pKa determinations, the platinum 
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complexes were reacted with 1.96 equiv AgNO3 (24 h, RT), and then filtered to 
remove AgC1. All samples were prepared in 90% H20/10%  D20 unless otherwise 
stated. 
Kinetic Analyses: The concentration/time data for each complex were computer-
fitted to the first order rate equation [Eq.(1)]: 
A = Co + Cie t 
where Co and C1 are computer-fitted constants, and A is the concentration 
corresponding to time t. All kinetic data were computer-fitted using the program 
Microcal Origin 7.5 to give the hydrolysis rate constant kF120 (k). 
pH Measurements: The pH values of solutions were determined using a Corning 
145 pH meter equipped with a micro combination electrode, calibrated with Aldrich 
buffer solutions at pH 4, 7 and 10. The pH was adjusted with dilute solutions of 
HC104 and NaOH. No correction has been made for deuterium isotope effects on the 
glass electrode. 
PKa Values: These were determined by fitting the NMR pH titration curves for 
samples in 90% H20/10% D20 to the Henderson-Hasselbaich equation using the 
program Kaleidagraph (Synergy Software, Reading, PA, USA). 
Mass Spectrometry: Ion electrospray mass spectrometry was performed on a 
Platform II mass spectrometer (Micromass, Manchester, UK). The samples were 
infused at 8 iL/min and the ions produced in an atmospheric pressure ionization 
(API)/ESI ion source. The source temperature was 383 K, and the drying gas flow 
rate was 300 L/h. A potential of 3.5 kV was applied to the probe tip, and cone 
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voltage gradients of 20 - 40 V over 200 - 1000 Da were used. Data acquisition was 
performed on a Mass Lynx (V2.5) Windows NT PC data system. All samples were 
prepared in water. 
Table 3.2 X-ray crystal structure data for complexes I - 3. 
1 2 3 
Empirical formula C6H10Cl2N2Pt C6H,0C12N2Pt C6H,0C12N2Pt 
Mr 376.15 376.15 376.15 
Crystal System Orthorhombic Monoclinic Orthorhombic 
Space group Pccn P21 /c Pccn 
a(A) 10.5710(12) 8.5867(2) 11.5185 (4) 
b (A) 22.826(3) 22.8583 (7) 22.3413(7) 
c (A) 7.9743(9) 9.8514(3) 7.6232(3) 
90 90 90 
90 93.506(2) 90 
y(°) 90 90 90 
V(A3) 1924.1 (4) 1929.99(9) 1961.74 (12) 
z 8 8 8 
2(A) 0.71073 0.71073 0.71073 
T(K) 150(2) 150(2) 150(2) 
Pcalcd (g CM-3) 2.597 2.589 2.547 
4t1caIcd (mm') 15.080 15.034 14.791 
F(000) 1376 1376 1376 
2 Grange (°) 1.78-28.70 1.78-28.62 1.82 -30.50 
Refls. Collected 14380 13928 11084 
Independent refi. 2374 4576 2828 
Refins. (R1) (0.0429) (0.0428) (0.04 18) 
R 	(170>4(Fo)) 0.0431 0.0386 0.0307 
wR2 (all data) 0.0921 0.0865 0.0668 
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Table 3.3 Selected bond lengths (A) and angles (°) for complexes 1 - 3. 
1 	- 2 3 
Pt - N(l) 2.028(7) 2.014(6) 2.014(4) 
Pt-N(2) 2.037(8) 2.047(6) 2.043(4) 
Pt-Cl(1) 2.313(2) 2.293(2) 2.2918(11) 
Pt - C1(2) 2.307(2) 2.292(3) 2.3002 (12) 
- Pt-N(2) 178.9(3) 176.9(3) 179.22 (15) 
N(1)-Pt-Cl(1) 90.1(2) 90.61 (19) 90.95(11) 
- Pt - Cl(1) 89.6(2) 88.35 (19) 88.32 (12) 
- Pt - C1(2) 92.0(2) 91.26 (19) 90.63(11) 
- Pt - C1(2) 88.4(2) 89.8(2) 90.08 (12) 
Cl(2)- Pt -C1(1) 177.48(8) 178.12(7) 177.40 (5) 
N(1) = N of 2-picoline, N(2) = N of NH3 
3.4 Results 
X-ray Crystal Structures: X-ray crystallographic data and details of the refinement 
of the structures of the trans ammine/2-picoline, 3-picoline and 4-picoline complexes 
(1, 2 and 3, respectively) are listed in Table 3.2, and selected bond lengths and angles 
are given in Table 3.3. All complexes have a square-planar configuration with angles 
close to the ideal values of 90° and 180°, as shown in Figure 3.2. Pt - Cl bond 
lengths range from 2.292 - 2.313 A and are close to the expected values. The Pt - N 
bond lengths of 2.014 - 2.047 A are comparable to those of related structures. The 
most notable feature of the structures is the orientation of the picoline ring with 
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3 
Figure 3.2 Space filling models of the X-ray crystal structures of complexes 1 - 3 
showing the steric hindrance caused by the 2-methyl group in complex 1. 
respect to the platinum square plane. In complex 1, the 2-picoline ligand is tilted by 
69.2°, in complex 2 3-picoline is tilted by 60.00  and 57.8° (2 molecules per unit cell), 
and for 4-picoline in 3 by only 56.2°. The tilt angle therefore decreases in the order 
2-pic > 3-pic, 4-pic. In complex 1, the 2-methyl group lies over the square plane 
(H3C ... Pt: 3.207 A), whereas in complexes 2 and 3 the methyl group is much further 
away from Pt (H3C ... Pt: 5.452, 5.458 A for 2 and 6.312 A for 3). The space-filling 
models in Figure 3.2 demonstrate that in complex I there is significantly more steric 
hindrance to an axial approach to Pt from above than in either complexes 2 or 3. 
Strong intermolecular hydrogen bonds are involved in the crystal packing of 
all complexes (Figure 3.3). For complexes 1 and 3, the three H-atoms of the NH3  
ligand are H-bonded to three Cl ligands from neighbouring molecules. Similarly for 
1 and 3, chains of complexes are connected by H-bonds and also interact with one 
another through interleaving 7t-stacks. Such intermolecular H-bonds are common in 
chloro Pt 11 am(m)ine complexes. However, there appears to be an additional H-
bonding interaction in complex 1 between the aromatic H5 proton of the 2-picoline 
ring and a Cl ligand (2.853 A). For complex 2, H-bonds of similar strength are 
formed, but only to two Cl ligands, giving infinite chains composed of channels lined 
by Cl and NH3 along the c-direction. 
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CIIA 
HZ 	 H203 
3 
Figure 3.3 Intermolecular H-bonding in crystals of complexes 1 - 3. N - 1 ... Cl 
distances range from 2.46 - 2.85 A for complex 1, 2.49 - 2.55 A for complex 2 and 
2.49 - 2.70 A for complex 3. 
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Hydrolysis of complexes 1 - 3: The hydrolysis of 15 NH3-labelled 1 - 3 in aqueous 
solutions containing 0.1 M NaC104 was monitored by ['H,' 5N] 2D NMR for over 20 
h at 277 K. This low temperature was chosen because the rates were too fast at 
ambient temperature to allow determination by NMR. Initially for 1, a single cross-
peak was observed at 6 = 3.63, -70.11, which was assigned to the dichioro complex 
1. After 2 h, a weak cross-peak was detected at 6 = 3.69, -68.30, which was assigned 
to the monoaqua species. The peak for 1 decreased in intensity as the monoaqua peak 
increased in intensity over a period of 21 h. No peak assignable to a diaqua species 
was observed within the time the reaction was followed (48 h). At 310 K (Figure 
3.4), two peaks were initially observed. Peak a, at 8 = 3.78, -69.26, corresponds to 1 
and peak b at ö = 3.98, -67.87 is the monoaqua species. An additional peak at ö 4.07, 
-65.99 ppm assignable to the diaqua adduct was observed after 4 h, but its intensity 














4.4 	4.0 	 3.6 
(1H) 
Figure 3.4 2D [1H,15N] HSQC NMR spectra of a 5 mM aqueous solution of frans-
[PtC12(1 NH3)(2-pic)] (1) at 310 K after A) 0.4 hand B) 21.4 h. Peak a is assigned to 
1, peak b to the monoaqua complex and peak c to the diaqua complex, * = 
satellites. 
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For the 3-picoline complex 2, initially, two cross-peaks were observed. The 
most intense peak at 6 = 3.64, -70.60 was assigned to the dichloro complex 2 and the 
less intense peak at 6 = 3.77, -69.21 to the monoaqua species. Again, no diaqua 
species was observed. The time-dependence of the [1 H,15N] 2D NMR spectrum was 
similar to that of complex 1, except that equilibrium was reached more quickly (< 7 h 





4.' 	 14.U 	 15.0 
Figure 3.5 2D [1 H,15N] HSQC NMR spectrum of 5 mM aqueous solution of trans-
[PtCl2(15NH3)(4-pic)] (3) at 277 K after 21.3 h. Peak a is assigned to 3, peak b to the 
monoaqua complex. 
The hydrolysis of the 4-picoline complex 3, followed a similar time-
dependence but, interestingly, reached equilibrium significantly more slowly than for 
the 3-picoline complex 2. The chemical shifts for the dichloro complex and 
monoaqua species are similar to those of 1 and 2, with the dichloro complex 3 having 




(Figure 3.5). No diaqua species was observed under these experimental conditions. It 
is noteworthy that the 'H NMR peaks, in particular, tended to shift downfield 
throughout the course of the reaction. This is a consequence of a decrease in pH 
caused by deprotonation of coordinated water to produce the monohydroxo complex. 
The time-dependence of the concentrations of species detected during 
hydrolysis of complexes 1 - 3 is shown in Figure 3.6. The assignments of the peaks 
of the aqua complexes were confirmed by pH titrations (Figure 3.7), using aqua 
adducts of complexes 1 - 3 which had been generated by reactions with Ag' to 
produce a mixture of monoaqua, diaqua and dichloro species. These allowed the 
determination of pKa value for each monoaqua complex as well as two pKa values 
for each diaqua complex. 
Table 3.4 Rate constants (k) and equilibrium constants (K) for the hydrolysis 
reactions of complexes 1 —3 and AMD473. 
Complex TI K k (x105 	1)a K (x104 M)a 
1 277 2.6 ± 0.2 3.9 (37)b 
2 277 12.7 ± 0.8 2.0 
3 277 5.2 ± 0.3 4.0 
AMD473c 310 32d 2.2e 121d 21.4e 
a Based on concentrations derived from integration of 2D ['H,' 5N] NMR cross-peaks, 
b 310 K, C  Data from ref. 33, d  trans to 2-Pic, e  trans to NH3. 
The NMR data allow the determination of the rates for monoaquation of 
complexes 1 - 3 at 277 K, and these are listed in Table 3.4. It is notable that the rate 
of monoaquation of the 3-picoline complex 2 is more than twice as fast as that of 
complex 3, and ca. five times as fast as complex 1. However, the extent of hydrolysis 
of complex 2 was ca. 75 % that of complexes 1 and 3. An estimate of the half-lives 
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for hydrolysis of complex 1 at 310 K is included in Table 3.6 and compared with 
related complexes. Half-lives for hydrolysis (3 10 K) and pKa values (298 K) for 
complex I are shown in Scheme 3.1. The enthalpy of reaction (AH°) for the 
monoaquation step was calculated, using the van't Hoff expression, t241 to be -1.0 
KJmol1. The negative sign of AH° indicates the equilibrium constant (K) decreases 
with increasing temperature. 
+ 	 2+ 
Cl, 	.NH3 t112 : 0.9 h 	C1,pt..NH3 t112 : 70.2 h 	H20...pt.._NH3 
c~CH3 
pK8 : 5.55 	 pK: 4.03 
+ 
Ck.. Pt -NH3 	
H20... FIt ...-NH3 - 
I 	 ri - 11 
:Ka : 7.01 




Scheme 3.1 Half-lives for hydrolysis (3 10 K) of complex 1 and pKa values (298 K) 


















Figure 3.6 Time dependence of the concentrations of the dichioro complexes A) 1, 
B) 2 and C) 3 and the aqua adducts during hydrolysis at 277 K. Concentrations are 
based on integration of 2D NMR cross-peaks. Labels: I - 3 (.), monoaqua 
complexes (.). The full lines represent computer fits giving the first order rate 
constants listed in Table 3.4. 
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3.8 1.. 
2 	4 	6 	8 	10 
pH 
Figure 3.7 pH-dependence of the 1H NMR chemical shifts of NH3 in the monoaqua 
and diaqua complexes A) 1, B) 2 and C) 3. The curves represent computer fits to the 
Henderson-Hasselbaich equation giving the pKa values listed in Table 3.7. Labels: 
monoaqua complexes (.), diaqua complexes (+). 
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3.5 Discussion 
cis-[PtC12(NH3)(2-picoline)] is currently on clinical trial as an anticancer 
drug. Its trans isomer, complex 1, shows in vitro cytotoxicity 251 even higher than 
that of cisplatin in a panel of human tumour cell lines (mean IC50 = 3.5 and 33.7 jiM, 
respectively), whereas the trans 4-picoline complex 3, tested by Kasparkova et al .,126J  
exhibits a lower activity (mean IC50 = 80.3 jiM), Table 3.5. The 3-picoline complex 2 
has not yet been evaluated for its cytotoxic activity. Complex 1 overcomes cisplatin 
resistance in the resistant cell lines tested, but complex 3 is cross-resistant, implying 
that complex I may have a different mechanism of action to complex 3. IC50 values 
for these and related compounds are listed in Table 3•5J25271  Interestingly, trans -
[PtC12(NH3)(pip)] (where pip = piperidine) and trans-[PtCl2(NH3)(pz)f (where pz = 
piperazine) are less cytotoxic than both trans- [PtC12(NH3)(2-pic)] (1) or trans-
[PtCl2(py)2] in the cell lines tested. Moreover, trans-[PtC12(py)2] overcomes cisplatin 
resistance whilst trans- [PtC12(Nl-13)(2-pic)] has a small average resistance factor of 
Ca. 1.5. 
Table 3.5 Mean IC50 values for trans Pt complexes and cisplatin against various cell 
[ lines. [25-27]  
Complex' 	 IC50 (jiM)b 
A2780 A2780(R) CHI CH1(R) 41M 41M(R) 
cisplatin 	 2.2 	38 	6 	23 	26 	107 
transpiatin 	 > 200 	> 200 	> 200 	> 200 	> 200 	> 200 
trans- {PtC12(py)2] 	 - 	- 1.6 1.7 2.2 2.0 
trans-PtC12(NII-J3)(pip)1 	5 	20 15 94 27 150 
trans- [PtCl2(NH3)(pz)r 5 	44 12 34 52 155 
trans-[PtC12(NH3)(2-pic)] (1) 	1.6 	6 3.8 5.2 2.8 1.7 
trans-[PtC12(NH3)(4-pic)] (3) 	7 	80 22 154 32 187 
a py = pyridine, pip = piperidine, pz = piperazine, R = cisplatin-resistant cell line 
MR 
' 5N-labelling of 1 - 3 and use of [IH,bN]  NMR spectroscopy has allowed 
study of the speciation of these complexes in aqueous solution. The [13N,'H] NMR 
method has the advantage that the concentrations of aquated species can usually be 
measured directly at low (micromolar) concentrations, even when other species are 
present in the solution. However, due to the extremely fast rate of the monoaquation 
step, rates were measured at lowered temperature (277 K). At 277 K, only peaks for 
the monoaqua species were detected, although a peak for the diaqua species was 
detected after ca. 4 h of hydrolysis of complex 1 at 3 10 K. 
The t112 values for the first hydrolysis step at 277 K follow the order of I 
(7.43 h) > 3 (3.68 h) > 2 (1.52 h). Even at equilibrium, the monoaqua species of 
complexes I and 3 account for only ca. 24 % of all platinum species present and the 
monoaqua species of complex 2 only accounts for Ca. 18 % of all platinum species. 
The steric hindrance due to the picoline ligand in complexes 2 and 3 is similar, and it 
is apparent that the faster hydrolysis of complex 2 relative to complex 3 is due to 
electronic factors. A methyl substituent at the 2- and 4- positions (complexes 1 and 3, 
respectively) increases electron density on the platinum centre, making nucleophilic 
attack by the incoming water molecule less favorable. However, at the 3-position 
(complex 2), the methyl substituent directs less electron density to the platinum 
centre and thus promotes the hydrolysis reaction. Complex 1 is the slowest to 
hydrolyse due to both steric and electronic effects. The more sterically demanding 2-
picoline ligand hinders axial approach of the incoming water molecule from above. 
Substitution reactions of square-planar Pt 11  complexes (i.e. PtL2XY + Z -* PtL2YZ + 
X) usually occur through formation of a five-coordinate intermediate (PtL2XYZ) in 
an associative processJ28' The use of a more sterically-hindering non-leaving group 
(i.e. Y or L) compared to NH3 raises the energy of the five-coordinate intermediate 
(i.e. increases the activation energy associated with entry of Z into the coordination 
sphere). 
Table 3.6 Half-lives (t,12) for hydrolysis of various Pt 11  complexes. 
Complex 	 Dichioro 	Monoaqua Reference 
t112 (h) 	t112 (h) 
trans-[PtC12(NH3)(2-pic)] (1)a 7.43 (09)b - (702)b 	This work 
trans- [PtCl2(NH3)(3-pic)J (2)a 	 1 .52 	 - 	This work 
trans-[PtC12(NH3)(4-pic)] (3)a 	 3.68 	 - 	This work 
transpiatinc 	 1.96 	 3.85 	[29] 
transplatin' 	 10.13 	 - 	[301 
trans- [PtC12(NH3)(4_pic)]c 	 0.33 	 - 	[311 
trans-{PtCl2- {E-HNC(OMe)Me } 2] 0.92 	77.02 	
[321 
cis [PtC12(NH3)(2 pic)]b 6.04, 8.71 	2.64, 55.01 	[331 
cis-[PtC12(NH3)(3-pic)]' 1.86, 4.31 	2.47, 5.50 	[331 
cisplatinb 1.9 	 2.1 	[341 
a 277 K, ° 310 K, c 298 K, ° 298.2 K, calculated from the activation parameters, 
which were determined from the temperature dependent intercepts of plots of k0b vs. 
[CL]. 
When hydrolysis of complex I was monitored at 310 K, approximate values 
of t,,'2 were determined as 0.9 h for the monoaquation and 70.2 h for the diaquation 
steps. These values compare well with t1!2 = 0.92 h and t1!2 = 77.0 h (T = 298 K) for 
mono- and di-aquation, respectively, of trans- [PtC12-{E-I-INC(OMe)Me}2]J321  
Farrell et a1.1311 have obtained a t112 value of 0.33 h for trans- [PtC IAN  H3)(4-pic)] (3) 
at T = 298 K. Table 3.6 lists ti/2  values of various related compounds. 29341 Only a 
few studies of transplatin hydrolysis have been reported and there appears to be a 
large disparity between the reported half-lives. Aprile and Martin [29]  reported a t112 
value of 1.96 h (1 = 0.318 M, T = 298 K) for monoaquation of transpiatin, whereas 
Miller et alJ301 calculated a t112 value of 10.13 h (1 = 0.1 M, T = 298.2 K) based on 
the activation parameters, calculated from the temperature dependent intercepts of 
plots of k0b versus [C1]. 
The equilibrium constants for mono-aquation determined for complexes 1-3, 
2 —4 x 10 M 1 (Table 3.4), are an order of magnitude less than reported values (298 
K) for cisplatin f29, 30, 351 of 33 - 68 x 10-4  M* The equilibrium constants reported for 
transplatin,129' 301  3.2 x 10 M' and 6.2 x I0 M 1 , are also an order of magnitude 
smaller than those of cisplatin, and our values for complexes 1-3 fall within this 
range. Thus the amount of (reactive) mono-aqua species formed by the trans 
complexes at intracellular chloride concentrations (4 - 23 mM) is likely to be < 10 %, 
much smaller than for the cis analogues (Table 3.4). A consequence of the higher 
stability of the trans chloro complexes is that little of the diaqua adduct is formed 
during the hydrolysis. It has been suggested for cisplatin that the diaqua complex 
plays a key role in the attack on DNA. 1361 
['H,' 5N] NMR allowed also the determination of the pKa values of the aqua 
ligands in the monoaqua and diaqua species of complexes 1 - 3. Movement of the 
methyl group from the 2- to the 3- to the 4-position has little affect on the PKa values 
of the aqua ligands. A comparison of pKa values for mono-aqua adducts, Table 
37,[3721 shows those for complexes 1 - 3 are fairly typical for trans-
{Pt(NH3)(amine)}-type complexes (5.3 - 5.9), and significantly lower than those of 
'S 
cis complexes such as cisplatin and AMD473. Also, the first pKa value for the trans 
diaqua complexes is Ca. I unit lower than those for related cis complexes (Table 3.7). 
Table 3.7 Comparison of pKa values for a selection of cis and trans diam(m)ine Pt 11 
aqua complexes. 
Complex 	 PKa 	Reference 
trans- [PtCI(0H2)(' 5NH3)(2-pic)f 5.55 This work 
trans-[Pt(0H2)2( '5NH3)(2-pic)]2 4.03, 7.01 This work 
trans- [PtCI(0H2)(15  NH3)(3-pic)]+  5.35 This work 
trans-[Pt(0H2)2( 
15NH3)(3-pic)]2 3.97, 6.78 This work 
trans- [PtCI(0H2)( 5NH3)(4 pic)fF 5.39 This work 
trans-[Pt(0H2)2(' 5NH3)(4-pic)]2 3.94, 6.88 This work 
trans- [PtC1(0H2)(15  NH3)21'  5.63 [371 
trans-[Pt(0H2)2(' 5NH3)2]2 4.35, 7.40  
trans- [PtCI(0H2)( 1 5  NH3)(2-Me-(  5N)butylamine)] 5.90 
 
trans-[Pt(0H2)2(' 5NH3)(2-Me-(15  N)butylamine)]2  4. 16, 7.1 7 [381 
trans- [PtC1(0H2)(isopropylamine)((S)-2-methyl(15  N) 5.86  
butylamine)f 
trans-[Pt(0H2)2(isopropy lam ine)((S)-2-methyl(15  N)  4.21, 7.33 [391 
butylamine)]2 
[{trans-PtCI(' 5NH3)2 } {trans-Pt(0H2)(' 5NH3)2 } (t- 
' 5NH2(CH2)61 NH2)]3  
[{frans-Pt(0H2)(' 5NH3)2  } 2(Jt 13NH2(CH2)6 ' 5NH2)]4 
 5 .62 a  [40] 
trans- [PtCl(0H2)(15  N  H3)(c-C6H 11 1 4j)] 5.40  
cis-[PtC1(0H2)(15  NH3)(2-pic)]+  6. 13, 6.49 
[33] 
cis-[Pt(0H2)2(' NH3)(2-pic)}2 5.22, 7.16 [331 
cis- [PtCl(OH2)('5NH3)(3-pic)] 5.98, 6.26 [33] 
cis-[Pt(0H2)2(' 5NH3)(3-pic)]2 5.07, 6.94 [33] 
cis-[PtCl(OH2)('5NH3)2J 6.41  
cis-[Pt(0H2)2(' 5NH3)2]2 5.37, 7.21 [42] 
a Average value 
In recent years, there has been an increasing number of investigations of trans 
platinum complexes. 19, 13, 43] One of the most striking differences between cis and 
trans isomers apparent from such investigations is the variation in formation and 
reactivity of the diaqua species. However, Arpalahti 1441  reported that for cisplatin and 
transpiatin, the second complexation step in the formation of the bis(inosine) adduct 
appears to be kinetically similar. In the case of multinuclear platinum am(m)ine 
complexes, which hydrolyse only to a small extent, and yet have a high DNA affinity 
(rapid DNA binding), it has been suggested that formation of aqua species may not 
be a necessary step in DNA adduct formation of such compoundsJ401 Moreover, the 
high cytotoxicity of the trans-[PtC12(NH3)(planar amine)] class of compounds has 
been attributed to an alteration of the mode of DNA binding in comparison to 
cisplatin, resulting in an altered spectrum of antitumour activity and enhanced 
reactivity in cisplatin-resistant cell lines. For example, an intercalative manner of 
interaction of the quinoline or thiazole moiety with the duplex has been proposed for 
all or a significant fraction of the DNA adducts of trans- [PtC12(NH3)(quin)] and 
trans- [PtC12(NH3)(tz)] 4 (where quin = quinoline, tz = thiazole). Also, it has been 
reported that the mechanism of antitumour activity of trans-[PtCl2(NH3)(pip)] does 
not involve recognition of its DNA adduct by HMG domain proteins as a crucial 
step, 1461  in contrast to the proposals for cisplatin and its analogues. Thus, further 
studies are warranted to develop the potential of such trans platinum anticancer 
complexes which act by a different mechanism and exhibit activity complementary 
to agents such as cisplatin. 
3.6 Conclusions 
1 H,15N NMR studies of the aquation of the trans-ammine-picoline-dichioro 
complexes 1 - 3 (2-pic, 3-pic and 4-pie, respectively) showed that the monoaquation 
step is relatively rapid (t112 1.5 - 7.5 h at 277 K). However, aquation occurs only to a 
limited extent (18-24 % hydrolysis, 5 mM Pt, 277 K), the equilibrium favouring the 
dichloro species, with little formation of the diaqua complex. Increased steric 
hindrance to an axial approach to Pt" in the 2-picoline complex I was apparent in the 
X-ray crystal structure. This hindrance has the effect of destabilising the expected 
trigonal bipyramidal transition state, an effect well-known in substitution reactions of 
square-planar pt" complexes. The low pKa values of the monoaqua complexes 1 - 3 
(5.3-5.6) implies that these complexes will be largely in the less reactive hydroxo 
forms at physiological pH. However, the extent of hydrolysis at intracellular chloride 
concentrations (4 - 23 mM) is expected to be low (<10%). This, together with the 
faster rate of hydrolysis, due to the higher trans effect of Cl- compared with NH3, are 
likely to have a major influence on the biological activity of trans compared to cis 
complexes. 
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Chapter 4 
G-G Base-Pairing in Nucleobase 
Adducts of the Anticancer Drug 
Cis- PtC12(NH3)(2-pico1ine)J and its 
Trans Isomer 
4.1 Abstract 
Cis- [PtC12(NH3)(2-picol me)] (AMD473) is a sterically-hindered anticancer 
complex with a profile of chemical and biological activity that differs significantly 
from that of cisplatin. Adducts of AMD473 with neutral 9-ethylguanine (9-EtGH) 
and anionic (NI -deprotonated) 9-ethylguanine (9-EtG) as perchiorate and nitrate 
salts, and also a nitrate salt of the trans isomer (AMD443), have been prepared and 
their structures determined by X-ray crystallography: cis- [Pt(N H3)(2-pic)(9-
EtGH)2](C104)2 (4)2H20 Me7CO, cis- [Pt(NI-13)(2-pic)(9-EtGH)2](NO3)2 (5)21-120, 
cis- [Pt(NH3)(2-pic)(9-EtGH)(9-EtG)]NO3 	(6)3 .5H20, 	trans-[Pt(N H3)(2-pic)(9- 
EtGH)(9-EtG)]NO3 (7)8H2O. In all cases, platinum coordination is through N7 of 
neutral (4, 5) and anionic (6, 7) guanine. In each complex, the guanine bases are 
arranged in the head-to-tail conformation. In complex 4, there is an infinite array of 
6-molecule cycles, based on hydrogen bonding interactions. Pt 11  coordinated at N7 
acidifies the Ni proton of neutral 9-ethylguanine (pKa = 9.57) to give PKaI = 8.40 
and PKa2 = 8.75 for complex 5, and pKai = 7.77 and pK = 9.00 for complex 7. In 
complexes 6 and 7, three intermolecular hydrogen bonds are formed between neutral 
and deprotonated guanine ligands involving 06, Ni and N2 sites. Unusually, both of 
the platinated guanine bases of complexes 6 and 7 participate in this triple GG 
hydrogen bonding. This is the first report of X-ray crystal structures of nucleobase 
adducts of the promising anticancer drug AMD473. 
4.2 Introduction 
Cisplatin, the world's best-selling anticancer drug, has been the subject of 
intense research over the last thirty-five years. The antitumour activity of cisplatin 
and various other anticancer platinum drugs is attributed to their ability to modify the 
structure of the DNA of cancer cells.111 Cisplatin reacts with genomic DNA and 
yields a variety of mono-adducts and intra- and interstrand cross-links, [2]  as well as 
protein-DNA cross-links.111 
The most nucleophilic sites in duplex DNA are guanine (G) residues, 
especially those located adjacent to a second guanine residue. For Pt 11  coordination, 
guanine N7 appears to be the preferred binding site. Therefore, it is not surprising 
that the major adduct of cisplatin with DNA is an intrastrand cross-link between the 
N7 atoms of adjacent guanine residues. 13  The coordinated guanine bases are 
orientated in a head-to-head (HH) conformation. However, the head-to-tail (HT) 
forms, characteristic of minor interstrand adducts, are thermodynamically favoured 
in all simple cis-[PtA2G2] models (A = amine or half of a diamine), and the head-to-
head form is relatively rare. 13 ' 41  
cis- [PtC12(NH3)(2-picoline)] (AMD473) is a sterically-hindered anticancer 
complex with a profile of chemical and biological activity that differs significantly 
from that of cisplatin. AMD473 has been administered to over 500 cancer patients 
in phase I and phase II clinical trials, in which it has demonstrated activity against a 
wide range of tumours and a manageable safety profile. AMD473 also has the 
potential to be administered as an oral formulation. The 2-methyl group hinders axial 
approach to Pt" in AMD473, and as a result, hydrolysis occurs approximately four 
times more slowly than for cisplatin. 61 The introduction of steric bulk by the 2- 
01 
picoline ligand (Figure 4.1) in AMD473, may give rise to novel DNA platination 
reactions, such as differential binding to nucleobases and structures locked in a single 
conformation. 
CH 
Figure 4.1 Schematic representation of 2-picoline and 9-ethylguanine (9-EtGH), 
including conventional numbering. 
To gain further insight into stereochemical effects on the structure and 
dynamics of nucleobase adducts, adducts of AMD473 and its trans isomer, trans-
[PtC12(NH3)(2-pic)](AMD443), with 9-ethylguanine (9-EtGH) (Figure 4.1) have 
been studied in solution and in the solid state. The trans isomer also exhibits high 
cytotoxicity in a variety of cancer cell lines. 7' 
4.3 Experimental 
Preparations: 9-Ethylguanine was purchased from Sigma. cis- [PtC12(NH3)(2-pic)] 
was kindly provided by AstraZeneca. The synthesis of trans-{PtCl2(NH3)(2-pic)] was 
based on previously published procedures.181 
cis- LPt(NH3)(2-pic)(9-EtGH)21 (d04)2 (4)2H20Me2CO: cis- [PtC l2(NH3)(2-pic)] 
was reacted with 1.98 equiv of AgC104 (5 h, 323 K), followed by filtration of AgC1, 
and then addition of 2 mol equiv 9-EtGH (4 d, 323 K). Recrystallisation from 
acetone, and slow evaporation yielded 4 as colourless cubes. 
IM 
cis- iPt(NH3)(2-pic)(9-EtGH)21 (NO3)2 (5)-2H20: cis- [PtC12(NH3)(2-pic)] was 
reacted with 1.96 mot equiv AgNO3 (24 h, 323 K), followed by filtration of AgCI, 
and then addition of 2 mot equiv 9-EtGH (4-5 d, RT). Recrystallisation from hot 
water, and slow evaporation yielded 5 as colourless cubes from a solution at pH 3.55. 
cis-[Pt(NH3)(2-pic)(9-EtGH)(9-EtG)I NO3 (6)3.5H20: cis-[PtC12(NH3)(2-pic)] was 
reacted with 1.96 mot equiv AgNO3 (24 h, 323 K), followed by filtration of AgC1, 
and then addition of 2 mot equiv 9-EtGH (24 h, 323 K). Recrystallisation from hot 
water, and slow evaporation yielded 6 as colourless cubes (at a measured pH of 
I 
trans- IPt(NH3)(2-pic)(9-EtGH)(9-EtG)I NO3 (7)8H20: trans- [PtC12(NH3)(2-pic)] 
was reacted with 1.96 mot equiv AgNO3 (24 h, RT), followed by filtration of AgCl, 
and then addition of 2 mot equiv 9-EtGH (4-5 d, 323 K). Colourless needles of 7 
were obtained upon slow evaporation of an aqueous solution at pH 7.83. 
NMR Spectroscopy: NMR spectra were recorded at 298 K, unless otherwise stated, 
on a Bruker DMX500 spectrometer ('H 500.13 MHz), using 5 mm NMR tubes. 
Spectra were referenced to TSP via dioxane, 8 3.75. Water suppression was achieved 
by presaturation. Spectra were processed using XW1NNMR (Version 3.5, Bruker UK 
Ltd) 
Sample Preparation: NMR samples were prepared by taking aliquots of the 
aqueous solutions from the preparations of complexes 4 - 7. All samples were 
prepared in 90% H20/1 0% D20 unless otherwise stated. 
pH Measurements: The pH values of solutions were determined using a Corning 
145 pH meter equipped with a micro combination electrode, calibrated with Aldrich 
buffer solutions at pH 4, 7 and 10. No correction was made for deuterium isotope 
effects. 
pKa Values: These were determined by fitting the NMR pH titration curves (all 90% 
H20/10% D20) to the Henderson-Hasselbaich equation, assuming fast exchange on 
the NMR timescale of the protonated and deprotonated forms, using the program 
Kaleidagraph (Synergy Software, Reading, PA, USA). 
Mass Spectrometry: Ion electrospray mass spectrometry was performed on a 
Platform Ii mass spectrometer (Micromass, Manchester, UK). The samples were 
infused at 8 iL/min and the ions were produced in an atmospheric pressure 
ionization (API)/ESI ion source. The source temperature was 383 K, and the drying 
gas flow rate was 300 L/h. A potential of 3.5 kV was applied to the probe tip, and 
cone voltage gradients of 20 - 40 V over 200 - 1000 Da were used. Data acquisition 
was performed on a Mass Lynx (V2.5) Windows NT PC data system. All samples 
were prepared in water. 
X-ray Crystallography: Diffraction data for all crystals were collected with MOKa 
radiation on a Bruker Smart Apex CCD diffractometer equipped with an Oxford 
Cryosystems low-temperature device. Data for 6 were collected at 293 K, 5 and 7 
were collected at 150 K, but those for 4 were collected at 240 K, as the sample 
appeared to undergo a phase change between this temperature and 220 K. All 
structures were solved by Dr. S Parsons using Patterson methods (DIRDIF) 9' and 
refined by full-matrix least squares against F2 (SHELXTL)J'°' H-atoms were 
generally placed in calculated positions (see below); only full-weight atoms were 
refined with anisotropic displacement parameters. Crystal and refinement data are 
summarised in Table 4.1. Additional geometric calculations were accomplished with 
the program PLATON,111 structures were visualised in SHELXTLXPH°I  and 
MERCURY.1121 
In structure 4, the 9-Et groups are disordered. That attached to N91 is 
disordered over two positions in the ratio 70:30; the group attached to N92 was 
modelled similarly; however, the displacement parameters refined to large values, 
implying that the disorder is more extensive. Similarity restraints were applied to 
both 9-ethylguanine ligands. The anions and solvent of crystallisation were barely 
recognisable in difference maps, and were treated using the method of van der Sluis 
and Spek,1 13] accounting for 150 e per formula unit. The formula, M, p etc. have all 
been calculated assuming that this complex contains 2004 , 2H20 and one acetone 
molecule per formula unit. 
Crystals of 5 were found to be non-merohedrally twinned through a two-fold 
rotation about [0 1 0]. This information was obtained using the program GEMINI.1141 
Diffraction data from both domains were integrated simultaneously (SAINT version 
7)[15] and all data were used for refinement. The twin law can also be expressed 
using the following matrix 
—1 0 0 
—0.65 1 —0.33 
0 0 —1 
The twinning has an affect on data with 2h + 1 = 3n; it can be interpreted as a 
two-fold rotation about the b-axis of a metrically monoclinic super-cell with 
dimensions a = 11.91, b = 66.75, c = 12.40 A, 3 = 114.30, obtained with the 
following transformation 
—1 0 0 
2 —6 1 
0 0 1 [!6] 
Coset decomposition of 2/rn with respect to -1 implies that no further twinning needs 
to be considered.[ 17] 
In 6, the picoline ligand is disordered by a 180° rotation about the Pt-N bond. 
The occupancies of the alternative methyl positions were fixed at 0.75 and 0.25 after 
refinement. The two C-Me bonds were restrained to be of equal length. The 
molecules of water of crystallization based on 03W and 04W make unfavourable 
contacts with the minor disorder component, and the assumption was made that they 
have the same occupancy as the major component (0.75). The displacement 
parameter of 03W refined to a large value (0.14 A2), and it is possible that in reality 
its occupancy is less than 0.75; correlation between the occupancy and the 
displacement parameters means that it is difficult to draw the distinction from X-ray 
data alone. H-atoms were located on 01 W, 02W and 04W in difference maps; after 
adjustment of the 0-H distances and H-0-H angle to normal values, the entire 
molecules were treated as freely-rotating rigid groups. H-atoms have not been 
positioned on 03W. 
The complexes in 6 are connected across -1 sites via N41-H41N41A and 
N42-H42N42A (NI-H---NI) hydrogen bonds. Thus, neither H41 nor H42 can be 
fully-occupied, as this would lead to the formation of a very close H H contact 
across the inversion centres. Both of these sites were, therefore, assigned 
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occupancies of 0.5, which also ensures charge-balance. Similar comments apply to 
complex 7. 
The solvent and anion regions in the structure of 7 were treated in the same 
way as in 4, amounting to 108.5 e per formula unit. The values of Mr, p etc. have 
been calculated on the assumption that these regions contain NO3 and 8H20 
molecules per formula unit. 
Crystallographic data for the reported structures have been deposited with the 
Cambridge Crystallographic Data Centre: CCDC 264834 (4), 264835 (5), 264836 
(6), and 264837 (7). 
4.4 Results 
X-ray Crystallography 
Crystals containing cis-{Pt(NH3)(2-pic)(9-EtGH)2]X2 (X = C104, 
42H20Me2CO; X = NO3, 5.2H20) and cis- (63.5H20) or trans- (78H20) 
[Pt(NH3)(2-pic)(9-EtGH)(9-EtG)]NO3 were obtained by reaction of the respective 
isomer of [PtC12(NH3)(2-pic)] with slightly less than 2 mol equivalents of Ag, 
followed by reaction with 2 mol equivalents of 9-ethylguanine in water, and 
recrystallisation from acetone in the case of complex 4, from water at pH 3.55 for 
complex 5, and from water at pH 7.98 and 7.83 for complexes 6 and 7, respectively. 
Crystallographic data and details of the refinement are listed in Table 4.1. Selected 
bond lengths and angles are given in Table 4.2, and the cations of 4 - 7 are shown in 
Figure 4.2. Hydrogen bond lengths and angles are given in Table 4.3. Rocking angles 
(4) and torsion angles (8) are listed in Table 4.4. 
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Figure 4.2 a) The cation cis- {Pt(NH3)(2-pic)(9-EtGH)2]2 in complex 4. The planes 
of the 9-EtGH and 2-picoline rings are 70 - 800 relative to the Pt square-plane. The 9-
EtGH bases are approximately perpendicular to one another. Intermolecular 
interactions are shown in Figure 4.3. b) The cation cis-[Pt(NH3)(2-pic)(9-EtGH)2]2 
in complex 5. The change in the anion compared to complex 4 has resulted in a 
significant decrease in the angle between the guanine base cis to 2-picoline and the 
Pt square-plane. The dihedral angle between the guanine bases is also reduced. There 
are additional H-bond interactions mediated by the anion. c) Intermolecular triple H-
bonding in the structure of complex 6, cis-{Pt(NH3)(2-pic)(9-EtGH)(9-EtG)]. The 
guanine bases are almost perpendicular to one another and each of the guanine bases 
and the 2-picoline are tilted by 70 - 80° relative to the platinum square plane. The 
cations form an infinite chain. d) Intermolecular triple H-bonding in the structure of 
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complex 7, trans- {Pt(NH3)(2-pic)(9-EtGH)(9-EtG)It Two molecules are shown, 
which form part of an infinite chain. The dihedral angle between the G bases is much 
smaller in this case, only 52°. The crystallographic numbering relates to the chemical 
numbering given in Figure 4.1, as follows: Complexes 4 and 5: N71, N72 = N7. 
Complex 6: N31 = C2NH2; N41 = NI; 051 = 06. Complex 7: NI I, N12 = N7; 082 
= 06; N71, N72 = Nl; N61, N62 = C2NH2. 
Table 4.1 Crystallographic data for complexes 4 - 7, in which 4 = cis-[Pt(NH3)(2-
pic)(9-EtGH)21(Cl04)2, 5 = cis- [Pt(NH3)(2-pic)(9-EtGH)2](NO3)2, 6 = cis-
[Pt(NH3)(2-pic)(9-EtGH)(9-EtG)]NO3 and 7 = trans-[Pt(NH3)(2-pic)(9-EtGH)(9-
EtG)]NO3. 
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In each complex, platinum coordination is through the N(7) sites of the two 
9-ethylguanine ligands, which adopt the head-to-tail orientation. Platinum(II) has the 
usual square-planar geometry, and Pt - N bond lengths range from 1.999(6) A to 
2.047(8) A, which is within the normal range for these types of complexes. 
Table 4.2 Selected bond lengths (A) and angles (°) for 4 - 7, in which 4 = cis-
[Pt(NH3)(2-pic)(9-EtGH)2](C104)2, 5 = cis- [Pt(NH3)(2-pic)(9-EtGH)2](NO3)2, 6 
cis- [Pt(NH3)(2-pic)(9-EtGH)(9-EtG)]NO3 and 7 = trans- [Pt(N H3)(2-pic)(9-EtGH)(9-
EtG)]NO3. 
Bond /Angleral4 5 6 7[h] 
Pt-N(1) 2.041(5) 2.023(4) 2.047(4) 2.034(7) 
Pt-N(13) 2.018(5) 2.019(4) 2.022(4) 2.047(8) 
Pt - N(7 1) 2.008(4) 2.015(4) 2.009(4) 1.999(6) 
Pt-N(72) 2.018(5) 2.020(4) 2.017(4) 2.011(6) 
N(13)-Pt-N(1) 90.99(19) 88.18(15) 90.03(16) 177.8(3) 
N(72) - Pt - N(1) 179.05(15) 178.74(17) 178.53(15) 90.0(3) 
N(71)-Pt-N(1) 90.11(18) 88.31(15) 89,26(16) 89.1(3) 
N(72)- Pt- N(13) 89.37(18) 91.69(15) 89.94(15) 91.2(3) 
N(71)- Pt- N(13) 175.18(16) 174.70(14) 177.53(14) 89.8(3) 
N(71) - Pt - N(72) 89.60(17) 91.90(14) 90.83(15) 178.5(3) 
PtN4 I GI 73.62(19) 72.22(14) 86.00(15) 71.0(3) 
PtN4 / G2 71.24(19) 52.83(19) 70.78(17) 58.0(3) 
GI 1G2 86.17(18) 71.25(14) 88.39(15) 51.9(3) 
Note that the crystallographic atomic numbering schemes (Figure 4.2) differ from 
the chemical numbering scheme used in the text. 
Numbering scheme in complex 7 differs from that of cis complexes but for 
comparison Nil =N71 and N12=N72. 
In 	complex 	42H20Me2CO, 	cis-{Pt(NH3)(2-pic)(9- 
EtGH)2](ClO4)2 2H2OMe2CO, the cis 9-ethylguanine ligands are approximately 
perpendicular to one another (Figure 4.2a). The large dihedral angle of 86.17(18)° 
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between the guanine bases prevents any substantial intramolecular base—base 
interaction. The plane angles of the 9-ethylguanine ligands relative to the 2-picoline 
are 89.2(3)° and 6.0(3)°. There is high thermal motion and at temperatures lower 
than 240 K, the system appeared to undergo a phase change, but no data were 
collected at lower temperatures. The ethyl groups at the 9-position are disordered. 
In addition, there are hydrogen bonds between NH3 groups and the 06 of 
guanine (N - 0 2.88 A), as well as double hydrogen bonds between N3 positions and 
NH2 groups (N - N 3.00, 3.03 A) on neighbouring molecules. These features 
combine to create an infinite array of 6-molecule cycles, Figure 4.3. 
Figure 4.3 The six-molecule cyclic arrangement present in crystals of complex 4. 
The intermolecular interactions involve alternating Pt - NH3  ... 0(6) H-bonding and 
double N(2)H2 ... N3, N3 ... H2N(2) H-bonding. 
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Table 4.3 Selected hydrogen bond lengths (A) (with H A < r(A) + 2.000) and angles 
(°) (<DHA> 110). 
D - H d(D - H) d(H"A) <DHA d(DA) A 
4: 
Ni -H1C 0.900 2.090 146.40 2.883 051 
N31-H31A 0.870 2.157 175.94 3.025 N21 1  
N32-H32A 0.870 2.137 169.77 2.997 N22 
5: 
N32-H32A 0.880 2.055 166.61 2.919 O51 
6: 
N31 - H3 1B 0.860 1.971 178.08 2.831 
N41 -H41 0.860 2.078 172.81 2.934 N41'1 
N32-H32B 0.860 1.999 168.37 2.847 052 
N42-H42 0.860 2.104 168.46 2.951 N42 
7: 
N61 -H61B 0.880 1.929 172.10 2.803 082 
N62-H62B 0.880 2.084 166.03 2.945 081 11, 
N72-1-172 0.880 2.059 177.00 2.938 N71 
N64-H64B 0.880 1.965 170.69 2.837 0851c ' 
N74-H74 0.880 2.042 172.71 2.917 N75k1  
N65-H65A 0.880 1.964 164.04 2.821 084 
Equivalent positions: [a] -x -y+l, -z+l, [b] -x, -y+2, -z+1, [c] -x+1, -y+1, -z, [d] - 
x+l, -y, -z+l, [e] x-1/2,-y+1/2, z-1/2, [f] x+1/2, -y+1/2, z+1/2. 
Relationship between crystallographic and chemical numbering schemes: 
Complex 4: NI = NH3; N31, N32 = C2NH2; N21, N22 = N3; 051 = 06 
Complex 5: N32 = C2NH2; 051 = 06 
Complex 6: N31, N32 = C2NH2; N41, N42 =N1; 051,052 = 06 
Complex 7: N61, N62, N64, N65 = C2NH2; N71, N72, N74, N75 = Nl; 081, 082, 
084, 085 = 06. 
In complex 521-120, cis- [Pt(NH3)(2-pic)(9-EtGH)2](NO3)2 2H20, the dihedral 
angle between the cis 9-ethylguanine ligands is slightly smaller, 71.25(14)° (Figure 
4.2b). The plane angles of the 9-ethylguanine ligands relative to 2-picoline are 
76.5(2)° and 20.4(2)°. There is extensive hydrogen bonding between NH3, Nl, 
C2NH2 and the NO3 counterion, and 06, N3, and C2NH2 are involved in H-bonding 
with solvent water molecules. The only intermolecular H-bonding is between the 
C2NH2 group and 06 (N - 0 2.92 A). 
Table 4.4 Values for rocking angle zi, which represents the difference between the 
two bond bending angles [C(5)-N(7)-Pt and C(8)-N(7)-Pt] and torsion angle /3 [C(8)-
N(7)-Pt-NH3(cis)I, for complexes 4 - 7. 
4 5 6 7 
Rocking Anglezl (0) 	-7.68 4.35 -0.41 4.98 
-5.25 10.63 1.87 3.52 
Torsion Angle /3 (0) 	74.3 73.6 94 108.5I 
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[a] Average value. 
In 	the cation of complex 63.51-120, cis- [Pt(NH3)(2-pic)(9-EtGH)(9- 
EtG)}N03 3.5H20, the 9-ethylguanine ligands are again almost perpendicular to one 
another, with a dihedral angle of 88.39(15)0  (Figure 4.2c). The plane angles of the 9-
ethylguanine ligands relative to 2-picoline are 88.9(2)° and 2.9(2)°. There is disorder 
about the Pt - N (pic) bond of 180° to give a distribution for the C2 and C6 positions 
of the 2-picoline ligand of 75% and 25%, respectively. There is intermolecular triple 
hydrogen bonding between the Ni of 9-EtG of one molecule and the NI H of 9-EtGH 
of an adjacent molecule (N - N 2.93 A), which, together with C2NH2 - 06 hydrogen 
bonds (N - 0 2.83 A), gives rise to a G - G base pair. The proton shared between 
the two Ni atoms of the 9-ethylguanine ligands appears to be disordered over two 
positions, a 1:1 mixture ofNiH --- N1A and Nl --- HN1A. 
The trans 9-ethylguanine ligands in the cation of complex 781-120, trans-
[Pt(NH3)(2-pic)(9-EtGH)(9-EtG)]N03 8H20, have a dihedral angle of 51.9(3)', and 
the plane angles of the 9-ethylguanine ligands relative to the 2-picoline ligand are 
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85.5(5)° and 81.2(5)° (Figure 4.2d). This complex forms a triple hydrogen bond, 
similar to that in complex 6, giving rise to a G - G base pair. The hydrogen bond 
lengths are 2.80 - 2.95 A for NH2 - 06 and 2.92 - 2.94 A for N 1(H) - N!. There are 
effectively two parallel chains formed through it - it stacking, which run in the same 
direction and interact with one another. 
Solution Studies 
Cis- [Pt(NH3 )(2-pic)(9-EtGH)2] (d04)2 (4) 
The peak at m/z 763 in the positive-ion electrospray mass spectrum of complex 1 in 
water is assigned to the parent ion with an associated C104 counterion, [Pt(NH3)(2-
pic)(9-EtGH)2 CI041-'. The other peaks were assigned as follows: m/z = 584 
[Pt(NH3)(2-pic)(9-EtGH)C104], m/z = 483 [Pt(NH3)(2-pic)(9-EtGH) - H], m/z = 
466 [Pt(2-pic)(9-EtGH) - Hf. 
The 1 H NMR spectra of complex 4 in D20 and acetone at 298 K are shown in 
Figure 4.4. Clearly, the solvent has a large effect on chemical shift; however, most 
noticeable is that the H8 signals for the 9-ethylguanine ligands are indistinguishable 
in aqueous solution, whereas in acetone, they are separated by 0.2 ppm. Therefore, 
the change in chemical shift of H8 in various acetone/H20 mixtures was examined. 
The variation in chemical shift is plotted in Figure 4.5a. The spectra (Figure 4.5b) 
show the convergence of the two H8 signals as the molar fraction of water increases. 
The chemical shift of one of the H8 peaks (G1H8) is solvent dependent to a much 
greater extent than the other (G21-18). 
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Figure 4.4 a) 'H NMR spectrum of complex 4 in D20. b) 'H NMR spectrum of 
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Figure 4.5 a) Plot of 6 H8 for the two 9-EtGH ligands in complex 4 in d6-acetone 
versus the % (v/v) of water, showing how the separation of the H8 signals decreases 
as the percentage of water increases. b) 9-Ethylguanine H8 region of the 'H NMR 
spectra of complex 4 in acetone as a function of increasing water concentration. 
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The temperature dependence of the 'H NMR spectrum of complex 4 in D20 
was further investigated between 278 K and 313 K (Figure 4.6). At low temperature, 
there are two individual H8 signals. Although the resonance for the H8 proton of one 
of the 9-ethylguanine ligands (GI H8) appears to be highly temperature dependent, 
the H8 peak for the other 9-ethylguanine (G2H8) is almost unaffected. This is clearly 
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Figure 4.6 a) Plot of ö H8 versus temperature for complex 4 in D20. b) 'H NMR 
spectra of complex 4 in D20 showing the H8 region over the temperature range 
278Kto313 K. 
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A 2D ROESY spectrum of complex 4 in acetone (Figure 4.7) was recorded at 
278 K to investigate the solution structure of this complex. Only one of the two H8 
signals (GIH8) exhibits an NOE cross-peak to the 2-picoline methyl group. This H8 
signal (G 11-18) also exhibits an NOE cross-peak to the aromatic H6 proton of the 2-
picoline ligand. 
]............I I  
b 
10 
10 	8 	6 	4 
4 	8(1H)/ppm 
Figure 4.7 2D ['H,'H] ROESY NMR spectrum of complex 4 in d6-acetone at 278 K. 
Assignments: a = 2-pic CH3; b = Et CH2; c = NH3; d = H5 2-pic; e = H3 2-pic; f 
H4 2-pic; g = H8 of 9-EtGH (G2); h = H8 of 9-EtGH (GI); i = H6 2-pic. 
Trans- [Pt(NH3)(2-pic)(9-EtGH)(9-EtG)]NO3 8H20 (7) 
Positive-ion electrospray mass spectrometry showed peaks for the parent ion 
at m!z 662, assigned to [Pt(NH3)(2-pic)(9-EtGH)2 - H], together with peaks 
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assignable to fragments: m/z = 645 [Pt(2-pic)(9-EtGH)2 - H]E, rn/z = 466 [Pt(2-
pic)(9-EtGH) - H]. 
The 'H NMR spectrum of complex 7, recorded in 90% H20/10% D20 
(Figure 4.8), contains only one set of peaks, corresponding to the two coordinated 9-
ethylguanine ligands. The 'H NMR chemical shifts of the peaks of complex 7 were 
not temperature dependent between 278 K and 318 K. A 2D NOESY spectrum 
revealed that there is an NOE cross-peak for the H8 signal of the 9-ethylguanine 
ligands and the 2-picoline CH3 group. 
C H 2C H 3 
H2N 1N 
"> 
HNX ,NH3 o 
O Pt 	II / 
JNH 
2 	
1:CH3 N LL 
CH2CH3 
GH8 
H6 	1H4 H3 H5 
H2 
CH3  
2-pic CH3  
OH2 
dioxane 
* 	 * 
6.0 	 21.0 
ö(1 H)/ppm 
Figure 4.8 'H NMR spectrum of complex 7 in 90% H20/10% D20. The complex 
was prepared in situ by mixing trans- [Pt(NH3)(2-pic)(0H2)2](NO3)2 with a slight 
excess of 9-EtGH and hence small peaks for 9-EtGH are also present, labelled *• 
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In the pH range from 2 - 12, the pH-dependent 'H NMR chemical shift 
measurements for complex 5 in 90% H20/10%  D20 show two acid-base equilibria, 
corresponding to the deprotonation of the two inequivalent N 1 H sites of the 9-
ethylguanine ligands (Figure 4.9a). The pKa values are 8.40 and 8.75. Complex 7 
also has two acid-base equilibria (Figure 4.9b), with pKa values of 7.77 and 9.00. The 
PKa values for free 9-ethylguanine under the same conditions were determined to be 
3.22 (N7) and 9.94 (NI H). These values are compared with those of cisplatin adducts 
in Table 4.5. 
Table 4.5 Comparison of PKa values for N1H of 9-EtGH in the complexes studied 
here (5 and 7), and for related adducts. 
Species pKa N 1(H) Reference 
9-ethylguanine 9.57 1181 
cis-[Pt(N H3)(2-pic)(9-EtGH)2
]2+ 8.40, 8.75 Present work 
trans-[Pt(NH 3)(2-pic)(9-EtGH)2]2  7.77, 9.00 Present work 
cis- [Pt(NH3)2(9-EtGH)2I2 7.76, 8.36  
cis-[PtNH3)2(9-EtGH)2]2 8.01, 8.66  
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Figure 4.9 Dependence of the H8 chemical shifts of a) complex 5 and b) complex 7 
and free 9-ethylguanine on pH. Note that there are two distinguishable H8 peaks for 
complex 5, but unambiguous assignments cannot be made. The solution of 7 also 
contained a small amount of free 9-ethylguanine. The curves are computer fits to the 
Henderson-Hasselbalch equation, and give the pKa values listed in Table 4.5. 
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4.5 Discussion 
In the past, structural investigations of platinum-nucleobase complexes 
concentrated almost exclusively on cisplatin compounds, [20-351 and consequently, 
relatively few structural studies of nucleobase complexes of trans Pt" compounds 
have been reported. Details of many of these trans complexes are summarised in a 
review by LippertJ361 Here, bisnucleobase adducts of the sterically-hindered 
anticancer compound cis-[PtC12(NH3)(2-pic)] (AMD473) and its trans isomer 
AMD443 have been studied. Three crystal structures of AMD473 adducts and one of 
an AMD443 adduct containing the model nucleobase 9-ethylguanine have been 
determined (4 - 7). These are the first X-ray structures of nucleobase adducts of 
{Pt(NH3)(2-pic)} anticancer complexes. 
Coordination at the N7 position of guanine was confirmed in each case, as 
was a head-to-tail orientation of the bases. The head-to-tail forms are characteristic 
of the minor interstrand adducts formed by cisplatin with DNA, and are 
thermodynamically favored in all simple cis-[PtA2G2] models (A = amine or half of a 
diamine, G = guanine derivative). 131  However, there are few examples of the head-to-
head conformation, which is the more realistic model for a Pt-DNA complex. 2022' 
The main difference between complexes 4 and 5 is the anion; perchiorate and 
nitrate, respectively. Complex 4 exhibits a rare case of negative rocking angles (-
7.68°, -5.25°; i.e. C(8)-N(7)-Pt angles > C(5)-N(7)-Pt angles). For complex 5, the 
rocking angles are positive, as observed typically in structures of related 
complexes. 371 In complex 5, the nitrate anion acts as a spacer between molecules and 
dominates the H-bond interactions. Consequently, there is only one type of 
intermolecular H-bond, between C2NH2 and 06, and hence complex 5 is unable to 
form the type of cycle described for 4. Other structural differences may be simply a 
consequence of crystal packing. Complexes 5 and 6 differ in the charge on the 
complex and in the number of counterions and water molecules in the unit cell. A 
further and most intriguing difference is that in complex 5, the guanine base in the 
head orientation with respect to the methyl group of 2-picoline is trans to the 2-
picoline ligand, whereas in complex 6, the analogous guanine base is cis to the 2-
picoline ligand. This indicates that both head and tail orientations of 9-ethylguanine 
relative to the cis 2-picoline ligand are possible, although intermolecular interactions 
may favour only one of these orientations. It is expected that complexes 4, 5 and 6 
adopt the same structure in solution (at the same pH). 
Complex 7 is a rare example of a trans bis(nucleobase) Pt" complex that has 
a large dihedral angle of 5 1.9(3)'  between the two bases. Another example is trans-
[Pt(MeNH2)2(1-MeC)2](PF6)2, with a dihedral angle of 56(1)0J381  In most other 
bisnucleobase complexes of trans-[(am)2Pt], the bases are reasonably coplanar. 3842 
This large dihedral angle may result from the steric hindrance imposed by the bulky 
2-picoline ligand. 
Complexes 6 and 7 have the most interesting structural features. Both exhibit 
intermolecular triple hydrogen bonding involving NH2, NH and 06, which give rise 
to a G - G base pair. There are various reports of PtG - G and PtG - GPt hydrogen 
bonding caused by deprotonation at the Ni position of Pt"-bound guanine. [32-35, 38, 39, 
43,441 Five X-ray structures for such complexes have been reported. Three of these are 
monoguanine 	complexes: 	cis- [Pt(NH3)2(9-EtGH)(1-MeC)][Pt(NH3)2(9-EtG)(1 - 
MeC)] (dO4)3,1331 	trans-[ { Pt(NH3)2(tmade)(9-EtGH) }. { Pt(NH3)2(tmade)(9- 
EtG) } ] (C104)2 NO3 1 .6H20 (where tmade = 00,IV9-trimethyIadenine),1381 {trans, 
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trans- [(NH3)2Pt( 1 -MeU)(9-EtA)Pt(NH7CH3)2(9-EtGH0  5)1 (dO4)2 s I .25H20} 2J 1 
The other two, cis- [Pt(NH3)2(9-EtG)2]9-EtGH7H2O 321 and [{Pt(NH3)(9-MeGH)2(9-
MeG)} {Pt(NH3)(9-MeGH)3 } { 1 -Med } ] (dO4)3 4H2O,1441 contain two coordinated 
guanine residues, but only one of these is involved in triple H-bonding. In complexes 
6 and 7, both platinated guanines are involved in GG triple hydrogen bonding. As a 
result, complexes 6 and 7 form infinite chains, but complex 7 does so in a more 
zigzag manner. This appears to be the first report of structures in which both 
platinated guanines participate in GG triple hydrogen bonding. The triple H-bond 
lengths for complexes 6 and 7 range from 2.80 - 2.95 A for NH2 - 06 and 2.92 - 
2.95 A for N1(H) — NI; these values are comparable with 2.83(1) A and 2.90(1) A, 
respectively, in trans-[ { Pt(NH3)2(tmade)(9-EtGH) } { Pt(NH3)2(tmade)(9-EtG) } 
For the cation in complex 4, cis-[Pt(NH3)(2-pic)(9-EtGH)2]2 , there are four 
different stereoisomers (2 x HT and 2 x HH). Because the 2-methyl group can be on 
the upper or lower side of the platinum plane, four geometrical head-to-tail isomers 
are possible. Only two of these will be distinguishable, however, by NMR, and 
therefore, four H8 signals should be observed. In reality, only two H8 peaks are 
observed. An explanation for this is either fast interconversion of head-to-tail 
conformations on the NMR timescale, or the molecule is locked into a single 
configuration at this temperature. The 2D ROESY spectrum of complex 4 at 278 K 
clearly shows an NOE cross-peak for only one of the two H8 signals of 9-
ethylguanine (G1H8) and the methyl group of the 2-picoline ligand (Figure 4.7), 
suggesting a head-to-tail orientation of the guanine bases. If the solution structure 
was locked into the same configuration as that observed by X-ray crystallography for 
the solid state, the only observable NOE contact between the methyl group of the 2- 
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picoline ligand and an H8 proton would correspond to the 9-ethylguanine ligand 
trans to 2-picoline. Interestingly, G1H8 exhibits a greater solvent and temperature 
dependence than the second H8 peak, G2H8 (Figure 4.5 and Figure 4.6). It can be 
argued that the 9-ethylguanine cis to the 2-picoline exhibits the more marked 
temperature and solvent dependence, especially if there is rapid rotation about the Pt 
- N bonds. Rapid interconversion of head-to-tail conformers is common in Pt(II) 
diamine compiexesJ45' 461  Rapid rotation should give rise to H8 CH3 NOEs for both 
coordinated guanine bases, whereas only one ROESY cross-peak is detected. This 
suggests that the two 1-18 peaks observed contain four overlapping H8 signals. The 
major contribution to the observed NOE is probably from the 9-ethylguanine ligand 
cis to 2-picoline, in view of its intensity (medium compared to strong for the H6/1-15 
of 2-pic), and for which the H8 CH3 distance is much shorter (ca. 3 A versus 4.9 A 
for a trans 9-ethylguanine; NOE oc  r 6). However, it is difficult to interpret NOEs 
quantitatively in a dynamic system. Moreover, the NOE cross-peak between the 
Gl1-18 peak and the aromatic H6 peak of the 2-picoline ligand further substantiates 
the argument that G I H8 corresponds to the 9-ethylguanine ligand cis to 2-picoline. 
For trans-[Pt(NH3)(2-pic)(9-EtGH)2]2+  from 7, there are also four different 
stereoisomers (2 x HT and 2 x HH; Figure 4.10). The two HT isomers (Figure 4.1 Oa) 
are enantiomers. Therefore, only one HT configuration will be observed by NMR. As 
the two 9-ethylguanine ligands are in slightly different environments, we expect to 
observe two sets of peaks, however, experimentally, only one set of peaks is 
observed. This could be due to fast rotation about the Pt-2-pic bond, or to fast 
rotation of the guanine bases. Although Reedijk and co-workers [471  reported slow 
rotation about the Pt-2-pic bonds at room temperature in cis- [Pt(2-pic)2(Puo)2]2 (Puo 
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= guanosine or 9-methyihypoxanthine), they confirmed that rotation of these 6-





P4\ NH3  
(S 
Figure 4.10 a) Head-to-tail enantiomers of trans- [Pt(NH3)(2-pic)(9-EtGH)212 . b) 
Head-to-head isomers of trans- [Pt(NH3)(2-pic)(9-EtGH)2J2 '. Solid arrows represent 
the orientation of the 9-ethylguanine ligands, and dotted arrows represent that of the 
2-picoline methyl group with respect to the platinum square plane. 
The pKa values of 8.40 and 8.75 for complex 5, and 7.77 and 9.00 for 
complex 7, which are assignable to NI H deprotonation of coordinated 9-
ethylguanine, are 0.6 - 1.8 units lower than that for free 9-ethylguanine (Table 4.5). 
This observed acidification is a consequence of the inductive effect of Pt at the N7 
position of guanine, and lies within the range observed for similar amine complexes 
(Table 4.5). 
The guanine-guanine pairing pattern observed in complexes 6 and 7 
represents a model for a nucleobase mispair. There is probably little chance of 
formation of such a guanine pair in DNA, as it is necessary to have independently 
metallated guanines in close proximity. However, with RNA and its enormous 
structural diversity, such possibilities are more likely. 
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4.6 Conclusions 
In this study of bisnucleobase adducts of the sterically-hindered anticancer 
drug AMD473 and its trans isomer AMD443, three AMD473 adducts and an 
AMD443 adduct containing 9-ethylguanine have been synthesised and characterised. 
Each of the complexes has a head-to-tail arrangement of the guanine bases in 
contrast to the head-to-head arrangement preferred in DNA. Platination at the N7 
position was confirmed in each case. Interesting triple hydrogen bonding was 
revealed in the structures of both the cis and trans 9-ethylguanine adducts, giving 
rise to G-G base pairs for both coordinated guanine bases. The PKa value ofNlH of 
9-ethylguanine was lowered significantly by N7 coordination to Pt'1, most notably for 
the trans complex (7) relative to free 9-ethylguanine. 
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Chapter 5 
Interactions of Guanine Nucleosides 
with Sterically-Hindered Platinum 
Picoline Anticancer Complexes 
W. 
5.1 Abstract 
Adducts of the promising anticancer drug cis-[PtC12(NH3)(2-pic)] (AMD473) 
and its trans isomer, which is also cytotoxic in a variety of cancer cell lines, with 
guanosine (Guo) and 2'-deoxyguanosine (2'-dGuo) have been prepared and 
characterised in solution by ID 'H, 2D ['H,'H] NMR spectroscopy and ESI mass 
spectrometry. Pt1' coordination at the N7 position is confirmed in all cases, increasing 
the acidity of the N1H sites of neutral guanosine and 2'-deoxyguanosine. 
Interestingly, there is a slightly larger effect on the pKa ofNlH in the trans complex 
compared to the cis complex, lowering the PKa values by about 1.4 log units and 0.8-
1.2 log units, respectively, as compared to the free nucleoside. Based on the NOEs, 
the complexes cis- [Pt(NH3)(2-pic)(Guo)2]
2 , cis- [Pt(NH3)(2-pic)(2 -dGuo)2]2+  and 
trans- [Pt(N H3)(2-pic)(2'-dGuo)2]2  are assigned as head-to-tail conformations. A 
chromatographic study of AMD473 with guanosine and substituted guanosine bases 
confirmed the preference for N7 platination and revealed that the rates of reaction 
followed the order Guo> l -MeGuo> 7-MeGuo, implying that substituents at the NI 
position of guanosine may cause some steric retardation. Reactions between aquated 
'5N-labelled AMD473 and guanosine (1:2) at 298 K have been studied in aqueous 
solution at millimolar concentrations using 2D ['H,'5N] HSQC NMR spectroscopy. 
The reaction proceeds through two mono(guanosine) intermediate species to yield 
the dominant product cis-[Pt(NH3)(2-pic)(Guo)2]2 . Initial guanosine substitution 
trans to 2-picoline is faster than substitution cis to 2-picoline due to steric hindrance, 
but the rates for the second guanosine substitution appear similar. 
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5.2 Introduction 
Cisplatin is one of the most successful antitumour drugs developed in recent 
years and many studies of the molecular mechanism of antitumour effect of platinum 
drugs have revealed that the antitumour activity stems from the interaction of these 
compounds with intracellular DNA. 11 The complex cisplatin and related Pt" 
analogues cross-link adjacent purine bases (two Gs or one A and one G) of a DNA 
strand that are capable of inhibiting replication and transcription) 1-3] 
The major site of attack by Pt am(m)ine anticancer complexes is N7 of 
guanine, which is readily accessible in the major groove of duplex DNA and is the 
strongest electron donor of the four bases. 471 Complexes containing Pt - NI binding 
have been prepared previously 181 but under physiological conditions NI of guanine in 
duplex DNA is involved in Watson-Crick base-pairing. This position is therefore not 
available for metal binding. The nature of the non-leaving groups of platinum 
anticancer complexes, i.e. the amine ligands, plays an important, but not completely 
defined role in the anticancer activity of the drug. The requirement that at least one H 
be attached to each amine for significant anticancer activity9' 0]  has led to the 
speculation that this NH group forms a hydrogen-bond to the 06 of guanine [10,  or 
a phosphate oxygen. [6, 12171 In DNA, these platinum compounds cross-link adjacent 
purine residues [1-3]  in a 'head-to-head' conformation in which both the H8 atoms are 
on the same side of the platinum coordination plane. [7, 14, 16, 18-211 When the two 
nucleot(s)ide moieties are not linked by a phosphodiester group, the purines can have 
orientations in which the H8s are on opposite sides of the platinum coordination 
plane, designated 'head-to-tail'. Normally only head-to-tail complexes are detected 
in solution and in most solid state crystallographic studies. [1, 22-261 The head-to-head 
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atropisomers are difficult to isolate and have been found in only a few crystal 
structures of cis- [Pt(NH3)2(9-EtGH)21X2J27' 281 
The X-ray structure determination of cis-[Pt(NH3)2{d(pGpG)}] by Sherman 
et al in 1985[2h1  provided the first detailed picture of the effects of cisplatin binding to 
a dinucleotide segment of DNA. The structure (four independent molecules in the 
asymmetric unit) revealed essential features predicted by the 9-EtGH model 
compounds (e.g. large dihedral angles between G planes of 76-87°, destacking of 
guanines, only minor deviations of platinum from U planes), but in addition showed 
that the guanines are in the normal (for B-DNA) anti conformation, with the 5'-
sugars in C3'-endo (C2'-exo) and the 3'-sugars in the C2'-endo (and Cl'-exo) 
puckering, as predicted by NMR spectroscopy. ' 91 Another, potentially significant 
feature of these structures are the H-bonding interactions between a NH3 group and a 
5'-phosphate oxygen. 2' 2 
 11 
The characterisation of DNA adducts of transplatin is not as detailed and 
complete as that of cisplatin adducts. As a consequence of the inherent difference in 
geometry, cisplatin and transplatin form different adducts I29311  Specifically, 
transplatin cannot form the 1 ,2-intrastrand cross-links, which represent by far the 
most abundant adducts of cispiatinJ3' On the other hand, the trans isomer displays a 
greater variation in nucleobase donor sites. 311  
Apart from stereochemical considerations the question concerning changes in 
electronic structure, as well as in acid-base and hydrogen-bonding properties of 
guanine as a consequence of metal binding appears to be of considerable significance 








Guanosine (Guo) 2'-deoxyguanosine (2'-dGuo) 
In this work, the reactions of the platinum anticancer complex, cis-
[PtCl2(NH3)(2-pic)] (AMD473), and various guanosine derivatives have been 
investigated primarily by HPLC followed by a combination of ESI mass 
spectrometry and ID 'H and 2D ['H,' 5N] HSQC NMR spectroscopy to identify the 
principal reaction products. A kinetic study of the reaction of aquated ' 5N-AMD473 
and guanosine has been performed by 2D ['H,' 5N] HSQC NMR spectroscopy. 
Finally, a selection of bis(guanosine) adducts of AMD473 and its trans isomer, 
which is also cytotoxic in a variety of cancer cell lines, has been prepared and 
characterised. 
5.3 Experimental 
Materials: 1 -methylguanosine was purchased from ICN Biomedicals, 7-
methylguanosine and guanosine were purchased from Sigma and 2-deoxyguanosine 
was purchased from Acros. cis-{PtC12(NH3)(2-pic)] was kindly provided by 
AstraZeneca. cis- [PtCl2('5NH3)(2-pic)] was synthesised based on a previously 
published procedure, [32]  employing cis-[PtC12(15NH3)2] as the starting material. The 
synthesis of trans-[PtC12(NH3)(2-pic)] was based on previously published 
procedures [331  and is described in Chapter 3. 
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HPLC: Analytical separations were carried out on a Gilson HPLC station with a 306 
pump system, 234 auto-injector and series 1100 Hewlett Packard diode array 
detector, using a Nucleosil C18 reversed-phase column (250 x 4.6 mm, Hichrom). 
The time courses of reactions between cis-[PtC12(NH3)(2-pic)] (2 mM, 400 
iL) and guanosine, 1-methylguanosine, and 7-methylguanosine (2 mM, 400 pL) at 
1:1 molar ratios were carried out at 310 K and followed chromatographically by 
injections of aliquots of the mixture onto the HPLC column at various time intervals 
after mixing, with detection at 220 nm. All samples were prepared in an aqueous 
solution of 0.02 M NaC104, pH 5.5. A gradient elution method was employed using a 
water/acetonitrile mixture, with 0.1 % TFA. 
The samples for semipreparative separation contained 4 mM cis-
[PtC12(15NH3)(2-pic)] and 4 mM guanosine or 1-methylguanosine. The fractions 
collected were frozen in liquid nitrogen and lyophilized using a Modulyo Edwards 
freeze-drier. 
Kinetic NMR Experiment: cis-[PtC12(15NH3)(2-pic)] (3 mM) was firstly reacted 
with 1.96 mol equiv AgNO3 (24 h, 323 K), and filtered to remove AgCl. The reaction 
of the aquated species with guanosine was conducted at a 1:2 molar ratio. Samples 
contained 0.1 M NaC104 to maintain a constant ionic strength. The pH value at the 
beginning of the experiment was 6.46. 
IPt(NH3)(2-pic)(G)21(NO3)2: Adducts were prepared by reaction of cis-
[PtC12(NH3)(2-pic)J or trans-[PtC12(NH3)(2-pic)] with 1.96 mol equiv AgNO3 (24 h, 
323 K), filtration of AgC1, and then addition of 2 mol equiv of guanosine or 2 
deoxyguanosine and left to react for 24 h at 323 K. 
133 
NMR Spectroscopy: NMR spectra were recorded at 298 K, unless otherwise stated, 
on a Bruker DMX500 spectrometer ('H 500.13 MHz), using 5 mm NMR tubes. 
Spectra were referenced to TSP via dioxane, 8 3.75. Water suppression was achieved 
by presaturation. Spectra were processed using XWINNMR (Version 3.5, Bruker UK 
Ltd). 
pH Measurements: The pH values of solutions were determined using a Corning 
145 pH meter equipped with a micro combination electrode, calibrated with Aldrich 
buffer solutions at pH 4, 7 and 10. No correction was made for deuterium isotope 
effects. 
PKa Values: These were determined by fitting the NMR p1-I titration curves (all 90% 
H20/10% D20) to the Hen derson-Hasselbalch equation, with the assumption of fast 
exchange on the NMR timescale of protonated and deprotonated forms, using the 
program Kaleidagraph (Synergy Software, Reading, PA, USA). 
Mass Spectrometry: Ion electrospray mass spectrometry was performed on a 
Platform II mass spectrometer (Micromass, Manchester, UK). The samples were 
infused at 8 tL/min and the ions produced in an atmospheric pressure ionization 
(API)/ESI ion source. The source temperature was 383 K, and the drying gas flow 
rate was 300 L/h. A potential of 3.5 kV was applied to the probe tip, and cone 
voltage gradients of 20 - 45 V over 200 - 1000 Da were used. Data acquisition was 
performed on a Mass Lynx (V2.5) Windows NT PC data system. All samples were 
prepared in water. 
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5.4 Results 
1. HPLC Reactions of cis-IPtC12(NH3)(2-pic)1 with Guanosine Derivatives 
The hydrolysis of cis- [PtC12(Nl-13)(2-pic)} at 310 K was firstly monitored by 
HPLC (Appendix 1). Initially, only one peak was detected at 16.8 mm, assigned to 
the dichloro species. Two major species were detected after I h with elution times of 
11.3 and 19.1 mm. A number of smaller peaks were detected also during the time 
course with elution times of 9.9, 11.3, 15.4, 22.2 and 31.5 mm. This allowed ready 
identification of any hydrolysis products formed during reactions with nucleobases. 
Reactions between cis-[PtCl2(NH3)(2-pic)] (2 mM) and guanosine or 1-
methylguanosine or 7-methylguanosine (1:1 molar ratio, pH 5.5, 310 K) were 
investigated by HPLC time course experiments. HPLC chromatograms for these 
reactions are shown in Figure 5.1. 
For the reaction of cis-[PtC12(NH3)(2-pic)] with guanosine, initially only two 
peaks are observed corresponding to cis- [PtCl2(NH3)(2-pic)] with an elution time of 
ca. 15.4 min and guanosine Ca. 19.3 mm. As the reaction progresses, these peaks 
decrease in intensity and small peaks for intermediates and products emerged. The 
peaks at 10.4 and 18.5 min appear to be intermediate species from hydrolysis and 
they initially increase in intensity and then decrease slightly as the main product 
peaks at the far end of the chromatogram (26.8 mm, Fl and 29.3 mm, F2) become 
more prominent (Figure 5.1). 
In the reaction of 1-methylguanosine and cis-[PtC12(NH3)(2-pic)], the 1-
methylguanosine peak is at 20.0 min and it appears that there is a small intermediate 
species formed, likely due to hydrolysis, which elutes immediately before 1-
methyl guano sine. At around 2 h of reaction two new peaks appear towards the end of 
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Figure 5.1 Chromatograms of reactions of AMD473 with a) guanosine, b) 1-
Meguanosine and c) 7-Meguanosine (1:1) in 0.02 M NaC104 at 310 K, pH 5.5 
(the sloping lines at the top and bottom represent the gradient of aqueous and 
organic eluents, respectively). 
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the chromatogram. The peak at Ca. 27.0 mm (F3) becomes the dominant product and 
that at 30.1 mm (F4) behaves as an intermediate (Figure 5.1). 
For the reaction of 7-methylguanosine and cis-[PtCl2(NH3)(2-pic)], the 7-
methylguanosine peak eluted just before 20 mm. There are two small hydrolysis 
peaks between 10 and 12 min and several small product peaks appear at the far end 
of the chromatogram. Interestingly, this reaction is much slower than that of I-
methylguanosine as the product peaks are only evident after 24 hours whereas for 1-
methylguanosine there are product peaks after only 2 hours (Figure 5.1). 
To 	obtain further structural information, cis- [PtC12(1 5 N H3)(2-pi c)1 was 
reacted with guanosine and I -methylguanosine and the fractions eluting at 26.8 (Fl) 
and 29.3 mm (F2) for the guanosine reaction and those at 27.0 (F3) and 30.1 mm 
(F4) for the I -methylguanosine reaction from the 48 h reaction mixtures were 
collected by HPLC separation and analysed by direct infusion ESI-MS and a 
combination of ID 1 H and 2D [H,'5N] HSQC NMR spectroscopy. 
ESI-MS Identification of Adducts 
For the reaction of cis-[PtC12('5NH3)(2-pic)] and guanosine, the mass 
spectrum at a cone voltage of 45 eV for the fraction Fl is shown in Figure 5.2. There 
are a large number of fragment peaks but the majority of these can be easily 
assigned. The parent ion at m/z 871.4 corresponds to the bis(guanosine) adduct, 
[Pt('5NH3)(2-pic)(Guo)2-Hf. The other major peaks are assigned as follows: m/z 
625.3 - [PtCl(15NH3)(2-pic)(Guo)], m/z 588.3 - [Pt(5NH3)(2-pic)(Guo)-H], mlz 
532.1 - [PtC1('5NH3)(Guo)], m/z 514.1 - [PtCl2('5NH3)(2-pic)]TFANa, m/z 496.2 
- {PtCl)(2-pic)]TFANa, m/z 456.3 - {Pt(13NH3)(2-pic)(Guanine)-H], mlz 438.1 - 









Figure 5.2 EST mass spectra at a cone voltage of 45 eV for a) fraction Fl and b) 
fraction F2 from the reaction of 15N-AMD473 and guanosine, see Figure 5.1. 




parent ion at mlz 702.4 corresponds to [Pt('5NH3)(2pic)(Guo)H]tTFA.  The other 
major peaks are assigned as follows: m/z 625.3 - [PtC1(15NH3)(2-pic)(Guo)f, m/z 
607.3 - [PtCI(2-pic)(Guo)], m/z 588.4 - [Pt(15NH3)(2-pic)(Guo)-H], m/z 570.3 - 
[Pt(2-pic)(Guo)-H], m/z 493.1 - [PtC1(15NH3)(2-pic)(Guanine)f, m/z 456.3 - 
[Pt(' 5NH3)(2-pic)(Guanine)-H]4 , m/z 438.2 - [Pt(2-pic)(Guanine)-H]. 
For the reaction of cis-[PtCl2(15NH3)(2-pic)] and 1-methylguanosine, the 
mass spectra at 45 eV for the fractions F3 and F4 are shown in Appendix 2. 
Likewise, there are a large number of fragment peaks but assignments are similar to 
those of fractions Fl and F2. The parent ion for fraction F3 at m/z 899.5 corresponds 
to the bis(guanosine) adduct, [Pt('5NH3)(2-pic)(1-MeGuo)2-H]t The other major 
peaks are assigned as follows: m/z 871.4— [Pt(' 5NH3)(2-pic)(Guo)2-H], m/z 716.3 - 
[Pt(' 5NH3)(2-pic)( 1 MeGuo)2IJ]tTFA,  m/z 702.3 	[Pt(' 5NH3)(2-pic)(Guo)- 
H]TFA, m/z 639.3 - [PtCl(15NH3)(2-pic)(1-MeGuo)], m/z 625.3 - [PtCI(15NH3)(2-
pic)(Guo)], m/z 588.3 - [Pt(15NH3)(2-pic)(Guo)-H], m/z 546.3 - [PtCI('5NH3)(1-
MeGuo)], m/z 532.1 - [PtC1('5NH3)(Guo)], m/z 514.2— [PtC12(15NH3)(2-pic)]TFA 
Nat, m/z 496.2 - [PtC12(2-pic)]TFANa, m/z 470.3 - [Pt(15NH3)(2-pic)(1-
MeGuanine)-H], m/z 452.3 - [Pt(2-pic)(1-MeGuanine)-H]1 , m/z 438.1 - [Pt(2-
pic)(Guanine)-H], m/z 399.1 - [PtC12(15NH3)(2-pic)INa. 
The mass spectrum for the fraction F4 has a parent ion at m/z 716.3, 
corresponding to [Pt(15NH3)(2pic)(1MeGuo)H]tTFA.  The other major peaks are 
assigned as follows: m/z 639.3 - {PtC1(15NH3)(2-pic)(1-MeGuo)f, mlz 621.3 - 
[Pt(2-pic)(1-MeGuo)Cl], m/z 584.3 - [Pt(2-pic)(1-MeGuo)-H], m/z 452.3 - [Pt(2-







9.5 	9.0 	8.5 	8.0 	7.5 	7.0 	6.5 	6.0 	5.5 	5.0 	4.5 	4.0 	3.5 	3.0 	2.5 	2.0 	1.5 
1 H 
b) 
9.5 	9.0 	8.5 	8.0 	7.5 	7.0 	6.5 	6.0 	5.5 	5.0 	4.5 	4.0 	3.5 	3.0 	2.5 	2.0 	1.5 
Figure 5.3 1 H NMR spectra in H20/D20 at 298 K of a) fraction Fl and b) fraction 
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Figure 5.4 1 H NMR spectra in H20/D20 at 298 K of a) fraction F3 and b) fraction 
F4, from the reaction of 15N-AMD473 and 1-Meguanosine, see Figure 5.1. 
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Figure 5.5 2D [1 1-1,15N] HSQC NMR spectra in H20/D20 at 298 K of a) fraction Fl 
and b) fraction F2 from the reaction of 15N-AMD473 and guanosine, and c) fraction 
F3 and d) fraction F4 from the reaction of 1 N-AMD473 and 1 -Meguanosine. 
NMR Characterisation 
The 'H NMR chemical shift data for fractions F1-F4 are summarised in 
Table 5.1. 'H NMR spectra for fractions F! and F2 are given in Figure 5.3 and those 
for F3 and F4 in Figure 5.4. The 'H NMR spectra for fractions Fl and F3 for the 
reaction of c/s-[PtC12(15NH3)(2-pic)] with guanosine and 1-methylguanosine, 
respectively, are very similar. Likewise, fractions F2 and F4 appear almost identical. 
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There are clearly two species present in fractions Fl and F3, as indicated from two 
sets of aromatic picoline peaks in a ratio of approximately 3:1. Integration of the 
spectra implies that the major species is the bis(nucleobase) Pt adduct, along with an 
additional AMD473 species, likely to be a mono(nucleobase) adduct. 
Table 5.1 'H NMR chemical shifts for fractions Fl - F4 (see Figure 5.1). 
Fraction 	 611-1 a 
H8 	 HI' 
Fl 	 8.42(s) 5.79 (t) 
8.44(s) 	 5.90 (d) 
8.50 (5)b 	 587b 
F2 	 8.57(s) 	 5.99 (d) 
F3 	 8.42(s) 	 5.78 (t) 
8.48 (5)b 	 5.90 (t) 
5.87" 
F4 	 8.56(s) 	 5.94(d) 
8.58 (s) 
a Note that multiplicities given in parenthesis are as they appear but as discussed in 
the text may be composed of overlapping signals. b  Minor species. 
['H,'5N] 2D HSQC NMR spectra for fractions F!, F2 and F3, F4 are shown 
in Figure 5.5. For fraction Fl there are two peaks at 4.30, -67.47 ppm and 4.56, - 
66.03 ppm, the latter corresponding to the bis(guanosine) adduct. The F3 fraction has 
a peak with chemical shifts of 4.5 5, -66.14 ppm, assigned as the bis(1-Meguanosine) 
adduct, and a second peak with chemical shifts of 4.30, -67.59 ppm, which are 
almost identical to those of fraction F!. Similarly, a peak at 4.48, -64.75 ppm is 
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observed for fraction F2 whilst that of fraction F4 is at 4.46, -64.85 ppm. These 
peaks are assigned as mono(guanosine) adducts. 
2. Time Course of cis-[Pt('5NH3)(2-pic)(0H2)21(NO3)2 with guanosine (1:2) 
15 NH
3-labelled cis-[PtC12('5NH3)(2-pic)J, from which the chloride ligands 
were previously removed with AgNO3 (forming the diaqua adduct), was reacted with 
2 mol equiv guanosine in an aqueous solution containing 0.1 M NaC104 and 
monitored by [1 H,15N] 2D HSQC NMR spectroscopy for 20 h at 298 K. Figure 5.6 
shows the HSQC spectra at the beginning and end of the reaction. Initially, there are 
eight cross-peaks present, five of which can be attributed to hydrolysis species 
(labeled *). The principal hydrolysis peak a, at 4.70, -83.81 ppm, has a '5N chemical 
Figure 5.6 2D [1H,15N] HSQC NMR spectra for the reaction of aquated 15N-
AMD473 and guanosine (1:2) at 298 K a) 0.33 h and b) 19.94 h after the start of the 
reaction. Assignments: a, cis- [Pt(' 5NH3)(2-pic)(OH2)2]2 ; b, cis- [Pt(' 5NH3)(2-
pic)(OH2)(Guo)]2 with OH-) trans to 15  NH,; c, cis-[Pt('5NH3)(2-pic)(OH2)(Guo)]2 
with guanosine trans to 15  NH3; d, cis-[Pt(15NH3)(2-pic)(Guo)2]2; * hydrolysis 
products. 
shift indicative of ammine trans to oxygen and is attributed to cis-[Pt(' 5NH3)(2-
pic)(OH2)2]2 . Peak a gradually decreases in intensity as the peaks b (4.60, -83.37 
ppm) and c (4.59, -65.50 ppm) both increase for a time and then gradually decrease, 
implying they are assignable to intermediate species. Peaks b and c are likely to be 
cis- [Pt(bNH3)(2pic)(OH2)(Guo)]2+ adducts with H20 trans to '5NH3 and 2-pic, 
respectively. Peak d at 4.49, -66.09 ppm, which is very weak in the initial spectrum, 
becomes the dominant product over time and is assigned as the cis-[Pt(15NH3)(2-
pic)(Guo)2]2 adduct. A simplified time-dependence of the concentrations of the 
main species detected during the reaction is shown in Figure 5.7. The proposed 
reaction pathway is shown in Scheme 5.1 and a fit of the data was attempted using 
the program SCIENTIST (Version 2.01, MicroMath Inc.). However, it was not 
possible to attain a satisfactory fit of the data with this scheme and therefore no rate 
constants were determined. 
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Scheme 5.1 Proposed pathway for reaction of cis-[Pt(1 NH3)(2-pic)(OH2)2]2 with 
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Figure 5.7 Concentration versus time profile for the reaction of cis-[Pt(' 5NH3)(2-
pic)(0H2)2](NO3)2 and guanosine (1:2) at 298 K. Concentration values were 
calculated from the integration of the 2D cross-peaks in the ['H,15N] spectra. (•) a, 
cis-[Pt(' 5NH3)(2-pic)(OH2)2]2 ; (•) b, cis-[Pt(' 5NH3)(2-pic)(0H2)(Guo)]2 with OH2 
trans to 15NH3; (Y) c, cis- [Pt(' 5NH3)(2-pic)(0H2)(Guo)]2 ' with guanosine trans to 
"NH3; (A) d, cis-[Pt(' 5NH3)(2-pic)(Guo)2]2 . 
3. Guanosine Adducts of cis- and trans-IPtC12(NH3)(2-pic)I 
Adducts of both cis- and trans-[PtC12(NH3)(2-pic)] with guanosine (Guo) and 
2'-deoxyguanosine (2-dGuo) were prepared and characterised in solution by ESI 
mass spectrometry and both 1 D 'H and 2D NMR spectroscopy. 
cis- [Pt(NH3)(2-pic)(Guo)2] (NO3)2 
The parent ion at m/z 870.6 in the positive ion electrospray mass spectrum in 
water, is assigned to [Pt(NH3)(2-pic)(Guo)2-H]. The other peaks were assigned as 
follows: m/z 738.4 - [Pt(NH3)(2-pic)(Guo)(Guanine)-H], m/z 606.4 - [Pt(NH3)(2-
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Figure 5.8 'H NMR spectra of cis- [Pt(NH3)(2-pic)(Guo)2](NO3)2 at 298 K in a) d6-
DMSO and b) H20/D20. 
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Figure 5.9 a) 'H NMR spectra showing the temperature dependence of the H8 
signals and b) plot of 5 H8 versus temperature of cis- [Pt(NH3)(2-pic)(Guo)2](NO3)2 
in H20/D20. 
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[Pt(NH3)(2-pic)(Guanine) - Hf, m/z 438.2 - [Pt(2-pic)(Guanine) - Hf. 
The 'H NMR spectra of cis- [Pt(NH3)(2-pic)(Guo)21(NO3)2 in H20/D20 and 
DMSO at 298 K are shown in Figure 5.8. A selection of peaks is listed in Table 5.2. 
Clearly the solvent has a large effect on chemical shift, but most noticeable is that the 
H8 signals for the guanosine ligands only give rise to two H8 peaks in H20/D20, 
whereas in DMSO four H8 peaks are distinguishable. Moreover, in H20/D20 the HI' 
sugar protons appear to give rise to a doublet and triplet, which is most unexpected 
as two doublets would be expected. In DMSO two triplets are observed. Therefore, a 
further 1 H spectrum in H20/D20 was recorded at a different frequency and it was 
found that the coupling constants" at 500 MHz are 4.5 and 4 Hz whilst at 800 MHz 
the "coupling constants" are 4.8 and 5.6 Hz. This implies that in fact there are two 
sets of overlapping doublets. 
The temperature dependence of the 'H NMR spectrum was investigated 
between 278 K and 323 K (Figure 5.9). At low temperature there is only one broad 
H8 signal which is gradually resolved into two and the separation of the signals 
increases with increasing temperature. This is clearly demonstrated by the plot of 
H8 shift versus temperature shown in Figure 5.9. 
A 2D NOESY spectrum in H20/D20 was recorded at 298 K in order to 
investigate the solution structure of the complex (Figure 5.10). However, only one 
H8 signal for the two H8 protons can be distinguished and this exhibits an NOE 
cross-peak to the 2-picoline methyl group. An NOE cross-peak between the aromatic 
H6 proton of the 2-picoline ligand and the H8 peak is also observed. 
In the pH range from 2 - 12, the pH-dependent 'H NMR chemical shift 
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Figure 5.10 2D [1 H,'H] NOESY NMR spectrum of cis-[Pt(Nl-13)(2-
pic)(Guo)2](NO3)2 at 298 K in l-120/D20. 





2 	4 	6 	8 	10 	12 
pH 
Figure 5.11 pH dependence of the H8 chemical shifts of cis-[Pt(NH3)(2-
pic)(Guo)2](NO3)2. The curves represent computer fits to the Henderson-Hasselbaich 
equation, and give the PKa values listed in Table 5.3. 
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corresponding to the deprotonation of the two inequivalent NIH sites of the 
guanosine ligands (Figure 5.11). The PKa values of 8.07 and 8.17 were determined 
from computer fits to the Henderson -Hassel baich equation. 
cis-IPt(NH3)(2-pic)(2'-dGuo)2] (NO3)2 
The parent ion at m/z 838.5 in the positive ion electrospray mass spectrum in 
water, is assigned to [Pt(NH3)(2-pic)(2'-dGuo)2-H]. The other peaks were assigned 
as 	follows: m/z 722.3 - [Pt(NH3)(2-pic)(2 -dGuo)(Guanine)-H]
+  , m/z 606.2 - 
[Pt(NH3)(2-pic)(Guanine)2 - H], m/z 454.9 - [Pt(NH3)(2-pic)(Guanine) - H], m/z 
437.9 - [Pt(2-pic)(Guanine) - H]4 . 
The 'H NMR spectrum of cis- [Pt(NH3)(2-pic)(2'-dGuo)2](N 03)2 in H20/D20 
is shown in Appendix 3. A selection of peaks is listed in Table 5.2. In this case, there 
are four very close but distinguishable H8 signals and two symmetrical triplets for 
the H I' sugar protons. 
The temperature dependence of the 'H NMR spectrum was investigated 
between 278 K and 323 K (Figure 5.12). At low temperature there are four H8 
signals. With increasing temperature two of these signals gradually merge into one, 
as exemplified by the plot of 5 H8 shift versus temperature shown in Figure 5.12. 
A 2D ROESY spectrum in H20/D20 was recorded at 298 K (Appendix 4) in 
order to investigate the solution structure of the complex. The H8 signals at 8.36 and 
8.38 ppm are indistinguishable in the 2D spectrum, but it appears that only these H8 
peaks have an NOE cross-peak to the 2-picoline methyl group, ruling out the 
likelihood of a head-to-head configuration. This complex also exhibits an NOE 
cross-peak between the afore-mentioned H8 signals and the aromatic H6 proton of 
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Figure 5.12 a) 'H NMR spectra showing the temperature dependence of the H8 
signals and b) plot of 8 H8 versus temperature of cis-{Pt(NH3)(2-pic)(2'-
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Figure 5.13 pH dependence of the H8 chemical shifts of cis- [Pt(NH3)(2-pic)(2'-
dGuo)2](NO3)2. The curves represent computer fits to the Henderson-Hasselbaich 
equation, and give the PKa values listed in Table 5.3. 
In the pH range from 2 - 12, the pH-dependent 'H NMR chemical shift 
measurements of the H8 peaks in 90% H20/10% D20 show four acid-base equilibria 
corresponding to the deprotonation of inequivalent N 1 H sites of the guanosine 
ligands (Figure 5.13). The pKa values determined from computer fits are 8.00, 8.05, 
8.38 and 8.40. 
trans- IPt(NH3)(2-pic)(G uo)21 (NO3)2 
The parent ion at m/z 870.5 in the positive ion electrospray mass spectrum in 
water, is assigned to [Pt(NH3)(2-pic)(Guo)2-H]+. The other peaks were assigned as 
follows: m/z 738.4 - [Pt(NH3)(2-pic)(Guo)(Guanine)-H], m/z 606.2 - [Pt(NH3)(2-
pic)(Guanine)2 - H], m/z 588.2 - [Pt(NH3)(2-pic)(Guo) - HJ, m/z 437.9 - [Pt(2-
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Figure 5.14 a) 'H NMR spectra showing the temperature dependence of the H8 
signals and b) plot of 8 H8 versus temperature of trans- [Pt(NH3 )(2-
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The 'H NMR spectrum of trans- [Pt(NH3)(2-pic)(Guo)2](NO3)2 in H20/D20 is 
shown in Appendix 5. A selection of peaks is listed in Table 5.2. Again, only two H8 
peaks are observed and interestingly, there is only one doublet corresponding to the 
Hi' sugar protons. 
The temperature dependence of the H NMR spectrum was investigated 
between 278 K and 318 K (Figure 5.14). At low temperature there are two H8 signals 
which merge into one broad signal around 310 K. This is clearly demonstrated by the 
plot of 6 H8 shift versus temperature shown in Figure 5.14. 
A 2D NOESY spectrum in H20/D20 was recorded at 298 K in order to 
investigate the solution structure of the complex. However, only one H8 signal for 
the two H8 protons can be distinguished and this exhibits an NOE cross-peak to the 
2-picoline methyl group. Unfortunately, this does not elucidate any particular 
solution structure. 
pH 
Figure 5.15 pH dependence of the H8 chemical shifts of trans- {Pt(NH3)(2-
pic)(Guo)2](NO3)2. The curves represent computer fits to the Henderson-Hasselbalch 
equation, and give the pKa values listed in Table 5.3. 
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In the pH range from 2 - 12, the pH-dependent 'H NMR chemical shift 
measurements of the H8 peaks in 90% H20/10% D20 show two acid-base equilibria 
corresponding to the deprotonation of the two inequivalent N1H sites of the 
guanosine ligands (Figure 5.15). The associated pKa values are 7.84 and 7.85. 
trans- [Pt(NH3)(2-pic)(2' -dGuo)2  I (NO3)2 
The parent ion at m/z 838.6 in the positive ion electrospray mass spectrum in 
water, is assigned to [Pt(NH3)(2-pic)(2-dGu0)2-H]. The other peaks were assigned 
as follows: m/z 722.4 - [Pt(NH3)(2-pic)(2'-dGuo)(Guanine)-H]', m/z 606.2 - 
[Pt(NH3)(2-pic)(Guanine)2 - Hf, m/z 589.0 - [Pt(2-pic)(Guanine)2 - Hf, m/z 438.0 
- [Pt(2-pic)(Guanine) - Hf. 
The 	'H NMR spectrum of trans- [Pt(NH3)(2-pic)(2'-dGuo)2](NO3)2 in 
H20/D20 is shown in Appendix 6. A selection of peaks is listed in Table 5.2. Two 
1-18 signals for platinated 2'-deoxyguanosine are observed and unexpectedly, only a 
single triplet is observed for the H 1' sugar protons. 
The temperature dependence of the 'H NMR spectrum was investigated 
between 278 K and 318 K (Figure 5.16) and is almost identical to that of trans-
[Pt(NH3)(2-pic)(Guo)2](NO3)2, as there are two H8 signals at low temperature which 
merge into one broad signal around 310 K. A plot of 6 H8 shift versus temperature is 
shown in Figure 5.16. 
A 2D ROESY spectrum in H20/D20 recorded at 298 K revealed that the H8 
signals are again indistinguishable in the 2D spectrum (Figure 5.17) and have a 
cross-peak to the 2-picoline methyl group. As in the case of cis-[Pt(NH3)(2-
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Figure 5.16 a) 'H NMR spectra showing the temperature dependence of the H8 
signals and b) plot of 8 H8 versus temperature of trans-[Pt(NH3)(2-pic)(2'-
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Figure 5.17 2D ['H,1 H] ROESY NMR spectrum of trans- [Pt('5NH3)(2-pic)(2'-
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pH 
Figure 5.18 pH dependence of the H8 chemical shifts of trans-[Pt(NH3)(2-pic)(2'-
dGuo)2](NO3)2. The curves represent computer fits to the Henderson- Hassel baich 
equation, and give the pKa values listed in Table 5.3. 
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peak between the 2'-deoxyguanosine H8 signals and the aromatic H6 proton of the 2-
picoline ligand. 
In the pH range from 2 - 12, the pH-dependent 'H NMR chemical shift 
measurements of the H8 peaks in 90% H20/10% D20 show two acid-base equilibria 
corresponding to the deprotonation of inequivalent N 1 H sites of the guanosine 
ligands (Figure 5.18). The associated pKa values are 7.86 and 7.87. 
Table 5.2 'H NMR chemical shifts for the complexes cis- {Pt(NH3)(2-pic)(Guo)2] 
(NO3)2, cis-[Pt(N l-13)(2-pic)(2'-dGuo)2](NO3)2, trans- [Pt(NH3)(2-pic)(Guo)2](NO3)2 





cis- [Pt(NH3)(2-pic)(Guo)2](NO3)2 8.43 (s) 5.79 (t) 
8.44(s) 5.90 (d) 
cis- [Pt(NH3)(2-pic)(2'-dGuo)2](NO3)2  8.36(s) 6.16 (t) 
8.38(s) 6.27 (t) 
8.41 (s) 
8.41 (s) 
trans- [Pt(NH3)(2-pic)(Guo)2](NO3)2  8.52 (s) 5.89 (d) 
8.54 (s) 




Nucleobase complexes of platinum anticancer drugs have been extensively 
studied because they provide a basis from which to interpret reactions with DNA. 
1. HPLC Reactions of cis-[PtCl2(NH3)(2-pic)I with Guanosine Derivatives 
In order to both simplify and contrast the binding behaviour of cis-
[PtC12(NH3)(2-pic)] with nucleobases, guanosine and NI- and N7-methylated 
guanosines were employed as model compounds. Reverse phase chromatographic 
analysis using a water/acetonitrile gradient elution method revealed the formation of 
a significant intermediate (elution time 29-30 mm) and a predominant reaction 
product (-27 mm) for cis-[PtC12(NH3)(2-pic)] reactions with guanosine and 1-
methylguanosine. Reaction of cis-[PtC12(NH3)(2-pic)] with 7-methylguanosine was 
extremely slow and gave rise to very few reaction products, which are assumed to be 
NI-bound complexes. This is in agreement with a previous report that revealed 1-
methylguanosine reacts with [Pt(dien)(H20)]2 ten times more readily than 7-
methylguanosineJ341  
ESI-MS allowed identification of the isolated HPLC fractions F1-F4 (Figure 
5.1). Fractions Fl and F3 both contained a parent ion corresponding to the 
bis(guanosine) and bis( 1 -methyl guano sine) adducts, respectively. For fractions F2 
and F4, only mono(guanosine/l -methylguanosine) adducts were detected. In the 
present study, trifluoroacetate (TFA) was used as an ion-pairing reagent because of 
its volatility and the results show that with 0.1% TFA present and a suitable 
acetonitrile gradient, adducts of cis- [PtC l2(NH3)(2-pic)] with guanosine derivatives 
in aqueous solution can be easily separated. However, the subsequent ESI-MS assays 
indicate formation of various TFA adducts. 
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The 'H NMR spectra of fractions F! and F3 (Figures 5.3 and 5.4) 
unambiguously show the presence of platinated nucleobase in a 2:1 ratio of 
nucleobase to {Pt(15NH3)(2-pic)}, confirming that the dominant product is the 
bis(nucleobase) adduct. Nevertheless, both the 1D 'H and ['H,' 5N] 2D NMR spectra 
reveal the presence of an additional { Pt(15  NH3)(2-pic)l  species, having 15N chemical 
shifts of -67.47 and -67.59 ppm for fractions Fl and F3, respectively, which are 
consistent with that expected for an ammine ligand trans to chloride or nitrogen. It 
seems likely that this species is a mono(nucleobase) adduct, probably with the 
nucleobase cis to the 2-picoline ligand, which coincidentally elutes at the same time 
as the bis(nucleobase) adducts. This hypothesis is supported by the ESI-MS data in 
which peaks for [PtC1('5NH3)(2-pic)(Guo)] and [PtCl(15NH3)(2-pic)(1-MeGuo)] 
were obtained. 
The '5N chemical shifts of the cross-peaks for the bis(nucleobase) adducts 
verify that the ammine ligand is likely trans to nitrogen. The chemical shifts of the 
bis(nucleobase) adducts from Fl and F3 are in good agreement with the presence of 
cis-[Pt(15NH3)(2-pic)(Guo)2]2 , as formed in the kinetic reaction in section 2. 
Integration of the 2D cross-peaks in the ['H,' 5N] HSQC spectra of fractions F! and 
F3 (Figure 5.5) indicates there is a 3:1 ratio of the bis(nucleobase) adduct to the 
mono(nucleobase) adduct. 
From a combination of 'H and ['H,'5N] NMR spectra, fractions F2 and F4 
are compatible with a single platinated mono(nucleobase) species. The 15N chemical 
shifts again imply that the ammine is trans to chloride or nitrogen. Therefore, taking 
into account previously determined hydrolysis data for cis-[PtC12(15  NH3)(2-pic)] 
which reports faster hydrolysis trans to the 2-picoline ligand due to steric 
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hindrance, [351  along with the 15N chemical shifts and ESI-MS data, it seems likely 
that fractions F2 and F4 both contain cis-[PtCl(15NH3)(2-pic)(nucleobase)f, with the 
nucleobase trans to the 2-picoline ligand. 
2. Time Course of cis-[Pt('5NH3)(2-pic)(0H2)2](NO3)2 with guanosine (1:2) 
Since the reaction of cis-[PtCl2(15NH3)(2-pic)] with guanosine was slow when 
studied by NMR (67% reaction in 19 h), cis-[PtCl2('5NH3)(2-pic)1 was firstly reacted 
with 1.96 equiv AgNO3 to give mainly cis- [Pt('5NH3)(2-pic)(0H2)2](NO3)2, and 
some other minor hydrolysis products, and then reacted with guanosine (1:2). The 
principal hydrolysis peak a at 4.70, -83.81 ppm (Figure 5.6) is believed to be due to 
cis-[Pt(1 NH3)(2-pic)(OH2)2]2 . The hydrolysis peaks in the upper region of the 
spectra, i.e. less than -80 ppm for 'N, are likely to be cis-[Pt(15NH3)(2-
pic)(OH/OH2)(Cl/OH/OH2) species, whilst the hydrolysis peak at 4.52, -64.68 ppm 
is probably cis- [PtC1(15NH3)(2-pic)(0H2/OH)] with the chloride ligand trans to the 
ammine. Only the hydrolysis peak a undergoes a significant change in concentration 
during the time course of the reaction and for simplicity, the other hydrolysis species 
were omitted from the kinetic profile. From the ' 5N chemical shift data and reaction 
profiles, peaks b-d can be tentatively assigned as indicated in Scheme 5.1. It is 
noteworthy that the initial rate of formation of b, cis-[Pt(1 NH3)(2-pic)(OH2)(Guo)] 
with the guanosine trans to the 2-picoline ligand, is faster than that of c, cis-
[Pt('5NH3)(2-pic)(OH2)(Guo)] with the guanosine cis to the 2-picoline ligand. This 
may be expected as there is less steric hindrance for formation of b relative to c. 
However, the rates of the second guanosine substitution appear similar for b and c, 
which is quite unexpected. 
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3. Guanosine Adducts of cis- and trans-IPtC12(NH3)(2-pic)I 
The combination of ESI mass spectrometry, ID H and 2D ['H,'H] NMR 
spectroscopy unambiguously identify the platinum complexes as bis(nucleobase) 
adducts. Platination at the N7 position was confirmed in each case by the absence of 
a N7 protonation below pH 6 in the pH titrations (Figures 5.11, 5.13, 5.15, 5.18). 
Coordination of electrophilic Pt" to the ring atoms of the nucleobases withdraws 
electron density from the ring. As a result, the heteroatom of neutral nucleobases 
capable of deprotonation becomes more acidic and those capable to accept a proton 
become more basic. For example, the N( I )H proton of 9-substituted 6-oxopurines is 
acidified by 1.2 - 2 log units upon platination of the N(7) site, depending 
predominantly on the charge of the platinum compounds. 136-31  The pKa values for 
cis- [Pt(NH3)(2-pic)(Guo)2]2 ' (8.07, 8.17), cis- [Pt(NH3)(2-pic)(2'-dGuo)2]2 (8.00, 
8.05, 8.38, 8.48), trans- [Pt(NH3)(2-pic)(Guo)2]2 (7.84, 7.85) and trans- [Pt(NH 3)(2-
pic)(2'-dGuo)2]2 (7.86, 7.87) are in agreement with literature values 
[39]  (Table 5.3). 
It is noteworthy that the pKa values for both trans adducts are lower than those of the 
cis. This was also found to be the case for cis- and trans- [Pt(NH3)2(9-EtGH)2] 2+ but 
surprisingly, replacement of the coordinated ammonia by methylamine reverses the 
situation. 391  
For cis- [Pt(NH3)(2 pic)(Guo)2]2 F,  only one broad H8 peak is present at low 
temperature (Figure 5.9). This can be attributed to both coincidental overlap of H8 
and restricted rotation of guanosine, where a specific configuration is favoured. As 
discussed in Chapter 4, one of the H8 peaks (G2) is more affected by temperature 
than the other and it is probable that G2 corresponds to the guanosine cis to the 2- 
picoline ligand. 
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Table 5.3 Comparison of PKa values for N I H of 9-EtGH, Guo and 2'-dGuo in the 
complexes studied here and in cisplatin adducts. 
Species 	 pKa N 1(H) 	Reference 
9-EtGH 	 9.57 	 [391 
H(Guo) 	 9.22 	
[39] 
H(2'-dGuo) 	 9.24 	 [39] 
	
cis- [PtNH3)2(9-EtGH)2]2 ' 	 8.01, 8.66 	
[39j 
trans- [Pt(N H3)2(9-EtGH)2]2 	7.90, 8.54 	 1391 
cis- [Pt(N H3)7(2'-dGuo)C if 	 7.84 	 1391 
trans- [Pt(N H3)2(2'-dGuo)Cl] 	 8.24 	 1391 
cis- [Pt(NH3)(2-pic)(Guo)2]2 	8.07, 8. 17 	Present work 
cis-[Pt(NH3)(2-pic)(2'-dGuo)2]2 ' 	8.00, 8.05, 8.38, 8.40 	Present work 
trans- [Pt(NH 3)(2-pic)(Guo)2]2 	7.84, 7.85 	Present work 
trans- [Pt(NH3)(2-pic)(2'-dGuo)2]2 	7.86, 7.87 	Present work 
In the case of cis- [Pt(NH3)(2-pic)(2'-dGuo)2]2 , four H8 peaks are present 
even at low temperature, two of which coalesce around 320 K (Figure 5.12). 
Similarly, it seems that two of the four peaks (2G3 and 2G4) experience a greater 
temperature dependence and these are likely to be the guanosine bases cis to the 2-
picoline iigand in two different configurations. 
The trans adducts exhibit a very similar temperature dependence to one 
another, characterised by the coalescence of two H8 peaks around 310 K (Figures 
5.14 and 5.16). This can be attributed to slow rotation of the guanosine bases at low 
temperature. 
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For cis- [Pt(NH3)(2-pic)(2'-dGuo)2]2 , further credence for the assignment of 
the two upfield H8 peaks (2G3 and 2G4) to guanosine bases cis to the 2-picoline 
ligand is given from the 21) ROESY spectrum (Appendix 4) as there is an NOE 
cross-peak between the two upfield H8 peaks and the aromatic [-16 proton of the 2-
picoline ligand. An NOE cross-peak of this strength is only likely if the guanosine is 
cis relative to the 2-picoline ligand. 
For cis-[Pt(NH3)(2-pic)(Guo)2]2 , it is believed that the unexpected doublet 
and triplet obtained for the HI' protons (Figure 5.8) are due to two sets of 
overlapping doublets. Unusually, the nonequivalence of the guanosine ligands is not 
reflected in the H8 but in the HI' protons. This may be indicative of some particular 
stereoselective interaction of the ribose ring or of some particular sugar conformation 
originating from extensive hydrogen bonding. The situation is inversed for the trans 
isomer where two H8 signals and only one Hi' doublet are observed (Appendix 5). It 
seems likely that this Hl' doublet must be similarly overlapped. Platinum 
coordination to nucleobases and in particular, nucleotides, is known to induce a 
change in the sugar-ring conformation from S-type (C2'-endo) to N-type (C3'-endo), 
which changes the Hi' - H2' coupling constant.'4' 40]  For the cis- and trans-
[Pt(NH3)(2-pic)(Guo)2]2 adducts, the Hi' - H2' coupling constants were not 
measurable due to coincidental overlap of signals. The values of J j2 for the cis- and 
trans-[Pt(NH3)(2-pic)(2'-dGuo)2]2 adducts (ca. 6-6.5 Hz) are consistent with 
predominantly S-type configuration. H 4] 
It has been proposed that, in solution, rotation about the Pt - N7 bond is 
crucial in forming the DNA lesion between adjacent purines. Restricted rotation 
about the Pt - N7 bonds can potentially lead to three different bis(nucleobase) 
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stereoisomers for square-planar complexes having two cis ligands with C2 local 
symmetry: two head-to-tail (HT) and one head-to-head (HH) species, with the H8s of 
the guanosine bases on the opposite side or on the same side of the Pt coordination 
plane, respectively. The asymmetry of the ribose sugar influences the number of 
signals that can be observed in the NMR spectrum. Thus, the HT enantiomers 
become diastereoisomers and should be distinguishable by NMR. Each HT isomer is 
C2-symmetrical and has one H8 signal. Therefore, four H8 signals in total are 
expected for the three stereoisomers. If the cis-PtA2 moiety lacks local C2 symmetry 
(eg. two different As or an unsymmetrical chelate), four different stereoisomers (two 
HT and two HH) are possible. However, it has been found that the HT forms are 
thermodynamically favoured in most simple cis-[PtA2G2] models. 1411 Each H8 is non-
equivalent for both HT stereoisomers, giving a total of four H8 signals for the HT 
stereoisomers. For cis- [PtC12(NH 3)(2-pic)], the 2-methyl group can be on the upper 
or lower side of the platinum plane for each HT stereoisomer, so theoretically eight 
H8 signals should be observed for the two HT isomers, together with four methyl 
signals when there is slow rotation on the NMR timescale about both Pt - N7 
guanosine and Pt - N picoline bonds. In the cis-{Pt(NH3)(2-pic)(Guo)2]2 adduct, 
only two H8 signals and one methyl signal were observed, suggesting rotation about 
both Pt - N7 guanosine and Pt - N picoline bonds is fast on the NMR timescale. 
However, for the cis-[Pt(NH3)(2-pic)(2'-dGuo)2]2 adduct, four H8 signals and two 
methyl signals were observed. This suggests that rotation of 2-deoxyguanosine about 
the Pt - N7 bond is fast on the NMR timescale but slow about the Pt - N bond for 2-
picoline. 
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For 	cis- [Pt(NH3)(2-pic)(Guo)2}2 and cis {Pt(NH3)(2 pic)(2dGuo)2J2 an 
NOE is observed between 2-picoline H6 and guanosine H8, which corresponds to the 
guanosine cis to 2-picoline and in a tail orientation relative to the methyl group of 2-
picoline. Thus, the NOE observed for the methyl group of 2-picoline to guanosine 
H8 may arise as a consequence of a guanosine positioned trans to 2-picoline in a 
head orientation relative to the methyl group of 2-picoline. Therefore, it seems likely 
that both cis-[Pt(NH3)(2-pic)(Guo)2]2 and cis-[Pt(NH3)(2-pic)(2'-dGuo)2]2 adopt 
head-to-tail orientations. 
For the trans complexes there are four different stereoisomers (2 x HT and 2 
x HH). Because of the chiral ribose of the guanosine bases, the HT enantiomers 
again become diastereoisomers. Therefore, four H8 signals should be observed for 
the two HT isomers. In each of the trans adducts, only two 1-18 signals are observed 
implying that either there is fast rotation about the guanosine bases and/or the Pt - 2-
picoline bond or alternatively, that one configuration is particularly favoured. The 
NOEs observed for trans- [Pt(NH3)(2-pic)(2 -dGuo)2]
2+  from the H8 signal to 2-pie 
H6 and the 2-pie methyl group suggest a heat-to-tail orientation of the guanosine 
bases. 
5.6 Conclusions 
The subject of the conformational and dynamic properties of nucleobase 
complexes is of considerable fundamental chemical interest. A greater understanding 
of these phenomena may help to explain the high selectivity of platinum compounds 
towards guanine bases. 
This work has provided an insightful comparison of the binding of guanosine 
to cis- [PtC12(NH3)(2-pic)] (AMD473), a promising anticancer drug, and its trans 
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isomer. N7 platination was confirmed in all cases and a variety of Pt bis(guanosine) 
adducts were identified and characterised. Coordination of Pt" to the guanosine N7 
site lowers the basicity of the NiH site by about 0.8-1.2 log units and about 1.4 log 
units for the cis and trans isomers, respectively, as compared to the free nucleoside. 
Based on the NOEs, the complexes cis- [Pt(NH3)(2pic)(Guo)2]2F,  cis-[Pt(NH3)(2-
pic)(2'-dGuo)2]2 and trans- {Pt(NH3)(2-pic)(2'-dGuo)2]2 are assigned as head-to-tail 
conformations. The reaction of cis- [Pt('5NH3)(2-pic)(OH2)2]2 with guanosine (1:2), 
was followed by [1 H,15N] HSQC spectroscopy and proceeded through two 
mono(guanosine) intermediate species to yield the dominant product cis-[Pt(NH3)(2-
pic)(Guo)2]2 . interestingly, the initial rate of formation of the intermediate cis-
[Pt('5NH3)(2-pic)(0H2)(Guo)f was faster for guanosine substitution in the trans 
position than in the cis position to 2-picoline due to steric hindrance, though the rates 
of the second guanosine substitution appear similar for both intermediates. In a 
separate study, the preference for N7 binding was demonstrated by a 
chromatographic analysis of cis- [PtC12(N H3)(2-pic)] and substituted guanosine bases, 
which also confirmed the rate of reactions followed the order Guo > 1-MeGuo> 7-
MeGuo. 
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Kinetic studies of the reaction of the anticancer complex trans-
[PtC12(NH3)(2-picoline)] (AMD443) with the self-complementary 12-mer DNA 
duplex, d(TATGGTACCATA)2, using 1D 'H and 2D ['H,'5N] HSQC NMR 
spectroscopy at 298 K are reported, and compared to reactions of cisplatin and 
transplatin. Aquation of AMD443 is revealed to be the rate-limiting step in the 
formation of monofunctional DNA adducts. Models for monofunctional adducts 
indicate no particular stereoselective preference for G4 or G5. 
6.2 Introduction 
Coordination of Pt 11 to nucleic acid constituents and DNA has been the 
subject of numerous studies over the past two decades. 11-61  Great attention has been 
paid to the binding properties of Pt" compounds with cis geometry, in particular, 
because of the biological activity of cisplatin and related compounds. By contrast, far 
less is known of the clinically ineffective transplatin and corresponding trans 
derivatives. 71 However, detailed knowledge of the binding behaviour of transplatin 
and its structural analogues is of importance in understanding the factors which 
affect the biological activity of Pt" species. 
There is convincing evidence that the cytotoxicity of cisplatin is due to the 
bifunctional platination of DNA. 81 In the major adduct, cisplatin forms 1,2-cross-
links between adjacent purines in d(GpG) or d(ApG) sequences. 9' These lesions 
result in a roll of 26500  between the guanine bases involved in the cross-link and a 
global bend of the helix axis towards the major groove.110 '31 Also, the cisplatin cross-
link unwinds the duplex and induces a widening and flattening of the minor groove 
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in the vicinity of platination sites. These features result in the recognition of DNA by 
high mobility group protein (HMG), leading to blocking of gene transcription. 81  
Both cis- and trans-platin preferentially bind to GN7 and yield monofuctional 
adducts in the first platination step. However, unlike cisplatin, transplatin cannot 
form (N7, N7) intrastrand cross-links with adjacent purines due to geometrical 
constraints. On the other hand, transplatin has been shown to form 1 ,3-intrastrand 
adducts with d(GNG) 41 and d(ANG)1151 sequences (N = any nucleotide). The 
trinucleotides d(GpTpG)'61 and d(GpCpG) 71 have been used as models for studying 
1,3-chelation. Gel electrophoresis has shown that the trans- [Pt(NH 3)2(d(GTG)-GN7, 
GN7)] cross-link bends the DNA double helix 26° and unwinds it by 450)'81  An IF 
kink of the helix axis was observed for a 1,3-adduct of trans-
Pt(NH3)2[CCTCG*AG*TCTCC] and its complementary strand using NMR 
techniques. [141 
In addition to geometric differences between cis- and trans-platin adducts, 
kinetic factors may be responsible for differences in antitumour activity. It is 
believed that the hydrolysis to form monoaqua species prior to binding to DNA is the 
rate-determining stepJ19' Due to the trans effect, Cl>N>O, the non-active transplatin 
reacts faster than cisplatin in the first step of aquation and binding. This is probably 
the reason why transplatin is more reactive towards peptides in the extracellular 
medium, preventing the platinum complex from reaching the target DNA. 
As transplatin is kinetically more reactive than cisplatin, 1201 it was proposed 
that the antitumour activity of trans compounds could be increased by using 
sterically bulky ligands to reduce the rate of replacement of chioro ligandsJ211 Natile 
and Coluccia recently reviewed the progress of trans platinum anticancer agents. '3' 
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Three kinds of bulky ligands were described: (1) aliphatic amines, (2) pyridine-like 
ligands, 	and 	(3) 	iminoether 	ligands. 	The 	compound 	trans- 
[PtCl2(amine)(isopropylamine)I, for example, where the steric hindrance is enhanced 
by substitution of aliphatic amines for NH3 in transplatin, demonstrates higher 
cytotoxic activity than cisplatinJ221  
Pyridine-like ligands greatly enhance the cytotoxicity of trans-Pt" complexes. 
Generally, the cytotoxicity of the trans complexes, trans-[PtC12(L)(L')] [L = L' = 
pyridine or thiazole, or L = quinoline, L' = R'R"SO], are approximately one order of 
magnitude greater than transpiatin, and they are at least not lower than their cis 
isomers. A significant feature of such trans complexes is that they are not cross-
resistant to cisplatin in either L1210 leukaemia or human ovarian tumour cells. [23] 
Similarly, the iminoethers have been shown to be more active as trans isomers than 
as cis isomers. [24-26]  
The trans isomer (AMD443) of the promising anticancer drug cis-
{PtC12(NH3)(2-picoline)] (AMD473), which is currently in phase II clinical trials, 
exhibits a similar profile of cytotoxicity, and is indeed more cytotoxic than AMD473 
in a variety of cell lines. [27, 281 The bulky methyl group of the picoline ligand in 
AMD473 inhibits attack at the platinum and slows the rate of aquationJ29' The steric 
hindrance imposed by the methyl group is less in the trans complex than in the cis 
isomer (Chapter 3), but it is expected that it will still have a significant influence on 
the aquation and binding behaviour of AMD443. 
It is of interest to examine how the picoline ligand in the trans platinum(II) 
complex, AMD443, affects the DNA-binding profile. In this study, the reaction of a 
self-complementary 1 2-mer DNA duplex, d(TATGGTACCATA)2, with "NH3  
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labelled trans-[PtC12(15NH3)(2-pic)J was monitored by ID 'H and 2D ['H,'N] 
HSQC spectroscopy. The structures of the monofunctional adducts of 13-form DNA 
were also investigated by molecular modelling. The results are discussed in relation 
to similar studies performed on relevant complexes. 
6.3 Experimental 
Materials: 2-picoline was purchased from Aldrich. The 12-mer oligonucleotide, 
d(TATGGTACCATA), was prepared as a sodium salt by the Oligonucleotide 
Synthesis Service at Cancer Research UK. Trans-[PtCl2(15NH3)(2-pic)] was prepared 
by the procedure described in Chapter 3. 
The concentration of the 12-mer single strand was determined by UV 
according to its c value at 260 nm (c = 112.3 x iø M'cm'). The synthetic self-
complementary oligonucleotide was annealed by firstly dissolving in 1 mL of high 
purity water, then denatured by heating at 368 K for 5 mm. The oligonucleotide was 
then slowly renatured by stepwise cooling. The DNA was incubated at 338 K for 10 
mm, 310 K for 30 mm, 338 K for 10 mm, 310 K for 4 h and then slowly cooled to 
room temperature. The annealed oligonucleotide was stored at 253 K. 
NMR Spectroscopy: NMR spectra were recorded at 298 K, unless otherwise stated, 
on a Bruker DMX500 spectrometer ('H 500.13 MHz) or Bruker AVA600 ('H 599.81 
MHz) using 5 mm NMR tubes. All samples were prepared in 90% H20/10% D20 
and contained 0.02 M NaCI04 to maintain a constant ionic strength. Spectra were 
referenced to TSP via dioxane, 5 3.75. Water suppression was achieved by 
presaturation. Spectra were processed using XW[NNMR (Version 3.5, Bruker UK 
Ltd). 
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pH Measurements: The pH values of solutions were determined using a Corning 
145 pH meter equipped with a micro combination electrode, calibrated with Aldrich 
buffer solutions at pH 4, 7 and 10. No correction was made for deuterium isotope 
effects. 
Molecular Modelling: Molecular modelling was carried out by Dr. Vivienne Munk 
using SYBYL version 6.9 (Tripos Inc.). Models were energy-minimised using the 
Tripos force field. Models were considered energy-minimised when a constant 
energy was achieved. 
6.4 Results 
The reaction of trans-[PtC12('5NH3)(2-picoline)] with the 12-mer DNA 
duplex at an approximately 1:1 molar ratio (0.8 mM, pH 7.3, 0.02 M NaCI04, 90% 
H20/10% D20, 298 K) was followed by ID 'H and 2D ['H,'5N] HSQC NMR 
spectroscopy for a period of ca. 25 h. Figure 6.1 shows the HSQC spectra at various 
time intervals throughout the reaction. 
Initially, two cross-peaks are observed. The most intense peak a, at 3.80, - 
69.44 ppm, corresponds to trans- [PtCl2(' 5NH3)(2-picoline)]. Based on the chemical 
shifts, peak b at 3.80, -67.51 ppm is assignable to the monochloro monoaqua species, 
confirmed by NMR pH titration in Chapter 3. The intensity of the peak for the 
dichioro species decreases with time and the monochloro monoaqua species behaves 
as an intermediate, with the intensity increasing for the first three hours and then 
gradually decreasing. After ca. 1.6 h, two new but very weak peaks appear at 4.18, - 
65.30 ppm and 4.32, -65.29 ppm, peaks c and d, respectively. Peak c may be a 
monochloro monoguanine adduct, assigned on the basis of its reaction profile. Its 
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Figure 6.1 [1 H,15N] HSQC NMR spectra (298 K) of a 1:1 solution of trans-
[PtC12(15NH3)(2-pic)] and 12-mer DNA duplex a) 0.51 h, b) 8.25 h, c) 16.12 hand d) 
25.12 h after the start of the reaction. Peak assignments: a = trans- {PtCl2('5NH3)(2-
pic)], b = trans- [PtC1(OH2)('5NH3)(2-pic)], c = monochloro monoguanine adduct, d 
= monochloro monoguanine adduct, e, f and g are unassigned, * = 195Pt satellites. 
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intensity increases steadily and then appears to reach equilibrium after Ca. 10.5 h. 
Peak c represents the major reaction product, corresponding to ca. 40 % of the total 
Pt - 15 NH3  species. Peak d increases in intensity initially, levels off around 10 h and 
then starts to decrease slightly after ca. 15 h, indicating it may be an intermediate 
species. It seems likely that peak d corresponds to a monochloro monoguanine 
adduct also, as there are two guanines (G4 and G5) available for binding. A fifth peak 
(e) is observed after 2.2 h at 4.21, -63.44 ppm. The intensity of this peak also 
increases with time but even after ca. 25 h of reaction, only accounts for ca. 11.5 % 
of the total Pt - 15 NH3  species present. The cross-peaks experience significant 
broadening over time. At ca. 7.1 h two further peaks are observed at 4.28, -64.33 
ppm and 4.05, -66.28 ppm, f and g, respectively. Both increase in intensity over time 
although the intensity of peak g seems to decrease slightly towards the end of the 
reaction. It is difficult to assign the peaks unambiguously, but peak f appears to 
increase in intensity at the expense of peak d (particularly evident ca. 20 h) and may 
therefore be assignable to a bisadduct, such as a GC or GA interstrand cross-link. 
A time-dependence of the concentrations of the main species detected during 
the reaction is shown in Figure 6.2. Due to the complexity of the reaction and the 
presence of unassigned peaks no attempt was made to fit the data to obtain rate 
constants. Half-lives for peaks a and c were derived from the computer fits of the 
concentration versus time profiles using the program Microcal Origin 7.5 (Appendix 
7), and are listed in Table 6.1. 
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Figure 6.2 Kinetic profile for the reaction of trans-[PtC12('5NH3)(2-pic)] and 12-mer 
duplex DNA d(TATGGTACCATA)2 at 298 K as determined by integration of the 
2D cross-peaks shown in Figure 6.1. Assignments: (U) a = trans-[PtC12(N143)(2-
pic)], (0) b = trans- [PtCl(OH2)('5NH3)(2-pic)], (A)  c = monochloro monoguanine 
adduct, (V) d = monochloro monoguanine adduct, (4) e, (t') f and (•) g are 
unassigned. 
Table 6.1 Chemical shifts and half-lives for peaks a - g in the reaction of trans-
[PtCl2(1  5N H3)(2-pic)] with the self-complementary I 2-mer DNA duplex 
d(TATGGTACCATA)2 at 298 K (see Figure 6.1). 
Peak 8 1H, '5N Assignments 	 Half-life (h) 
a 3.80, 69.44 Dichloro 	 4.02 
b 3.80, -67.51 Monoaqua monochloro 	 - 
C 4.18, -65.30 Monochioro monoguanine 	3.82 
d 4.32, -65.29 Monochloro monoguanine 	- 
e 4.21, -63.44 - 	 - 
f 4.28, -64.33 - - 
9 4.05, -66.28 - 	 - 
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Figure 6.3 'H NMR spectra (298 K) of trans-[PtCl2(15NH3)(2-pic)] with 12-mer 




The 'H NMR spectra of the reaction are most intriguing. In the first 'H 
spectrum recorded 0.2 h after the start of the reaction (Figure 6.3), the aromatic 
proton signals and methyl signal of the 2-picoline ligand of trans-[PtCl2(NH 3)(2-
pic)] are clearly visible: 8.74 ppm (d), 1-16; 7.76 ppm (t), 1-14; 7.43 ppm (d), H3; 7.29 
ppm (t); 3.12 ppm (s), CH3. However, these signals decrease in intensity over time 
and are no longer visible after ca. 10.2 h. It is noteworthy that a plot of the intensity 
of the H6 aromatic peak of the 2-picoline ligand correlates approximately with the 
decrease in intensity in the 2D ['H,'5N] HSQC spectra of the dichloro species 
AMD443 (Figure 6.4). 
2 	4 	6 	8 	10 
Time (h) 
Figure 6.4 Plot of intensity of aromatic H6 'H NMR resonance of 2-picoline ligand 
versus time during the reaction of trans-[PtC12( 15  NH3)(2-pic)]  and 1 2-mer duplex 
DNA at 298 K. 
There are few observable changes in the 'H NMR spectrum of the 12-mer 
duplex DNA during the reaction but there appears to be a slight upfield shift of 0.01 
ppm for the signal around 7.54 ppm, assigned as the G5(H8) signal. Also, there are 
some very small signals visible at ca. 8.81, 8.90 and 8.92 ppm, which may be due to 
the H6 proton of bound AMD443. A 21) ['l-1,'H] NOESY spectrum of the free 12-
mer duplex (284 K) is shown in Figure 6.5 and this can be compared with the 2D 
['H,'H] NOESY spectrum (298 K) recorded after completion of the reaction, Figure 
6.6. The 'H NMR peaks for the duplex were partially assigned based on previous 
work by Sletten.130' The hydrogen-bonding in the imino region (12-14 ppm) seemed 
to remain unperturbed upon platination. Interestingly, there are less cross-peaks at 
higher temperature implying an increased fluxionality of the platinated duplex. 
Eight molecular models of the monofunctional G adducts of the I 2-mer 
duplex were built by docking {PtCl(NH3)(2-pic)} onto the G4 or G5 of the G4G5 site, 
and are shown in Figure 6.7. The models differed as follows: the 2-methyl group 
orientated towards the 3-end of the DNA (Methyl-Down) with the 2-picoline 
orientated either away from the G4 bound H8 (a) or towards the G4 bound H8 (b); the 
2-methyl group orientated towards the 5-end of the DNA (Methyl-Up) with the 2-
picoline orientated either away from the G4 bound H8 (c) or towards the G4 bound 
H8 (d); Methyl-Down with 2-picoline orientated either away from the G5 bound H8 
(e) or towards the G5 bound H8 (I); Methyl-Up with 2-picoline orientated either 
away from the G5 bound H8 (g) or towards the G5 bound H8 (h). There is only a 
small variation in the relative energies of the models (2033 - 2049 kcalmoi'). 
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Figure 6.5 2D [1 H,'H] NOESY NMR spectrum (mixing time 250 ms) of 12-mer 
duplex DNA d(TATGGTACCATA)2 in 0.02 M NaC104 at 284 K. CH4b is the 
cytosine amino proton involved in H-bonding in the CG base pair, CH4f is the non-
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Figure 6.6 2D [1H,1H] NOESY NMR spectrum (mixing time 250 ms) of trans-
[PtCl2(''NH3)(2-pic)] and 12-mer duplex DNA in 0.02 M NaC104 at 298 K. CH4b is 
the cytosine amino proton involved in H-bonding in the CG base pair, CH4f is the 












Figure 6.7 Molecular models of the G*  adduct of the 12-mer duplex DNA, where 
G* represents binding with trans-{PtCl(2-pic)(NH3)}. Unplatinated DNA - red, 
platinated DNA - green and atom colours are used for G bases of platinated DNA 
and trans- {PtC1(2-pic)(NH3)}. 
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hydrogen bonds to the coordinated guanine 06 (distances = 1.79 - 2.34 A), have the 
lowest energies. Hydrogen bonds are also observed in models a and c between a 
proton of the ammine group and the phosphate backbone (distances = 2.15 —2.22 A). 
No major steric clashes are observed for any of the models and it appears that only a 
slight movement of the guanine bases and nearest bases is sufficient to accommodate 
the platination. 
6.5 Discussion 
The differences in antitumour activity between cis-and trans- Pt(II) species 
have been attributed to three principal factors: 1) the structural perturbation of DNA 
induced by platination, 2) the kinetics of adduct formation, and 3) the sequence 
selectivity of binding to DNA. Therefore, in this work the interaction of trans-
[PtC12('5NH3)(2pic)] with duplex DNA has been investigated. 
['H,'5N] HSQC NMR has proven to be a powerful method for studying DNA 
platination reactions by cisplatin and its analogues. [3 	Unfortunately, this 
technique yields less information for trans complexes (as the 15N shifts are strongly 
influenced by the trans ligand which remains unchanged for trans complexes), but 
has nevertheless provided a useful insight into the reaction profile. Initially, only two 
cross-peaks, a and b, were present in the ['H,'5N] NMR spectrum (Figure 6.1), 
which were unambiguously assigned as trans-[PtCl 2( 15NH3)(2pic)] and trans-
[PtCl(0H2)('5NH3)(2pic)], respectively, based on a previous NMR pH titration 
described in Chapter 3. Three more cross-peaks, c, d and e, are visible Ca. 2 h after 
the start of the reaction. Peaks c and d were assigned as monochloro monoguanine 
adducts of G4 and G5, based on their reaction profiles. Although unconfirmed, peak f 
may be tentatively assigned as a bifunctional adduct, possibly a GC or GA 
IESI'] 
'S 
interstrand cross-link. Although the GC interstrand cross-link is favoured by 
transplatin,1361 molecular modelling indicates that the GG interstrand cross-link is 
sterically more compatible for trans complexes containing planar ligands, such as 
trans-[ PtC 12(N H3)(q ui no line)] and trans- [PtC]2(py)2] 
J3  No assignment has been 
made for cross-peaks e and g but they may be due to any of a variety of species 
including adenine and cytosine adducts or possibly a ApTpG intrastrand adduct for 
example. A further possibility is a monoguanine monoaqua adduct. The [1 H,15N] 
cross-peaks experienced significant broadening during the reaction which may be a 
consequence of tumbling due to the high molecular weights of the species formed. 
The rate-limiting step in the binding of cisplatin to DNA has long been 
considered to be aquation of the first chloro ligandJ191 The present study shows that 
this is also true for trans-[PtCl2(NH3)(2pic)] as the monochloro monoaqua species 
(peak b) is formed prior to any binding to DNA and hence, aquation is the rate-
limiting step in formation of the monofunctional adduct. 
The lack of change of the DNA proton signals in the 'H spectra remains 
unexplained and is worthy of further investigation. An H8 downfield shift of 0.3-0.6 
ppm would be expected upon pIatination 301 and the shifted signal may be overlapped 
with other signals such as A2H8. However, no additional cross-peak was observed in 
the 2D NOESY spectrum. The gradual decrease in intensity and subsequent loss of 
proton signals for the 2-picoline ligand suggests that the complex is binding to DNA 
and the signals for bound complex are broad. ['H,'5N] NMR also suggests binding of 
AMD443 in several sites. 
Experimentally determined rate constants for reactions of transplatin with 
double-stranded DNA are in the range for Cl- hydrolysis, k being between 5.4 x 10 
s (ti,2 = 3.6 h) 37' and 9.6 x 10 s1  (ti,2 = 2.0 h) 38' at 310 K. However, these values 
do not differ significantly from those of cisplatin, k = 10.2 x 10 s (t112 = 1.9 h) .1311 
In this work, a half-life of 3.8 h at 298 K (Table 6.1) has been determined for 
formation of one of the monoguanine adducts. This half-life is significantly slower 
than hydrolysis of the first chloride (ti/2 = 1.8 h, calculated based on values 
determined in Chapter 3) and this may be a consequence of the steric hindrance of 
the 2-picoline ligand. However, it has been reported that the presence of DNA can 
slow the aquation of cisplatin 1391  leading to a slower rate of monofunctional adduct 
formation also, assuming the reaction proceeds through the monoaquated species. 
Reported half-lives for closure of monofunctional to bifunctional adducts at 310 K 
vary between 3.1 h 38 and 24 h1401 to 30 ht4H  for transplatin. Possibly these 
discrepancies are due to differences in methods applied, 195  Pt NMR spectroscopy[38]  
and monoadduct trapping by nucleophilesJ40' 41]  In contrast, closure of the cisplatin 
monoadducts to the cross-links occurs somewhat faster, with k = 9.2 x 10-5  s to 4.5-
5 x iO s at 310 K, corresponding to t112 = 2.1 h1381 and ca. 4 h, 421 respectively. 
Molecular modelling of the various guanine-bound monofunctional adducts 
revealed that there is no particular energetic preference for any of the isomers. This is 
perhaps not very surprising given the fact that the monofunctional adducts have a 
greater degree of freedom. It is likely that a bifunctional adduct would be much more 
stereoselective, as reported in the case of cis-[PtC12(NH3)(2-pic)] which was found to 
form a highly selective GG intrastrand bischelate with a 14-mer DNA duplex. [35]  
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6.6 Conclusions 
A major rationale for these studies is the desire to compare the DNA-binding 
profile of a new trans-Pt(II) anticancer complex with that of cisplatin and transplatin. 
In particular, studies of both kinetics and structure may lead to an understanding of 
how distinct DNA-drug binding profiles may lead to improved antitumour activity. 
Labelling of the new trans anticancer complex trans- [PtCl2('5NH3)(2-pic)] 
has allowed an insight to be gained into the kinetics and mechanisms of its reactions 
with a DNA duplex. ['H,'5N] HSQC spectra clearly showed that trans-
[PtC12(15NH3)(2-pic)] is consumed in the reaction with the 12-mer duplex to produce 
an intermediate monoaqua adduct and a further five species, two of which have been 
assigned as monoguanine adducts in the G4 and G5 positions and a further species 
has been postulated to be a GC or GA interstrand cross-link. The 'NMR spectra 
were more difficult to interpret as there were few changes in the DNA signals. 
However, it was clear that platination did not cause major perturbations of the duplex 
structure. The apparent loss of signals for the 2-picoline ligand in trans-
[PtC12(15NH3)(2-pic)I1 is a further indication of binding to DNA as the new signals 
were broadened, indicative of formation of a higher molecular weight species. 
Models of the monofunctional guanine adducts revealed no isomer was particularly 
favourable. Further investigations of DNA interactions with trans-[PtC12(NH3)(2-
pic)] are warranted to unravel the origin of antitumour activity of platinum 
complexes with leaving ligands in the trans conformation. 
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Chapter 7 
Reactions of Sterically-Hindered 




The kinetics and mechanism of the reaction of the ' 5N-labelled anticancer 
compound trans- [PtC12('5NH3)(2-picoline)] (AMD443) with guanosine 5-
monophosphate (5'-GMP) and the tripeptide glutathione (GSH) have been 
investigated by 2D ['H,1 N] HSQC NMR spectroscopy. For the reaction of trans-
[PtC12(15NH3)(2-picoline)] with 5'-GMP, the products were readily identified by their 
cross-peaks in the 2D NMR spectra. The integrated peak intensities versus time were 
used to obtain rate constants by a non-linear optimization procedure. The formation 
of the monochloro GMP adduct takes place via a bimolecular process involving the 
monochloro monoaqua species and the entering nucleotide; the concentration of this 
adduct reaches a maximum value after about 10 hours at 298 K. Subsequently, 
monoaqua GMP and bifunctional GMP adducts are formed in successive steps. 
Competitive reactions of trans- [PtCl2('5NH3)(2-picoline)] with GSH and 5'-GMP 
show a clear preference for GSH adduct formation. The reactions of cis- and trans-
[PtC12(' 5NH3)(2-picoline)] with '5N-label led L-methionine have also been studied 
using ['H,15N] 2D NMR spectroscopy. The steric effect of 2-picoline reduces the 
reactivity of cis- [PtC 12(1 5N H3)(2-picoline)] towards L-methionine and the hydrolysis 
reaction predominates. Trans- [PtC12(15  NH3)(2-picoline)]  was very reactive in the 
presence of L-methionine and intriguingly lost ammonia at low pH suggesting the 
possibility of S, Nmethionine chelation. 
7.2 Introduction 
It is now widely accepted that the antitumour activity of platinum anticancer 
drugs is due to the platination of DNA, most commonly the guanine basesJ" 2] 
However, reactions with other molecules in biological fluids are likely to affect the 
efficiency with which platinum compounds reach that target, as well as being 
involved in drug toxicity. The interaction of platinum with the sulfur nucleophilic 
centres of certain biomolecules is believed to play important roles in the metabolism 
of cisplatin or of its analoguesJ36' Examples include platinum binding to the 
suithydryl group of kidney proteins, the likely origin of the renal toxicity of 
cisplatin; 17-91  interaction with intracellular glutathione, which leads to inactivation of 
the drug and cell resistance; [10, I I] the proposed use of extracellular glutathione, as 
protection of cisplatin toxicity, [121  use of sulfur nucleophiles (such as 
dithiocarbamates) as rescue agents in the case of acute toxicity; [131  also Pt binding to 
thiols in DNA polymerase-a is probably connected with the mechanism of 
cytotoxicityJ'4 '6' It has also been proposed that Pt-methionine complexes formed in 
vivo may provide a route for DNA platination'7' 181  and/or a way to dispose of 
platinum, since these kinds of complexes have been found in the urine of patients 
treated with cisplatin, 191 and in those of animals treated with carboplatin. 201  
Methionine (L-MetH) is an important amino acid which is involved in the 
metabolism of platinum drugs. The complex [Pt(L-Met-S,IV)21 which has been 
isolated from the urine of patients treated with cisplatin, exists in aqueous solution as 
a mixture of cis and trans isomers which undergo interconversion, 211 but these are 
unreactive species which can be considered to be a detoxified form of platinum. 
However, Deegan et al. have reported that in vivo, cisplatin incubated with 
methionine has reduced nephrotoxicity while the cytotoxicity against cancer cells is 
maintained. (22]  Methionine and its derivatives can form stable ring-opened complexes 
with carboplatin and its analogues. 201 Since carboplatin, [Pt(cbdca-0,0')(NH3)2] 
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(cbdca = 1,1 .-dicarboxycyclobutane), itself reacts with nucleobases very slowly, it is 
conceivable that a methionine-containing peptide or protein may play an important 
role in transport or activation of carboplatin and in the transfer of Pt onto DNA. S-
bound methionine can be displaced by N7 of the DNA base guanine. '8' 231 
Methionine is able to coordinate to Pt" in a very versatile manner in aqueous 
solution. A simple system of L-methionine and K2[PtC14] in molar ratio 2:1 generates 
over ten Pt species. 24' Thioether sulfur, amino nitrogen and carboxylate oxygen [25] 
are all capable of binding to Pt". The favoured binding site is sulfur, and S,N-
chelation is a common binding mode. In methionine-containing peptides, 
coordination of the amide N is also possible126,271 
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Glutathione (GSH), a cysteine-containing tripeptide (y-L-Glu-L-Cys-Gly), is 
the predominant intracellular thiol with concentrations typically ranging from 0.5-10 
mMJ' 11 It has a variety of physiologically important functions such as metabolism, 
catalysis, transport and the protection of cells against reactive oxygen species, 
peroxidase, and xenobioticsJ281 The cytotoxicity of cisplatin has been shown to be 
enhanced by depletion of cellular GSH in some tumour cells. GSH is over-expressed 
in cisplatin-resistant cells and the Pt-GS adducts can be pumped out of cells through 
a novel ATP dependent GS-X pump. [29, 301 At physiological pH, Pt"  complexes 
usually show a kinetic preference for the thiols cysteine and glutathione over 5'-
GMP, even in the presence of excess nucleotide.' Reactions of cisplatin and 
transpiatin with glutathione in intact human red blood cells have been 
investigated J3 11 Transplatin was found to react more rapidly, suggesting that in the 
case of cisplatin higher percentages of the drug dose may reach the cell nucleus, 
before inactivation with GSH takes place. 
The 	promising anticancer drug Cis-  [PtCl2(NH3)(2-picoline)J (AMD473) 
appears to circumvent thiol-mediated resistance mechanisms whilst still maintaining 
the ability to form cytotoxic lesions with DNA.132' 331  The 2-picoline ligand is almost 
perpendicular to the Pt square-plane such that the 2-methyl group lies directly over 
the square-plane and precludes access of incoming thiols. A recent study of the 
reactions of AMD473 with 5'-GMP and GSH reported both mono- and bis-OMP 
adducts were formed during competitive reactions. 1341  The trans isomer of AMD473, 
trans- [PtCl2(NH 3)(2-picoline)] (AMD443), is also cytotoxic in a variety of cancer 
cell-lines, [351  and it is therefore of interest to investigate and contrast the reactions of 
AMD473 and AMD443 with biologically-relevant thiols. In this work, the kinetics of 
interaction of AMD443 with 5'-GMP, and in the presence of GSH, have been 
investigated with the use of both ID 'H and 2D ['H,'5N] HSQC NMR spectroscopy. 
Also, the reactions of AMD473 and AMD443 with L-methionine have been studied 
using 2D [1 H,15N] HSQC NMR spectroscopy. 
7.3 Experimental 
Chemicals and preparations of complexes: 2-Picoline, glutathione and 5'- 
guanosine monophosphate were purchased from Aldrich and 	 from 
ICN Biomedicals. cis-[PtCl2( 5NH3)(2-pic)] was synthesised based on a previously 
published procedure, [36]  employing cis-[PtCl2(15NH3)2] as the starting material. The 
synthesis of trans- [PtC12(' 5NH 3)(2-pic)] is described in Chapter 3. 
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pH Measurements: The pH values of solutions were determined using a Corning 
145 pH meter equipped with a micro combination electrode, calibrated with Aldrich 
buffer solutions at pH 4, 7 and 10. The pH was adjusted with dilute solutions of 
HCI04 and NaOH. No correction was made for deuterium isotope effects. 
NMR Spectroscopy: NMR spectra were recorded at 298 K on Bruker DMX500 ('H 
500.13 MHz) or Bruker AVA600 ('H 599.81 MHz) spectrometers using 5 mm NMR 
tubes. All samples were prepared in 90% H20/10% D20 and contained 0.1 M 
NaCI04 to maintain a constant ionic strength. Spectra were referenced to TSP via 
dioxane for 'H (8 3.75), and 1 M 15NH4C1 in 1.5 M I-IC1 for ' 5N (external). Water 
suppression was achieved by presaturation. 2D ['H,'3N] HSQC NMR spectra were 
optimized for J(N,H) = 72 Hz. Spectra were processed using XWINNMR (Version 
3.5, Bruker UK Ltd). 
Kinetic Measurements: For kinetic analysis of NMR spectra, peak volumes were 
measured and the relative concentrations of each species were calculated at each time 
point. The appropriate differential equations were integrated numerically, and the 
rate constants were determined with the assistance of Dr. Junyong Zhang (University 
of Western Australia) by a non-linear optimization procedure using the program 
SCIENTIST (version 2.01, MicroMath Inc.). 
For the reaction of '5N-AMD443 with 5'-GMP (shown in Scheme 7.1), and 
assuming that at time t the concentrations of species a, b, c, d, e, CY and 5'-GMP are 
A, B, C, D, E, CL and L, respectively, the corresponding reaction rates are: 
A' = -krA + k2 BCL 
B' = k1 A - k2 BCL - k3 BL 
NOR 
C = k3 BL - k4 C 
D' = k4 C - k5-DL 
E' =  k5 DL 
CL'= k1 A - k2 BCL + k4 C 
L'= 43 BL - k5 DL 
The above model equations were used in least squares fitting of the NMR data (the 
change of concentration of each species with time), with a set of initial parameters 
chosen to perform the simulations. 
74 Results 
Reaction of trans- [PtCl2(' 5NH3)(2-pic)I and 5'-GMP 
Both 1D 'H and 2D ['H,'5N] HSQC NMR spectroscopy were used to monitor 
the reactions between trans-[PtCl2(15NH3)(2-pic)] (3 mM) and 5'-GMP in a 1:2 ratio 
at 298 K and pH 6.4. Figure 7.1 shows the aromatic region of a selection of 1 D 1  
spectra recorded at different time intervals after the start of the reaction. The H8 peak 
of free 5'-GMP gradually diminishes in intensity while three new H8 peaks emerge. 
The mono-adduct, represented by the new peaks c and d, is gradually converted to 
the bis-adduct represented by peak e. 
Three cross-peaks were present in the initial 2D ['H,'3 N] HSQC NMR 
spectrum. Spectra recorded 0.6 h and 24.3 h after the start of the reaction are shown 
in Figure 7.2. The iHbN  cross-peaks representing the different species are all well 
separated and easily integrated. The most intense peak, a, at 3.81, -69.39 ppm is 
trans- [PtC12(15NH 3)(2-pic)]. Peak a gradually decreases in intensity and is no longer 
detectable ca. 24 h after the start of the reaction. Peak b at 3.83, -67.47 ppm is known 
to be the monoaqua monochloro species, as determined previously by NMR pH 
201 
free 5'-GMP 	 48.5 h 
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Figure 7.1 Aromatic region of 1D 1 H NMR spectra in 1-120/D20 for the reaction 
between trans-[PtC12(15NH3)(2-pic)1  and 5'-GMP (1:2) at selected reaction times 
(298 K). Peaks c, d and e are assigned to the H8 peaks of trans- {PtCI(13NH3)(2-
pic)(5 '-GMP)], trans-[Pt(H20)( 1 5NH3)(2_pic)(5t_GMP)]2+ and trans-[Pt(' 5NH3)(2-
pic)(5'-GMP)2]2 , respectively. H3-H6 correspond to the aromatic protons of the 2-
picoline ligand. 
titration (Chapter 3). Peak b behaves as an intermediate as its intensity increases 
initially and then decreases steadily until Ca. 15 h when it is no longer detectable. The 
least intense peak c is assigned as the monochioro mono(5'-GMP) adduct on the 
basis of its reaction profile. Peak c increases in intensity for the first 10 h of the 
reaction and then its intensity steadily decreases as that of peak e increases. Peak d at 
4.10, -64.46 ppm begins to emerge ca. 3 h after the start of the reaction and is 
assigned as the monoaqua mono(5'-GMP) adduct. Peak d increases in intensity 


















ppm is observable Ca. 6 h after the start of the reaction and is assigned as the bis(5'-
GMP) adduct. This assignment was made on the basis of the reaction profile and 
from a previous 'H and ['H,'5N] NMR characterisation of trans- [Pt(NH3)(2-pic)(5'-
GMP)2](NO3)2. Peak e gradually increases in intensity throughout the reaction. 
'C 
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81H 	 6 1 H 
Figure 7.2 2D ['H,'5N] HSQC spectra for the reaction between trans-
[PtC12(15NH3)(2-pic)] and 5'-GMP (298 K) a) 0.6 h and b) 24.3 h after the start of the 
reaction. Peak assignments: a = trans-{PtC12(15NH3)(2-pic)], b 	trans- 
[PtCl(H20)(13NH3)(2-pic)f, c = trans- [PtCl(15NH3)(2-pic)(5'-GMP)], d 	trans- 
[Pt(H20)(' 5NH3)(2-pic)(5'-GMP)]2 and e = trans-[Pt( ' 5NH3)(2-pic)(5'-GMP)2J2 . 
A kinetic fit to the reaction profile in Scheme 7.1 is shown in Figure 7.3 and 
the rate constants for each step are listed in Table 7.1. The data are consistent with 
initial hydrolysis of the chloride ligand followed by 5'-GMP substitution in two steps 
to give the final bis(5'-GMP) product. 
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Scheme 7.1 Pathway for the reaction between trans-[PtCl2('5NH3)(2-pic)] and 5'-
GMP. The corresponding rate constants are listed in Table 7.1. Charges on 
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Figure 7.3 Computer best fits based on the rate constants in Table 7.1 and 
experimental NMR points for the time course of the reaction between trans-
[PtC12('5NH3)(2-pic)] and 5-GMP (298 K). Symbols represent calculated data for 5'-
GMP (x) and Cl- (+), and experimental data based on integration of 2D cross-peaks 
for a = trans-[PtC12(15NH3)(2-pic)J (D), b = trans- [PtCl(H2O)('5NH3)(2-pic)j (o), c 
= trans- [PtC1(' 5NH3)(2-pic)(5'-GMP)] (A), d = trans-[Pt(H20)( 
15NH3)(2-pic)(5'-
GMP)]2 (CO), e = trans-[Pt(15NH3)(2-pic)(5'-GMP)2]2 (*). 
Table 7.1 Rate constants for the reaction of trans-[PtC12(15NH3)(2-pic)] with 5'-GMP 
at 298 K (0.1 M NaC104), see Scheme 7.1. 
Step 	 Rate Constant 
k1 (s') 8.25 x iü 
k2 (M's 1) 2.46 x 10 2 
k3 (M's') 1.05 x 10' 
k4 (s') 5.28 x 10 6 
k5 (Ms') 1.28 x 102 
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Reaction of trans-IPtC12('5NH3)(2-pic)] with GSH 
The reaction of trans-[PtC12(1 NH3)(2-pic)] (3 mM) with GSH (1:2, pH 7.1) 
at 298 K was followed by 2D ['H,'5N] HSQC NMR spectroscopy. In the initial 
['H,15N] HSQC spectrum recorded ca. 0.6 h after the start of the reaction there are 
six cross-peaks present (Figure 7.4). The intense peak 2a, at 3.82, -69.36 ppm, is 
trans- [PtC12('5NH3)(2-pic)] and its intensity decreases steadily until ca. 9 h when it 
becomes undetectable. Peak 2b at 3.66, -68.24 ppm is unassigned but increases in 
intensity slightly throughout the reaction, though even at the end of the reaction it 
accounts for only Ca. 6 % of the total Pt - 15 NH3  species. Peak 2c at 3.87, -64.65 ppm 
increases in intensity for ca. 35 h and then experiences a sudden decrease in 
intensity, coincident with a similarly sharp increase in intensity of peak 2d. Peak 2d 
at 3.90, -64.29 ppm increases in intensity to become the major reaction product, 
accounting for ca. 38 % of the total Pt - 15 NH3  species at the end of the reaction. It 
seems plausible that peak 2d may correspond to trans- [Pt(' 5NH3)(2-pic)(GS)2]. Peak 
2e at 3.94, -64.31 ppm increases in intensity initially and then appears to level off ca. 
20 h after the start of the reaction. Peak 2f at 3.99, -65.05 ppm behaves as a typical 
intermediate such as trans-{PtCl('NH3)(2-pic)(GS)], with its intensity increasing for 
the first 6 h of reaction and then decreasing steadily. Peak 2g at 4.36, -59.28 ppm 
appears ca. 5 h after the start of the reaction and its intensity initially increases until 
ca. 10 h and then decreases slightly. After 5 h of reaction, peaks 2h (4.45, -60.11 
ppm) and 2i (4.47, -58.89) also appear. Peak 2h behaves as an intermediate and is 
consumed within 20 h of the reaction whilst peak 21 seems to maintain a very low 
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Figure 7.4 2D [11-1,15N] HSQC spectra for the reaction between trans-
[PtC12(15NH3)(2-pic)] and GSH (298 K) a) 0.6 h, and b) 24.2 h after the start of the 
reaction. 2a = trans-[PtC12(15NH3)(2-pic)], * = 195Pt satellites. 
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Figure 7.5 Concentration versus time profile for the reaction of trans- 
[PtC12(15NH3)(2-pic)] and GSH at 298 K. (•) peak 2a, (0) peak 2b, (A) peak 2c, 
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Intriguingly, no cross-peak corresponding to the monoaqua monochioro 
species was observed, implying that the reactions may proceed directly with the 
dichioro species or that any rnonoaqua monochioro species is being consumed as 
soon as it is produced. 
The concentration versus time profiles for the major species in the reaction 
are shown in Figure 7.5. 
Reaction of trans- IPtCl2('5NH3)(2-pic)I with GSH and 5'-GMP 
The reaction of trans[PtC12(15NH3)(2pic)]  (2 mm) with GSH in the presence 
of 5'-GMP (1:2:2) was followed by 2D ['H,'5N] HSQC NMR spectroscopy at 298 K, 
pH 7.0. Spectra recorded after 0.6 h and 24.2 h of reaction are shown in Figure 7.6. 
0 1H 
Figure 7.6 2D ['H,'N] HSQC spectra for the reaction between trans-
[PtC17(' 5NH3)(2-pic)] and 5'-GMP and GSH (298 K) a) 0.6 h, and b) 24.2 h after the 
start of the reaction. 3a = trans-[PtC12(15NH3)(2-pic)], 3a(aq.) = trans-
[PtC1(OH2)(15NH3)(2-pic)J, * = 195Pt satellites. 
In the initial spectrum the most intense peak 3a, at 3.81, -69.36 ppm, 
corresponds to trans-[PtCl 2(1 5  NH3)(2-pic)]  and its intensity decreases to zero within 
5 h of the start of the reaction. A further six cross-peaks are present initially. Peak 
3a(aq.) at 3.82, -67.46 ppm is attributable to trans- [PtCl(OH2)(15NH3)(2-pic)]. This 
peak is very weak and is no longer observable after only 2 h. Peak 3b at 3.66, -68.25 
ppm is the same as peak 2b from the reaction of trans-[PtCl2(15NH3)(2-pic)J and 
GSH. Its intensity increases throughout the reaction but in this case peak 3b accounts 
for ca. 35 % of the total Pt - 15NH3 species at the end of the reaction compared to ca. 
6 % in the trans-[PtC12(13NH3)(2-pic)] and GSH reaction. Likewise, peaks 3c (3.87, - 
64.59 ppm), 3d (3.90, -64.31 ppm), 3e (3.94, -64.35 ppm) and 3f (3.97, -65.92 ppm) 
correspond to peaks 2c, 2d, 2e and 2f, respectively, from the reaction of trans-
[PtC12(1 NH3)(2-pic)] with GSH. The reaction profiles are also comparable, with 
peak 3d as the major reaction product, assumed to be trans-[Pt(' 5NH3)(2-pic)(GS)2], 
accounting for ca. 39 % of the total Pt - 15 NH3  species at the end of the reaction and 
peaks 3c and 3e increasing initially and then leveling off. It is noteworthy however, 
that in this reaction peak 3f, tentatively assigned as trans-[PtCl(15NH3)(2-pic)(GS), 
is entirely consumed Ca. 36 h after the start of the reaction whereas in the reaction of 
trans-[PtC12(15NH3)(2-pic)] with GSH, peak 2f accounts for ca. 9 % of the total Pt - 
15 NH3  species at the end of the reaction. After ca. 2 h a peak at 3.99, -65.07 ppm, 
peak 3g, appears. This peak behaves as an intermediate, increasing in intensity until 
ca. 5 h then decreasing gradually to zero at Ca. 35 h. A very weak peak 3h at 4.09, - 
66.70 ppm is also observed after Ca. 2h. This peak resembles peak c, the monochloro 
mono(5'-GMP) adduct, from the reaction of trans-[PtC12( 1 5  NH3)(2-pic)]  and 5'-GMP. 
Its intensity increases slightly until ca. 5 h when it begins to decrease and disappears 
Ca. 35 h after the start of the reaction. At its maximum intensity, peak 3h accounts for 
only Ca. 6 % of the total Pt - 15 NH3  species. 
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The concentration versus time profiles for the major species in the reaction 
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Figure 7.7 Concentration versus time profile for the reaction of trans-
[PtC12('5NH3)(2-pic)] and 5'-GMP and GSH at 298 K. (•) peak 3a, (0) peak 3b, (A) 
peak 3c, (7) peak 3d, () peak 3e, () peak 3f, (•) peak 3g, (0) peak 3h (see Figure 
7.6). 
Reaction of cis-IPtC12('5NH3)(2-pic)] and 15N-L-MetH 
The reaction of cis-[PtC12('NH3)(2-pic)] (5 mM) and 15N-L-MetH in a 1:1 
molar ratio at pH 6.2 and 298 K was followed by 2D ['H,15N] NMR spectroscopy for 
a period of 24 h. In the initial ['H,'5N] spectrum, recorded 0.5 h after the start of the 
reaction (Figure 7.8), there are three cross-peaks present. Peak 4a at 4.20, -66.89 
ppm is the most intense peak and corresponds to cis-[PtC12(13NH3)(2-pic)]. This peak 
exponentially decreases in intensity and appears to reach an equilibrium ca. 23 h 
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Figure 7.8 2D [IH,bN]  HSQC spectra for the reaction between cis-[PtC12(15NH3)(2-
pie)] and 15N-L-MetH (298 K, pH 6.2) a) 0.5 h, and b) 24.2 h after the start of the 
reaction. 4a = cis [PtC12(
15NH3)(2 pic)],  4b = cis- [PtCl(OH2)(15NH3)(2-pic)], 4d = 
cis-[PtCl(OH2)(15NH3)(2-pic)], 4n = NH4, * = '95Pt satellites. 
+ 	15 	 . assignment to cis- [PtC1(0H2)(15  NH3)(2-pic)] , with a N shift diagnostic of 15  
trans to N or Cl, i.e. the water ligand is trans to the 2-picoline. This peak gradually 
increases in intensity but seems to reach a maximum intensity Ca. 10 h after the start 
of the reaction and then decreases slightly in intensity. This peak is the major 
reaction product and accounts for ca. 25 % of the Pt-15N species at the end of the 
reaction. The third peak, 4e, at 4.33, -44.77 ppm is initially relatively weak in 
intensity and is unassigned, but its intensity gradually increases throughout the 
reaction and it is also a significant product. After 1.6 h of reaction, a weak cross-peak 
- 4d at 4.35, -87.11 ppm is observable, assigned as cis- [PtCl(0H2)(15  NH3)(2-pic)]+  
with the water ligand trans to 15  NH3  as the 15N shift here is diagnostic of 15N trans to 
0. The intensity of this peak remains very low throughout the course of the reaction. 
Peak 4h (4.27, -61.91 ppm), which appears after ca. 3.3 h of reaction, increases in 
intensity to become one of the significant products. Also notable is the appearance of 
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an ammonium peak (peak 4n) at 7.08, -1.54 ppm Ca. 6.2 h after the start of the 
reaction, which can be seen in Figure 7.8. 
There are many different species formed in this reaction but their cross-peak 
intensities remain very low. A list of cross-peaks is given in Table 7.2. Due to the 
complicated nature of the reaction the concentration versus time profile includes only 
the major species involved in the reaction, Figure 7.9. 
Table 7.2 Proton and ' 5N chemical shifts for the reaction of cis-[PtC12(15NH3)(2-pic)] 
and 15N-L-MetH at pH 6.2, 298 K. Spectra are shown in Figure 7.8. 
Peak 	 ö ('H) 	 6('N) (trans to) 
4a 4.20 -66.89 (Cl, N) 
4b 4.54 -61.68 (CI, N) 
4c 4.33 -44.77(S) 
4d 4.35 -87.11(0) 
4e 4.46 -42.42(S) 
4f 4.44 -64.70 (Cl, N) 
4g 4.30 -61.20 (Cl, N) 
4h 4.27 -61.91 (Cl, N) 
4i 4.22 -61.26 (Cl, N) 
4j 5.55 -46.16(0) 
4k 5.46 -43.00(0) 
41 5.41 -41.78(0) 
4m 5.30 -41.72(0) 
4n 7.08 -1.54 
4o 5.34 -42.98(0) 
Ip 5.21 -42.03(0) 
The 2D NMR spectrum of the solution was recorded after 7 d at 298 K and 
the cross-peaks were unchanged. The pH was then raised to 8.8, and the time 
dependence of the resultant ['H,15  N]  2D NMR spectra investigated for a period of 24 
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Figure 7.9 Concentration versus time profile for the reaction of cis-[PtC12('5NH3)(2-
pic)] and 15N-L-MetH at 298 K, pH 6.2. (•) peak 4a, (0) peak 4b, (A) peak 4c, (V) 
peak 4h, () 15NH2-Pt-S species, (see Figure 7.8). 
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Figure 7.10 2D [1H,15N] HSQC spectra for the reaction between cis-
[PtC12(13NH3)(2-pic)] and 15N-L-MetH (298 K) a) pH 8.8, 0.5 h and b) pH 3.3, 0.7 h 
after the start of the reaction. Peaks are listed in Tables 7.3 and 7.4. 
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significant changes and there appeared to be no time dependence of the cross-peaks 
thereafter. The cross-peaks are listed in Table 7.3. 
Table 7.3 Proton and ' 5N chemical shifts for the reaction of cis-[PtC12(15NH3)(2-pic)] 
and 15N-L-MetH at pH 8.8, 298 K, see Figure 7.10. 
Peak 	 6 ('H) 	 6 (15N) (trans to) 
5a 3.66 -78.59(0) 
5b 3.89 -60.94 (Cl, N) 
5c 3.93 -60.81 (Cl, N) 
5d 4.14 -64.65 (Cl, N) 
5e 4.17 -63.98(C1,N) 
5f 4.20 -67.25 (Cl, N) 
5g 4.21 -62.10 (Cl, N) 
Sh 4.26 -62.22 (Cl, N) 
5i 4.29 -61.68 (Cl, N) 
5j 4.35 -44.15(S) 
5k 4.39 -44.27(S) 
51 4.46 -42.75(S) 
5m 4.90 -37.91 (C1,NI0) 
5n 4.92 -37.91 (Cl,N/0) 
So 5.06 -39.82 (Cl, N / 0) 
5.18 -41.81(0) 
5q 5.29 -42.41(0) 
Sr 5.41 -42.05(0) 
Ss 5.45 -43.17(0) 
The pH of the above solution was then lowered to 3.3 and the time 
dependence was again followed by [1 H,'5N] 2D NMR spectroscopy for 24 h at 298 
K. Similarly, only the first spectrum, recorded 0.7 h after the change of pH, showed 
any change in the cross-peaks, Figure 7.10. These peaks are listed in Table 7.4. 
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Table 7.4 Proton and '5N chemical shifts for the reaction of cis-[PtC12(15NH3)(2-pic)] 
and 15N-L-MetH at pH 3.3, 298 K, see Figure 7.10. 
Peak 6 ('H) ö (' 5N) (trans to) 
6a 3.95 -63.02 (Cl, N) 
6b 3.99 -62.65 (Cl, N) 
6c 4.15 -64.11 (Cl, N) 
6d 4.18 -63.93 (Cl, N) 
6e 4.20 -66.90 (Cl, N) 
6f 4.22 -62.04 (Cl, N) 
6g 4.27 -62.23 (Cl, N) 
6h 4.30 -61.60(Cl,N) 
6i 4.37 -87.85(0) 
6j 4.46 -64.91 (Cl, N) 
6k 4.35 -44.26(S) 
61 4.39 -44.29(S) 
6m 4.46 -42.96(S) 
6n 5.07 -43.68(0) 
6o 5.08 -43.92(0) 
5.25 -43.16(0) 
6q 5.34 -42.31 (0) 
6r 5.39 -43.64(0) 
6s 5.45 -42.99(0) 
6t 5.50 -43.59(0) 
6u 5.52 -43.64(0) 
6v 5.57 -46.83(0) 
6w 5.64 -46.50(0) 
6x 5.39 -22.15 (S/ Cl, N) 
5.45 -22.91 (S / Cl, N) 
6z 5.46 -22.91 (5 / Cl, N) 
6aa 5.23 -22.58 (5 / Cl, N) 
6bb 5.70 -22.82 (S / Cl, N) 
6cc 5.74 -22.00 (5 / Cl, N) 
6dd 5.76 -22.21 (5 / Cl, N) 
6ee 5.78 -22.04 (S / Cl, N) 
6ff 	 7.08 	 -1.96 
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Reaction of trans- IPtC12(15NH3)(2-pic)I and 15N-L-M etH 
The reaction of trans- [PtCl2('5NH3)(2-pic)] (5 mM) and 15N-L-MetH in a 1:1 
molar ratio at pH 6.3 and 298 K was followed by ['H,' 5N] 2D NMR spectroscopy for 






-60- 	 7d. 
6 15 N 	 - 
-50- 
7b 
-40- 	 - 
30..1 
5.5 	5.0 	4.5 	4.0 	3.5 
81H 
 
5.5 	5.0 	4.5 	4.0 	3.5 
3'H 
Figure 7.11 2D [1 H,1 N] HSQC spectra for the reaction between trans-
[PtCl2(15NH3)(2-pic)] and 15N-L-MetH (298 K, pH 6.3) a) 0.6 h, and b) 24.3 h after 
the start of the reaction. 7a = trans[PtC12(15NH3)(2pic)]. 
After 0.6 h of reaction only one new cross-peak at 5.78, -43.56 ppm (peak 
7b) was present in the spectrum in addition to cross-peak 7a (3.82, -69.41 ppm) of 
the starting complex, trans-[PtC12('5NH3)(2-pic)]. Peak 7a decreased in intensity 
with time and was no longer observable ca. 8 h after the start of the reaction. Peak 7b 
initially increased in intensity with time and then ca. 13 h after the start of the 
reaction, started to decrease slightly in intensity. A third cross-peak, peak 7c (4.30, - 
64.78 ppm), appears Ca. 1.2 h after the start of the reaction. Due to its shifts, it seems 
unlikely that this peak is due to hydrolysis products but no definitive assignment can 
be made. The intensity of this peak increases rapidly for the first 10 h of reaction and 
then decreases slightly. After 14.9 h of reaction a fourth cross-peak at 4.50, -60.61 
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ppm, peak 7d is observed. This peak then increases very slighty in intensity and is 
the second most intense peak at the end of the reaction. A further cross-peak is 
observed ca. 15.5 h after the start of the reaction at 4.06, -62.33 ppm (peak 7e). This 
peak increases slightly in intensity for the duration of the reaction but remains the 
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Figure 7.12 Concentration versus time profile for the reaction of trans-
[PtC12(15NH3)(2-pic)] and 15N-L-MetH at 298 K, pH 6.3. (•) peak 7a, (0) peak 7b, 
(A) peak 7c, (7) peak 7d, () peak 7e, (see Figure 7.11). 
After one week, the pH of the above solution was raised from 3.4 to 8.5, and 
the time dependence of the resultant ['H,''N] 2D NMR spectra was investigated for a 
period of 14 h. In the first spectrum (Figure 7.13), recorded 0.5 h after the pH 
adjustment, a very intense peak at 4.23, -62.94 ppm (peak 8a) was present together 
with a rather weak peak at 4.15, -63.00 ppm (peak 8b). A further two broad cross-
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Figure 7.13 2D [11-1,15N] HSQC spectra for the reaction between trans-
[PtC12(15NH3)(2-pic) and 15N-L-MetH (298 K, pH 8.5) a) 0.5 h, and b) 13.1 h after 
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Figure 7.14 Concentration versus time profile for the reaction of trans-
[PtCl2(15NH3)(2-pic)] and 15N-L-MetH at 298 K, pH 8.5. (U)  peak 8a, (0) peak 8b, 
(A) peak 8c, (V) peak 8d, (4) peak 8e, (>) peak 8f, (•) peak 8g, (0) peak 8h, (S) 
peak 8i, () peak 8j (see Figure 7.13). 
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also observed. Peak 8a decreases in intensity with time whilst peak 8b increases for 
the first 7 h and then decreases in intensity. The intensities of both peaks 8c and 8d 
are almost unchanged until ca. 8 h of reaction when they start to decrease slightly. 
Peak 8e at 4.39, -64.98 ppm is observable after 1 h of reaction. This peak increases in 
intensity to become the main reaction product. Two very weak cross-peaks, peak 8f 
at 5.30, -17.57 ppm and peak 8g at 5.19, -18.50 ppm, are also observed at 1 h but 
they are no longer detectable ca. 6 h after the start of the reaction. After ca. 9 h of 
reaction three further cross-peaks are observable at 5.20, -36.10 ppm, 5.12, -34.99 
ppm and 4.95, -35.14 ppm corresponding to peaks 8h, 8i and 8j, respectively. The 
intensity of peak 8h remains relatively constant whilst the intensities of peaks 8i and 









7 	6 	 5 	 4 
Figure 7.15 2D ['l-1,'5N] HSQC spectrum for the reaction between trans-
[PtC12(13NH3)(2-pic)] and 15N-L-MetH (298 K, pH 3.5) 0.5 h after the start of the 
reaction. 9e = 15NH4 . 
When the pH of the above solution was lowered to 3.5, there were five clear cross-
peaks present in the initial spectrum (Figure 7.15) at 4.30, -64.82 ppm, 4.39, -64.94 




1.69 ppm, peaks 9a-9e respectively. There were also some very broad signals 
between 5.4 to 5.8 and -20 to -25 ppm, attributable to 15NH2-Pt-S species. The 
progress of the reaction was monitored for 24 h but no changes were observed. 
7.5 Discussion 
Cis- [PtC12(N  H3)(2-picoline)] (AMD473) is an exciting new anticancer drug 
which has a different spectrum of biological activity compared to cisplatin and is 
active against cisplatin-resistant cell lines and xenographsJ33 Its trans isomer, trans-
[PtCl2(NH3)(2-picoline)] (AMD443), is also cytotoxic in a variety of cancer cell lines 
and similarly overcomes cisplatin resistance. 35' Cisplatin is renowned for its severe 
side-effects, some of which may arise from its interactions with sulfur-containing 
molecules, for example the dose-limiting nephrotoxicity may be due to the 
coordination of Pt" to the thiol residues of enzymes in the kidneysJ51 in contrast, cis-
[PtCl2(NH3)(2-pic)] exhibits reduced nephrotoxicityJ371 In order to shed light on the 
chemical reactivity of trans-[PtC12(NH3)(2-picoline)] and to elucidate the potential 
roles of both steric hindrance and trans geometry, kinetic studies of reactions of 
trans-[PtC12(15NH3)(2-pic)] with 5'-GMP and GSH have been made and compared to 
reported results for its cis isomer and related compounds. Also, the reactions of '5N-
labelled L-MetH with cis- [PtC12(15  NH3)(2-pic)]  and trans- [PtCl2(
15  NH3)(2-pic)]  at a 
variety of pH values have been investigated. 
Reactions with 5'-GMP 
The concentration versus time profile for the reaction of trans-
[PtC12(15NH3)(2-pic)] with 5'-GMP fitted well to the reaction mechanism shown in 
Scheme 7.1, confirming that it is two-step and two-stage: initial hydrolysis followed 
by 5'-GMP substitution to give the 1:1 Pt-5'-GMP adduct, and then further hydrolysis 
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and 5'-GMP substitution to give the final product, the bis(5'-GMP) complex. The rate 
of the first step is similar to that determined previously for hydrolysis of trans-
[PtC12( 5NH3)(2-pic)] (Chapter 3). Compared to the rate constant for the second stage 
of binding of 5'-GMP to cis- [Pt(NH3)2(5-GMP)(H2O)]2 (298 K, 0.24 M's'))381 that 
of trans-[PtCl2(NH3)(2-pic)] is an order of magnitude smaller. Also, for comparison, 
rate constants for trans-[PtC12(NH3)(2-pic)] and related compounds are listed in 
Table 7.5 .134,19,401  As expected, trans- [PtCl2(NH3)(2-pic)] tends to react faster than 
its cis isomer, except for the second hydrolysis stepJ34' This suggests that NH3 has a 
higher trans effect than N7 of GMP. Sletten et al. have also reported that the second 
chloride ligand in trans-EE monofunctional adducts is not easily displaced. 1391  
Despite the slower hydrolysis of the first chloride in trans-[PtCl2(NH3)(2-pic)], the 
rate of monofunctional binding with GMP is comparable in magnitude to those of 
trans-[PtCl2 {E-HN=C(OMe)Me} 21 	(trans-EE) 391 	and 	trans- [PtC12(NH3)(c- 
C6H1 NH2)]J40' The rate of formation of the bis-adduct is also comparable with 
trans- [PtC12(NH3)(c-C6H11NH2)], though that of trans-EE is particularly slow. 
Table 7.5 Rate constants for the reactions of trans-[PtCl2(NH3)(2-pic)] (AMD443), 
cis-[PtC!2(NH3)(2-pic)] (AMD473), trans- [PtC12(NH3)(c-C6H1 1 NH2)] and trans-
[PtCl2 {E-1-IN=C(OMe)Me} 21  (trans-EE) with GMP. 
AMD443a 	AMD473b 	trans-EE' 	trans-C6H1 1NH7d 
(298 K) 	(296 K) 	 (298 K) 	complex (3 10 K) 
k 1 8.25 x 10 	s_ I 6.87, 5.87 x 10-6S-1 1.95 x 10-4S-1 1.89 x 10-4s1 
Ic2 0.03 M's' - 0.08 M 1s' - 
Ic3 0.11 M 1s' 7.97, 6.67 x 10 	M's' 0.27 M's' 0.19 M's 1  
Ic4 5.28 x 10-6S-1 8.5 3, 2.77 x 10 	s' 1.31 x 10 5 M's' 2.91 x 10 5 s 
k5 0.01 M's' 4.2, 0.59 x 10.2  M's' 9.96 x iO' M's' 0.043 M's' 
a This work. Ref.34. There are two rate constants for each step depending on 
whether substitution occurs cis or trans to the 2-picoline ligand. C  Ref. 39. d  Ref. 40. 
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Reactions with GSH 
The reactions of cisplatin and related platinum compounds with S-containing 
nucleophiles usually occur via direct substitution without prior aquation,11 as 
observed for methionine, GSH and metal IothioneinJ413' The present work confirms 
that GSH mainly reacts directly with trans-[PtC12(NH3)(2-pic)]. On the contrary, the 
reaction of cis- [PtC12(NH3)(2-pic)] with GSH was found to proceed via 
hydrolysis. 114]  In light of the current results, it seems likely that this is due to the 
steric hindrance of cis-[PtCl2(NH3)(2-pic)]1441 whereby binding of GSH is slowed 
down and hydrolysis is fast enough to compete with direct substitution. 
The major product from reaction of cysteine derivatives with cis-
diam(m)inoplatinum(II) complexes is thought to be the bridged dimer [(am)2Pt(p2-
SR)2Pt(am)2], where am is am(m)ine or one half of a diamine.14' 461  These bridged 
complexes are unlikely to be reactive towards DNA bases, although the arnmine 
complexes can slowly release ammonia. Investigations of the reaction of cisplatin 
with GSH113' 41, 471 indicate that initially intermediate species such as cis-
[PtCl(NH3)2(GS)] and [Pt2(NH3)4(GS)2] can indeed be formed. These unstable 
products lose NH3 upon standing, eventually forming polymeric {Pt(GS)2] with 
coordination exclusively via the S atom, but with several different Pt - S and Pt - S 
Pt environments. 
The reaction of transplatin with two equivalents of GSH 147] results in the bis-
substituted complex trans-[Pt(NH3)2(SG)2} in which glutathione is coordinated 
exclusively via the S atom. Trans-[PtCl(NH3)2(SG)] was found in the first step and 
reacted either with GSH to form trans-[Pt(NH3)2(SG)2J, or with trans- [PtC12(NH3)21 
to give the S-bridged complex trans-[I(NH3)2PtCI}2SG]. This reacted with GSH 
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regenerating trans- [PtC1(NH3)2(SG)]. On this basis, peaks d and f (Figure 7.4) may 
therefore be tentatively assigned as trans-[Pt('5NH3)(2-pic)(SG)2] and trans-
[PtC1(15NH3)(2-pic)(SG)], respectively. 
No rate constants were determined for the reaction of trans-[PtCl2('5NH3)(2-
pic)] with GSH due to its complicated nature, but the time-dependent plot (Figure 
7.5) showed that trans-[PtC12(15NH3)(2-pic)] was quickly consumed to produce 
several different GSH adducts. 
Competitive binding of GSH and 5'GMP 
At neutral pH, GMP cannot usually compete with thiols for binding to Pt" 
when both ligands are present at equal concentrations. 115  Likewise, for the reaction 
of trans-[PtCl2(15NH3)(2-pic)] with GSH and 5'GMP, the majority of products were 
almost identical to those observed in the absence of nucleotide. However, a weak 
peak (peak h, 4.09, -66.70 ppm) possibly attributable to the monochioro mono(5'-
GMP) adduct was surprisingly observed. This adduct is normally formed via prior 
aquation. The corresponding cross-peak for trans-[PtCl(OH2)(5NH3)(2-pic)] was 
identified at 3.82, -67.46 ppm, peak 3a(aq.), but its intensity is very low and the peak 
is no longer observable after 2 hours. The presence of this peak is unexpected in this 
reaction when no such peak was observed in the reaction of frans-[PtCl2('5NH3)(2-
pic)] with GSH. It is possible that this may have arisen because trans-
[PtC12(1 NH3)(2-pic)] underwent aquation even before addition of the other reactants. 
Reedijk et al have previously reported that despite [Pt(dien)Cl] reacting more 
quickly with GSH and GS-Me in the presence of 5'GMP,  only binding of 5'-GMP 
was observed in a competition experiment of [Pt(dien)(H20)1+  with 5'-GMP and GS-
Me. [411 
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Reactions of L-MetH with cis- and trans- IPtCl2(NH3)(2-pic)I 
The NMR data show that at pH 6.2, initial binding of L-MetH to cis-
[PtCl2('5NH3)(2-pic)] is likely to take place via Cl- displacement by S which has a 
high affinity for Pt". However, there are also hydrolysis adducts present, as reported 
for the reaction of GSH with cis-[PtC12('5NH3)(2-pic)J.t341 The monoaqua adduct, cis -
[PtCl(0H2)(' 5NH3)(2-pic)f, with the water ligand trans to the 2-picoline, is by far 
the major reaction product. This result is perhaps not very surprising as cis-
[PtCl2(NH3)(2-pic)J was specifically designed to reduce drug inactivation by 
intracellular thiols by introducing steric bulk (2-methyl group of picoline) round the 
platinum atom, which restricts the access of thiols to the reactive centre of the 
moleculeJ331 Conversely, cisplatin is well known to react rapidly with sulfur 
containing amino acids such as methionine, and these reactions are reported to 
increase the nephrotoxicity of cisplatin. 481 The presence of an ammonium peak 
observed after ca. 6 h of the initial reaction (pH 6.2) and in the low pH reaction 
suggests the possibility of complexation by S,N-chelated L-methionine. Ammonia 
release has been reported for reactions of cisplatin and methionine with formation of 
ring-closed complexes such as [Pt(NH3)(Met-S)(Met-S,IV)] and [Pt(Met-S,IV)2]J5' 49]  
The Pt-S bond formed with methionine weakens the Pt-NH3 bond in cisplatin due to 
the trans influence. 
In contrast, trans-[PtC12(' 5NH3)(2-pic)] is very reactive in the presence of L-
MetH at pH 6.3. No peaks for hydrolysis adducts of trans-[PtC12(' 5NH3)(2-pic)I were 
observed, indicating that binding to L-MetH is also likely to occur via direct 
substitution, though this may be followed by subsequent hydrolysis. There are four 
cross-peaks present at the end of the reaction but it has not been possible to 
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unambiguously assign these peaks. However, it seems plausible that trans-
[PtC1(1 5NH3)(2-pic)(L-Met-S)], trans-[Pt(0H2)( 1 5  NH3)(2-pic)(L-Met-N)]'_,  and trans-
[Pt(15NH3)(2-pic)(L-Met-S)21 may be formed. A bis complex is also formed on 
reaction of methionine with transpiatin, i.e. [trans-Pt(NH3)2(Met-S)2] 	On raising 
the pH to 8.5, several new time-dependent peaks were observed, but due to the 
complexity of the reaction, no further analysis was attempted. Intriguingly, when the 
pH was lowered to 3.5, a cross-peak corresponding to free NH4 (7.09, 1.69 ppm) 
was observed. For trans-[PtC12(15  NH3)(2-pic)]  such ammonia release cannot be 
rationalised by a trans influence, and the formation of a S,N-methionine chelate 
appears to be involved which is unprecedented. 
7.6 Conclusions 
Labelling of the new anticancer complex trans-[PtC12(1 NH3)(2-pic)] has 
allowed detailed insight to be gained into the kinetics and mechanisms of its reaction 
with 5-GMP and glutathione. Trans-[PtC12(15NH3)(2-pic)] was very reactive in the 
presence of glutathione and in a competitive reaction with 5-OMP and glutathione, a 
clear preference was established for GSH adduct formation. Thus, there is a 
contrasting behaviour of the cis- and trans-[PtC12(15NH3)(2-pic)] isomers towards 
glutathione. The reactivity of cis- [PtC 12(15  NH3)(2-pic)]  with L-methionine was 
greatly reduced compared to cisplatin, in agreement with previous reports that the 
steric hindrance of the 2-picoline ligand precludes access to the Pt centre and is 
therefore less susceptible to reaction with incoming thiols. However, this was not the 
case for the reaction of trans-[PtC12(5NH3)(2-pic)] with L-methionine, which 
appeared to proceed via direct substitution, entirely consuming trans-
[PtC12(15NH3)(2-pic)] within 8 h of reaction. 
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Appendix 1 Chromatogram for hydrolysis of AMD473 in 0.02 M NaCI04, pH 5.5, 
310 K, ?. = 220 nm (the sloping lines at the top and bottom represent the gradient of 










Appendix 2 ESI mass spectra at a cone voltage of 45 eV for a) fraction F3 and b) 
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Appendix 3 'H NMR spectrum of cis- [Pt(NH3)(2-pic)(2'-dGuo)21(NO3)2 in H20/D20 










Appendix 4 [1 H,'H] ROESY NMR spectrum of cis- [Pt(NH3)(2-pic)(21-
dGuo)2](NO3)2 in H20/D20 (H6 corresponds to aromatic signal of picoline ligand). 
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Appendix 5 'H NMR spectrum of trans- [Pt(NH3)(2-pic)(Guo)2](NO3)2 in I-120/D20 
at 298 K (peaks H3-E-16 are aromatic proton signals of picoline ligand). 
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Appendix 6 1 H NMR spectrum of trans- [Pt(NH3)(2-pic)(2'-dGuo)2](NO3)2 in 
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Appendix 7 Pseudo-first order computer fits of the concentration versus time 
profiles for the reaction of trans-[PtC]2( 15 NH3 )(2-pic)] and 12-mer duplex DNA, 
d(TATGGTACCATA)2, at 298 K, as determined by integration of the 2D cross-
peaks shown in Figure 6. 1, a) peak a and b) peak c. 
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